0001156039-23-000088.txt : 20230719 0001156039-23-000088.hdr.sgml : 20230719 20230719163450 ACCESSION NUMBER: 0001156039-23-000088 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230719 DATE AS OF CHANGE: 20230719 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 231097105 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 10-Q 1 elv-20230630.htm FORM 10-Q elv-20230630
false2023Q2000115603912/31http://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent00011560392023-01-012023-06-3000011560392023-07-13xbrli:shares00011560392023-06-30iso4217:USD00011560392022-12-31iso4217:USDxbrli:shares00011560392023-04-012023-06-3000011560392022-04-012022-06-3000011560392022-01-012022-06-3000011560392021-12-3100011560392022-06-300001156039us-gaap:CommonStockMember2022-12-310001156039us-gaap:AdditionalPaidInCapitalMember2022-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:RetainedEarningsMember2022-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001156039us-gaap:NoncontrollingInterestMember2022-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2022-12-310001156039us-gaap:RetainedEarningsMember2023-01-012023-03-310001156039us-gaap:NoncontrollingInterestMember2023-01-012023-03-3100011560392023-01-012023-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001156039us-gaap:CommonStockMember2023-01-012023-03-310001156039us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001156039us-gaap:CommonStockMember2023-03-310001156039us-gaap:AdditionalPaidInCapitalMember2023-03-310001156039us-gaap:RetainedEarningsMember2023-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001156039us-gaap:NoncontrollingInterestMember2023-03-3100011560392023-03-310001156039us-gaap:RetainedEarningsMember2023-04-012023-06-300001156039us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001156039us-gaap:CommonStockMember2023-04-012023-06-300001156039us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001156039us-gaap:CommonStockMember2023-06-300001156039us-gaap:AdditionalPaidInCapitalMember2023-06-300001156039us-gaap:RetainedEarningsMember2023-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001156039us-gaap:NoncontrollingInterestMember2023-06-300001156039us-gaap:CommonStockMember2021-12-310001156039us-gaap:AdditionalPaidInCapitalMember2021-12-310001156039us-gaap:RetainedEarningsMember2021-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001156039us-gaap:NoncontrollingInterestMember2021-12-310001156039us-gaap:AccountingStandardsUpdate202006Memberus-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001156039us-gaap:AccountingStandardsUpdate202006Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:RetainedEarningsMember2021-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001156039us-gaap:RetainedEarningsMember2022-01-012022-03-310001156039us-gaap:NoncontrollingInterestMember2022-01-012022-03-3100011560392022-01-012022-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001156039us-gaap:CommonStockMember2022-01-012022-03-310001156039us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001156039us-gaap:CommonStockMember2022-03-310001156039us-gaap:AdditionalPaidInCapitalMember2022-03-310001156039us-gaap:RetainedEarningsMember2022-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001156039us-gaap:NoncontrollingInterestMember2022-03-3100011560392022-03-310001156039us-gaap:RetainedEarningsMember2022-04-012022-06-300001156039us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001156039us-gaap:CommonStockMember2022-04-012022-06-300001156039us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001156039us-gaap:CommonStockMember2022-06-300001156039us-gaap:AdditionalPaidInCapitalMember2022-06-300001156039us-gaap:RetainedEarningsMember2022-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001156039us-gaap:NoncontrollingInterestMember2022-06-30elv:medical_memberelv:countyelv:statesxbrli:pure0001156039elv:BioPlusMember2023-04-012023-06-300001156039elv:BioPlusMember2023-01-012023-06-300001156039elv:IntegraManagedCareMember2023-01-012023-06-300001156039elv:IntegraManagedCareMember2023-04-012023-06-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-06-300001156039us-gaap:ForeignGovernmentDebtMember2023-06-300001156039us-gaap:USStatesAndPoliticalSubdivisionsMember2023-06-300001156039us-gaap:CorporateDebtSecuritiesMember2023-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2023-06-300001156039us-gaap:CommercialMortgageBackedSecuritiesMember2023-06-300001156039us-gaap:OtherAggregatedInvestmentsMember2023-06-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310001156039us-gaap:ForeignGovernmentDebtMember2022-12-310001156039us-gaap:USStatesAndPoliticalSubdivisionsMember2022-12-310001156039us-gaap:CorporateDebtSecuritiesMember2022-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMember2022-12-310001156039us-gaap:OtherAggregatedInvestmentsMember2022-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2023-06-30elv:securities0001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-06-300001156039us-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2023-06-300001156039us-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-06-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2023-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2023-06-300001156039us-gaap:FixedMaturitiesMemberus-gaap:CommercialMortgageBackedSecuritiesMember2023-06-300001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2023-06-300001156039us-gaap:FixedMaturitiesMember2023-06-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2022-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2022-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2022-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2022-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:CommercialMortgageBackedSecuritiesMember2022-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2022-12-310001156039us-gaap:FixedMaturitiesMember2022-12-310001156039us-gaap:FixedMaturitiesMember2023-04-012023-06-300001156039us-gaap:FixedMaturitiesMember2023-01-012023-06-300001156039us-gaap:FixedMaturitiesMember2022-04-012022-06-300001156039us-gaap:FixedMaturitiesMember2022-01-012022-06-300001156039us-gaap:ExchangeTradedFundsMember2023-06-300001156039us-gaap:ExchangeTradedFundsMember2022-12-310001156039elv:CommonEquitySecuritiesMember2023-06-300001156039elv:CommonEquitySecuritiesMember2022-12-310001156039us-gaap:PrivateEquityFundsMember2023-06-300001156039us-gaap:PrivateEquityFundsMember2022-12-310001156039us-gaap:EquitySecuritiesMember2023-04-012023-06-300001156039us-gaap:EquitySecuritiesMember2022-04-012022-06-300001156039us-gaap:EquitySecuritiesMember2023-01-012023-06-300001156039us-gaap:EquitySecuritiesMember2022-01-012022-06-300001156039us-gaap:OtherInvestmentsMember2023-04-012023-06-300001156039us-gaap:OtherInvestmentsMember2022-04-012022-06-300001156039us-gaap:OtherInvestmentsMember2023-01-012023-06-300001156039us-gaap:OtherInvestmentsMember2022-01-012022-06-300001156039us-gaap:CashMemberus-gaap:MaturityOvernightMember2023-06-300001156039us-gaap:CashMemberus-gaap:MaturityOvernightMember2022-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:MaturityOvernightMember2023-06-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:MaturityOvernightMember2022-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:MaturityOvernightMember2023-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:MaturityOvernightMember2022-12-310001156039us-gaap:CashFlowHedgingMember2023-06-300001156039us-gaap:CashFlowHedgingMember2022-12-310001156039us-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:FairValueInputsLevel2Member2023-06-300001156039us-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtMember2023-06-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtMember2023-06-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtMember2023-06-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-06-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-06-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-06-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialMortgageBackedSecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialMortgageBackedSecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialMortgageBackedSecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherDebtSecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:OtherDebtSecuritiesMember2023-06-300001156039us-gaap:OtherDebtSecuritiesMember2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel2Member2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2023-06-300001156039us-gaap:EquitySecuritiesMemberelv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMember2023-06-300001156039us-gaap:EquitySecuritiesMemberelv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:EquitySecuritiesMemberelv:CommonEquitySecuritiesMember2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PrivateEquityFundsMember2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PrivateEquityFundsMember2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PrivateEquityFundsMember2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:EquitySecuritiesMember2023-06-300001156039us-gaap:OtherInvestmentsMemberelv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMember2023-06-300001156039us-gaap:OtherInvestmentsMemberelv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:OtherInvestmentsMemberelv:CommonEquitySecuritiesMember2023-06-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeMember2023-06-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeMember2023-06-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeMember2023-06-300001156039us-gaap:DerivativeMember2023-06-300001156039us-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:FairValueInputsLevel2Member2022-12-310001156039us-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtMember2022-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtMember2022-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtMember2022-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialMortgageBackedSecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialMortgageBackedSecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialMortgageBackedSecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherDebtSecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:OtherDebtSecuritiesMember2022-12-310001156039us-gaap:OtherDebtSecuritiesMember2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2022-12-310001156039us-gaap:EquitySecuritiesMemberelv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMember2022-12-310001156039us-gaap:EquitySecuritiesMemberelv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:EquitySecuritiesMemberelv:CommonEquitySecuritiesMember2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PrivateEquityFundsMember2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PrivateEquityFundsMember2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PrivateEquityFundsMember2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:EquitySecuritiesMember2022-12-310001156039us-gaap:OtherInvestmentsMemberelv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMember2022-12-310001156039us-gaap:OtherInvestmentsMemberelv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:OtherInvestmentsMemberelv:CommonEquitySecuritiesMember2022-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeMember2022-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeMember2022-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeMember2022-12-310001156039us-gaap:DerivativeMember2022-12-310001156039us-gaap:CorporateDebtSecuritiesMember2023-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2023-03-310001156039us-gaap:OtherDebtSecuritiesMember2023-03-310001156039us-gaap:EquitySecuritiesMember2023-03-310001156039us-gaap:CorporateDebtSecuritiesMember2023-04-012023-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2023-04-012023-06-300001156039us-gaap:OtherDebtSecuritiesMember2023-04-012023-06-300001156039us-gaap:EquitySecuritiesMember2023-04-012023-06-300001156039us-gaap:EquitySecuritiesMember2023-06-300001156039us-gaap:CorporateDebtSecuritiesMember2022-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-03-310001156039us-gaap:OtherDebtSecuritiesMember2022-03-310001156039us-gaap:EquitySecuritiesMember2022-03-310001156039us-gaap:CorporateDebtSecuritiesMember2022-04-012022-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-04-012022-06-300001156039us-gaap:OtherDebtSecuritiesMember2022-04-012022-06-300001156039us-gaap:EquitySecuritiesMember2022-04-012022-06-300001156039us-gaap:CorporateDebtSecuritiesMember2022-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-06-300001156039us-gaap:OtherDebtSecuritiesMember2022-06-300001156039us-gaap:EquitySecuritiesMember2022-06-300001156039us-gaap:EquitySecuritiesMember2022-12-310001156039us-gaap:CorporateDebtSecuritiesMember2023-01-012023-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2023-01-012023-06-300001156039us-gaap:OtherDebtSecuritiesMember2023-01-012023-06-300001156039us-gaap:EquitySecuritiesMember2023-01-012023-06-300001156039us-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:OtherDebtSecuritiesMember2021-12-310001156039us-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:CorporateDebtSecuritiesMember2022-01-012022-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-01-012022-06-300001156039us-gaap:OtherDebtSecuritiesMember2022-01-012022-06-300001156039us-gaap:EquitySecuritiesMember2022-01-012022-06-300001156039us-gaap:FairValueMeasurementsNonrecurringMember2023-06-300001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001156039us-gaap:OtherInvestmentsMember2023-06-300001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001156039us-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001156039us-gaap:OtherInvestmentsMember2022-12-310001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001156039us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001156039us-gaap:ShortDurationInsuranceContractAccidentYear2021Member2023-06-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2022Member2023-06-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2023Member2023-06-300001156039elv:SeniorUnsecuredNotesMember2023-06-300001156039elv:SeniorUnsecuredNotesMember2022-12-310001156039elv:SeniorUnsecuredNotesMemberelv:FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember2023-02-080001156039elv:SeniorUnsecuredNotesMemberelv:FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember2023-02-080001156039elv:SeniorUnsecuredNotesMemberelv:FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember2023-02-080001156039elv:SeniorUnsecuredNotesMemberelv:ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember2023-01-170001156039elv:ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMemberelv:SeniorUnsecuredNotesMember2023-03-150001156039elv:SurplusNotesMember2022-12-310001156039elv:SurplusNotesMember2023-06-300001156039us-gaap:RevolvingCreditFacilityMember2023-06-300001156039us-gaap:RevolvingCreditFacilityMember2023-01-012023-06-300001156039us-gaap:LineOfCreditMember2023-06-300001156039us-gaap:CommercialPaperMember2023-06-300001156039us-gaap:CommercialPaperMember2022-12-310001156039us-gaap:ConvertibleDebtMemberelv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember2023-03-152023-03-150001156039us-gaap:ConvertibleDebtMemberelv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember2023-04-012023-06-300001156039us-gaap:FederalHomeLoanBankAdvancesMember2023-06-300001156039us-gaap:FederalHomeLoanBankAdvancesMember2022-12-310001156039srt:MinimumMember2023-06-300001156039srt:MaximumMember2023-06-300001156039elv:BCBSAntitrustLitigationMember2023-01-012023-06-300001156039elv:BCBSAntitrustLitigationMember2023-06-300001156039elv:PharmacypricingMemberelv:AnthemInc.v.ExpressScriptsInc.Member2023-01-012023-06-300001156039elv:AnthemInc.v.ExpressScriptsInc.Memberelv:OperationalMember2023-01-012023-06-300001156039elv:AnthemInc.v.ExpressScriptsInc.Member2023-01-012023-06-300001156039us-gaap:SubsequentEventMember2023-07-180001156039us-gaap:SubsequentEventMember2023-07-182023-07-1800011560392021-01-260001156039elv:A2023To2025Memberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-06-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-06-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-06-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2023-03-310001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-03-310001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-12-310001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2021-12-310001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2023-04-012023-06-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-04-012022-06-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2023-01-012023-06-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-01-012022-06-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2023-06-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-06-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-12-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-04-012023-06-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-04-012022-06-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-01-012023-06-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-06-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-06-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-06-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-06-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-06-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-06-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001156039elv:FuturePolicyBenefitsMember2023-03-310001156039elv:FuturePolicyBenefitsMember2022-03-310001156039elv:FuturePolicyBenefitsMember2022-12-310001156039elv:FuturePolicyBenefitsMember2021-12-310001156039elv:FuturePolicyBenefitsMember2023-04-012023-06-300001156039elv:FuturePolicyBenefitsMember2022-04-012022-06-300001156039elv:FuturePolicyBenefitsMember2023-01-012023-06-300001156039elv:FuturePolicyBenefitsMember2022-01-012022-06-300001156039elv:FuturePolicyBenefitsMember2023-06-300001156039elv:FuturePolicyBenefitsMember2022-06-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-06-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-06-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-06-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001156039elv:A2023To2025Member2023-04-012023-06-300001156039elv:A2023To2025Member2023-01-012023-06-300001156039elv:A2022To2024Member2022-04-012022-06-300001156039elv:A2022To2024Member2022-01-012022-06-30elv:segment0001156039elv:HealthBenefitsSegmentMember2023-04-012023-06-300001156039elv:CarelonRxSegmentMember2023-04-012023-06-300001156039elv:CarelonServicesSegmentMember2023-04-012023-06-300001156039elv:CarelonTotalMember2023-04-012023-06-300001156039elv:CorporateOtherSegmentMember2023-04-012023-06-300001156039elv:SegmentEliminationsMember2023-04-012023-06-300001156039elv:UnaffiliatedMemberelv:HealthBenefitsSegmentMember2023-04-012023-06-300001156039elv:UnaffiliatedMemberelv:CarelonRxSegmentMember2023-04-012023-06-300001156039elv:UnaffiliatedMemberelv:CarelonServicesSegmentMember2023-04-012023-06-300001156039elv:UnaffiliatedMemberelv:CarelonTotalMember2023-04-012023-06-300001156039elv:UnaffiliatedMemberelv:CorporateOtherSegmentMember2023-04-012023-06-300001156039elv:UnaffiliatedMemberelv:SegmentEliminationsMember2023-04-012023-06-300001156039elv:UnaffiliatedMember2023-04-012023-06-300001156039elv:AffiliatedMemberelv:CarelonRxSegmentMember2023-04-012023-06-300001156039elv:CarelonServicesSegmentMemberelv:AffiliatedMember2023-04-012023-06-300001156039elv:CarelonTotalMemberelv:AffiliatedMember2023-04-012023-06-300001156039elv:AffiliatedMemberelv:CorporateOtherSegmentMember2023-04-012023-06-300001156039elv:AffiliatedMemberelv:SegmentEliminationsMember2023-04-012023-06-300001156039elv:HealthBenefitsSegmentMember2022-04-012022-06-300001156039elv:CarelonRxSegmentMember2022-04-012022-06-300001156039elv:CarelonServicesSegmentMember2022-04-012022-06-300001156039elv:CarelonTotalMember2022-04-012022-06-300001156039elv:CorporateOtherSegmentMember2022-04-012022-06-300001156039elv:SegmentEliminationsMember2022-04-012022-06-300001156039elv:UnaffiliatedMemberelv:HealthBenefitsSegmentMember2022-04-012022-06-300001156039elv:UnaffiliatedMemberelv:CarelonRxSegmentMember2022-04-012022-06-300001156039elv:UnaffiliatedMemberelv:CarelonServicesSegmentMember2022-04-012022-06-300001156039elv:UnaffiliatedMemberelv:CarelonTotalMember2022-04-012022-06-300001156039elv:UnaffiliatedMemberelv:CorporateOtherSegmentMember2022-04-012022-06-300001156039elv:UnaffiliatedMemberelv:SegmentEliminationsMember2022-04-012022-06-300001156039elv:UnaffiliatedMember2022-04-012022-06-300001156039elv:AffiliatedMemberelv:CarelonRxSegmentMember2022-04-012022-06-300001156039elv:CarelonServicesSegmentMemberelv:AffiliatedMember2022-04-012022-06-300001156039elv:CarelonTotalMemberelv:AffiliatedMember2022-04-012022-06-300001156039elv:AffiliatedMemberelv:CorporateOtherSegmentMember2022-04-012022-06-300001156039elv:AffiliatedMemberelv:SegmentEliminationsMember2022-04-012022-06-300001156039elv:HealthBenefitsSegmentMember2023-01-012023-06-300001156039elv:CarelonRxSegmentMember2023-01-012023-06-300001156039elv:CarelonServicesSegmentMember2023-01-012023-06-300001156039elv:CarelonTotalMember2023-01-012023-06-300001156039elv:CorporateOtherSegmentMember2023-01-012023-06-300001156039elv:SegmentEliminationsMember2023-01-012023-06-300001156039elv:UnaffiliatedMemberelv:HealthBenefitsSegmentMember2023-01-012023-06-300001156039elv:UnaffiliatedMemberelv:CarelonRxSegmentMember2023-01-012023-06-300001156039elv:UnaffiliatedMemberelv:CarelonServicesSegmentMember2023-01-012023-06-300001156039elv:UnaffiliatedMemberelv:CarelonTotalMember2023-01-012023-06-300001156039elv:UnaffiliatedMemberelv:CorporateOtherSegmentMember2023-01-012023-06-300001156039elv:UnaffiliatedMemberelv:SegmentEliminationsMember2023-01-012023-06-300001156039elv:UnaffiliatedMember2023-01-012023-06-300001156039elv:AffiliatedMemberelv:CarelonRxSegmentMember2023-01-012023-06-300001156039elv:CarelonServicesSegmentMemberelv:AffiliatedMember2023-01-012023-06-300001156039elv:CarelonTotalMemberelv:AffiliatedMember2023-01-012023-06-300001156039elv:AffiliatedMemberelv:CorporateOtherSegmentMember2023-01-012023-06-300001156039elv:AffiliatedMemberelv:SegmentEliminationsMember2023-01-012023-06-300001156039elv:HealthBenefitsSegmentMember2022-01-012022-06-300001156039elv:CarelonRxSegmentMember2022-01-012022-06-300001156039elv:CarelonServicesSegmentMember2022-01-012022-06-300001156039elv:CarelonTotalMember2022-01-012022-06-300001156039elv:CorporateOtherSegmentMember2022-01-012022-06-300001156039elv:SegmentEliminationsMember2022-01-012022-06-300001156039elv:UnaffiliatedMemberelv:HealthBenefitsSegmentMember2022-01-012022-06-300001156039elv:UnaffiliatedMemberelv:CarelonRxSegmentMember2022-01-012022-06-300001156039elv:UnaffiliatedMemberelv:CarelonServicesSegmentMember2022-01-012022-06-300001156039elv:UnaffiliatedMemberelv:CarelonTotalMember2022-01-012022-06-300001156039elv:UnaffiliatedMemberelv:CorporateOtherSegmentMember2022-01-012022-06-300001156039elv:UnaffiliatedMemberelv:SegmentEliminationsMember2022-01-012022-06-300001156039elv:UnaffiliatedMember2022-01-012022-06-300001156039elv:AffiliatedMemberelv:CarelonRxSegmentMember2022-01-012022-06-300001156039elv:CarelonServicesSegmentMemberelv:AffiliatedMember2022-01-012022-06-300001156039elv:CarelonTotalMemberelv:AffiliatedMember2022-01-012022-06-300001156039elv:AffiliatedMemberelv:CorporateOtherSegmentMember2022-01-012022-06-300001156039elv:AffiliatedMemberelv:SegmentEliminationsMember2022-01-012022-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended June 30, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission file number: 001-16751
eh_logo.jpg
ELEVANCE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-2145715
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (833) 401-1577
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueELVNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer☒  Accelerated filer☐
Non-accelerated filer☐  Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of July 13, 2023, 235,647,808 shares of the Registrant’s Common Stock were outstanding.


Elevance Health, Inc.
Quarterly Report on Form 10-Q
For the Period Ended June 30, 2023
Table of Contents
 
  Page
PART I. FINANCIAL INFORMATION
ITEM 1.
ITEM 2.
ITEM 3.
ITEM 4.
PART II. OTHER INFORMATION
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 3.
ITEM 4.
ITEM 5.
ITEM 6.
-1-

PART I. FINANCIAL INFORMATION
ITEM 1.    FINANCIAL STATEMENTS
Elevance Health, Inc.
Consolidated Balance Sheets
June 30,
2023		December 31,
2022
(In millions, except share and per share data)(Unaudited)(Restated)
Assets
Current assets:
Cash and cash equivalents$9,991 $7,387 
Fixed maturity securities (amortized cost of $29,915 and $28,226; allowance for credit losses of $7 and $9)
28,021 25,952 
Equity securities272 953 
Premium receivables7,431 7,083 
Self-funded receivables3,896 4,663 
Other receivables5,196 4,298 
Other current assets4,936 5,281 
Total current assets59,743 55,617 
Long-term investments:
Fixed maturity securities (amortized cost of $809 and $789; allowance for credit losses of $0 and $0)
775 752 
Other invested assets5,993 5,685 
Property and equipment, net4,547 4,316 
Goodwill25,274 24,383 
Other intangible assets10,703 10,315 
Other noncurrent assets2,133 1,687 
Total assets$109,168 $102,755 
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable$16,165 $15,596 
Other policyholder liabilities5,954 5,933 
Unearned income4,458 1,112 
Accounts payable and accrued expenses5,033 5,607 
Short-term borrowings265 265 
Current portion of long-term debt— 1,500 
Other current liabilities9,696 9,683 
Total current liabilities41,571 39,696 
Long-term debt, less current portion24,859 22,349 
Reserves for future policy benefits797 803 
Deferred tax liabilities, net1,852 2,015 
Other noncurrent liabilities1,777 1,562 
Total liabilities70,856 66,425 
Commitments and contingencies – Note 10
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none
— — 
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
235,861,650 and 237,958,067
2 2 
Additional paid-in capital8,761 9,084 
Retained earnings31,608 29,647 
Accumulated other comprehensive loss(2,166)(2,490)
Total shareholders’ equity38,205 36,243 
Noncontrolling interests107 87 
Total equity38,312 36,330 
Total liabilities and equity$109,168 $102,755 


See accompanying notes.
-2-

Elevance Health, Inc.
Consolidated Statements of Income
(Unaudited) 
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
2023202220232022
(In millions, except per share data)(Restated)(Restated)
Revenues
Premiums$36,589 $33,076 $72,457 $65,861 
Product revenue4,859 3,568 8,881 6,869 
Service fees1,929 1,838 3,937 3,638 
Total operating revenue43,377 38,482 85,275 76,368 
Net investment income416 381 803 741 
Net losses on financial instruments(121)(231)(234)(382)
Total revenues43,672 38,632 85,844 76,727 
Expenses
Benefit expense31,604 28,795 62,390 57,026 
Cost of products sold4,327 3,069 7,808 5,952 
Operating expense4,818 4,272 9,618 8,617 
Interest expense261 208 512 409 
Amortization of other intangible assets221 166 456 295 
Total expenses41,231 36,510 80,784 72,299 
Income before income tax expense
2,441 2,122 5,060 4,428 
Income tax expense585 488 1,200 1,015 
Net income1,856 1,634 3,860 3,413 
Net (income) loss attributable to noncontrolling interests(3)3 (18)13 
Shareholders’ net income$1,853 $1,637 $3,842 $3,426 
Shareholders’ net income per share
Basic $7.83 $6.80 $16.21 $14.22 
Diluted $7.79 $6.73 $16.10 $14.05 
Dividends per share$1.48 $1.28 $2.96 $2.56 















See accompanying notes.
-3-

Elevance Health, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited) 
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
(In millions)2023202220232022
(Restated)(Restated)
Net income$1,856 $1,634 $3,860 $3,413 
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments(119)(922)308 (1,991)
Change in non-credit component of impairment losses on investments
(1)(1)(3)(2)
Change in net unrealized gains/losses on cash flow hedges4 3 15 6 
Change in net periodic pension and postretirement costs3 9 5 16 
Change in future policy benefits (3)8 (1)17 
Foreign currency translation adjustments— (5)2 (8)
Other comprehensive (loss) income(116)(908)326 (1,962)
Net (income) loss attributable to noncontrolling interests(3)3 (18)13 
Other comprehensive loss (income) attributable to noncontrolling interests— 3 (2)8 
Total shareholders’ comprehensive income$1,737 $732 $4,166 $1,472 




















See accompanying notes.
-4-

Elevance Health, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Six Months Ended 
 June 30
20232022
(In millions)(Restated)
Operating activities
Net income$3,860 $3,413 
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses on financial instruments234 382 
Equity in net earnings of other invested assets73 (258)
Depreciation and amortization895 751 
Deferred income taxes(393)(181)
Share-based compensation139 122 
Changes in operating assets and liabilities:
Receivables, net(299)(662)
Other invested assets(42)32 
Other assets(529)(412)
Policy liabilities583 1,548 
Unearned income3,346 (182)
Accounts payable and other liabilities160 632 
Income taxes391 (159)
Other, net1 (33)
Net cash provided by operating activities8,419 4,993 
Investing activities
Purchases of investments(17,648)(13,253)
Proceeds from sale of investments5,339 7,140 
Maturities, calls and redemptions from investments10,656 4,347 
Changes in securities lending collateral145 (620)
Purchases of subsidiaries, net of cash acquired(1,651)(609)
Purchases of property and equipment(651)(549)
Other, net(46)(58)
Net cash used in investing activities(3,856)(3,602)
Financing activities
Net proceeds from commercial paper borrowings90 250 
Proceeds from long-term borrowings2,574 1,300 
Repayments of long-term borrowings(1,908)(943)
Proceeds from short-term borrowings— 1,275 
Repayments of short-term borrowings(90)(1,375)
Changes in securities lending payable(145)620 
Changes in bank overdrafts(500)817 
Repurchase and retirement of common stock(1,268)(1,169)
Cash dividends(701)(618)
Proceeds from issuance of common stock under employee stock plans81 116 
Taxes paid through withholding of common stock under employee stock plans(99)(88)
Other, net5 10 
Net cash (used in) provided by financing activities(1,961)195 
Effect of foreign exchange rates on cash and cash equivalents2 (10)
Change in cash and cash equivalents2,604 1,576 
Cash and cash equivalents at beginning of period7,387 4,880 
Cash and cash equivalents at end of period$9,991 $6,456 
See accompanying notes.
-5-

Elevance Health, Inc.
Consolidated Statements of Changes in Equity
(Unaudited)
Total Shareholders’ Equity
 Common StockAdditional
Paid-in
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Noncontrolling
Interests		Total
Equity
(In millions)Number of
Shares		Par
Value
December 31, 2022 (restated)238.0 $2 $9,084 $29,647 $(2,490)$87 $36,330 
Net income— — — 1,989 — 15 2,004 
Other comprehensive income— — — — 440 2 442 
Repurchase and retirement of common stock, including excise tax(1.3)— (51)(575)— — (626)
Dividends and dividend equivalents— — — (354)— — (354)
Issuance of common stock under employee stock plans, net of related tax benefits0.4 — 6 — — — 6 
Convertible debenture repurchases, conversions and tax adjustments— — (342)— — — (342)
March 31, 2023237.1 2 8,697 30,707 (2,050)104 37,460 
Net income — — — 1,853 — 3 1,856 
Other comprehensive income— — — — (116)— (116)
Repurchase and retirement of common stock, including excise tax(1.4)— (52)(600)— — (652)
Dividends and dividend equivalents— — — (352)— — (352)
Issuance of common stock under employee stock plans, net of related tax benefits0.2 — 116 — — — 116 
June 30, 2023235.9 $2 $8,761 $31,608 $(2,166)$107 $38,312 



















See accompanying notes.
-6-

Elevance Health, Inc.
Consolidated Statements of Changes in Equity (continued)
(Unaudited)
Total Shareholders’ Equity
 Common StockAdditional
Paid-in
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Noncontrolling
Interests		Total
Equity
(In millions)Number of
Shares		Par
Value
December 31, 2021 (restated)241.8 $2 $9,148 $27,142 $(197)$68 $36,163 
Adoption of Accounting Standards Update 2020-06— — — (23)— — (23)
January 1, 2022 (restated)241.8 2 9,148 27,119 (197)68 36,140 
Net income (loss) (restated)— — — 1,789 — (10)1,779 
Other comprehensive loss (restated)— — — — (1,049)(5)(1,054)
Noncontrolling interests adjustment— — — — — 3 3 
Repurchase and retirement of common stock(1.2)— (45)(500)— — (545)
Dividends and dividend equivalents— — — (312)— — (312)
Issuance of common stock under employee stock plans, net of related tax benefits
0.5 — 39 — — — 39 
Convertible debenture repurchases and conversions
— — 9 — — — 9 
March 31, 2022 (restated)241.1 2 9,151 28,096 (1,246)56 36,059 
Net income (loss) restated— — — 1,637 — (3)1,634 
Other comprehensive loss (restated)— — — — (905)(3)(908)
Noncontrolling interests adjustment— — — — — 5 5 
Repurchase and retirement of common stock
(1.3)— (48)(576)— — (624)
Dividends and dividend equivalents— — — (310)— — (310)
Issuance of common stock under employee stock plans, net of related tax benefits
0.2 — 111 — — — 111 
Convertible debenture repurchases and conversions
— — (80)— — — (80)
June 30, 2022 (restated)240.0 $2 $9,134 $28,847 $(2,151)$55 $35,887 













See accompanying notes.
-7-

Elevance Health, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
June 30, 2023
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
 
1.     Organization
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 48 million medical members through our affiliated health plans as of June 30, 2023. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (with the exception of 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also serve members in numerous states as Amerigroup, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, UniCare and/or Wellpoint. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services as CarelonRx and other healthcare-related services as Carelon Services, Aspire Health, Carelon Behavioral Health and CareMore.
As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans; and
•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable
-8-

segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Form 10-Q has been reclassified to conform to the new presentation. For additional discussion regarding our segments, including the changes made, see Note 14 “Segment Information.”
2.     Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) , unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and six months ended June 30, 2023 and 2022 have been recorded. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $391 and $258 at June 30, 2023 and December 31, 2022, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
-9-

probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $184 and $152 at June 30, 2023 and December 31, 2022, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $86 and $68 at June 30, 2023 and December 31, 2022, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $816 and $744 at June 30, 2023 and December 31, 2022, respectively.
-10-

Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at June 30, 2023. For the three and six months ended June 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our adoption as required by the new standard.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
3.    Business Acquisitions and Divestitures
Pending Divestiture
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected to close by the end of the first quarter of 2024 and is subject to standard closing conditions and customary approvals. The related net assets held for sale and results of operations for the employee benefits businesses to be divested as of and for the three and six months ending June 30, 2023 were not material.
Pending Acquisition
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health solutions to BCBSLA’s members. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.
Completed Acquisitions
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of June 30, 2023, the purchase price was allocated to the tangible and
-11-

intangible net assets acquired based on management’s initial estimates of their fair values, of which $820 has been allocated to finite-lived intangible assets and $877 to goodwill, including an increase to goodwill for measurement period adjustments of $149 during the quarter ended June 30, 2023. The majority of goodwill is not deductible for income tax purposes. As of June 30, 2023, the initial accounting for the acquisition had not been finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The initial accounting for this acquisition was finalized as of June 30, 2023. The purchase price was allocated to tangible and intangible net assets acquired based on management’s estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $139 to goodwill. Contractual purchase price adjustments during the quarter ended June 30, 2023 were $13 and resulted in an increase to goodwill. The majority of goodwill is deductible for income tax purposes. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
4.     Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.
-12-

A summary of current and long-term fixed maturity securities, available-for-sale, at June 30, 2023 and December 31, 2022 is as follows:
Cost or
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
June 30, 2023
Fixed maturity securities:
United States Government securities$1,957 $1 $(75)$— $1,883 
Government sponsored securities94 1 (4)— 91 
Foreign government securities337 2 (41)(1)297 
States, municipalities and political subdivisions, tax-exempt3,957 22 (207)— 3,772 
Corporate securities14,276 50 (997)(4)13,325 
Residential mortgage-backed securities3,617 11 (313)— 3,315 
Commercial mortgage-backed securities2,262 2 (180)(2)2,082 
Other asset-backed securities4,224 15 (208)— 4,031 
Total fixed maturity securities$30,724 $104 $(2,025)$(7)$28,796 
December 31, 2022
Fixed maturity securities:
United States Government securities$1,502 $2 $(103)$— $1,401 
Government sponsored securities82 1 (5)— 78 
Foreign government securities321 1 (46)(2)274 
States, municipalities and political subdivisions, tax-exempt4,389 19 (265)— 4,143 
Corporate securities13,721 31 (1,218)(5)12,529 
Residential mortgage-backed securities2,978 9 (324)— 2,663 
Commercial mortgage-backed securities2,055 1 (176)(2)1,878 
Other asset-backed securities3,967 12 (241)— 3,738 
Total fixed maturity securities$29,015 $76 $(2,378)$(9)$26,704 
Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities.
-13-

For fixed maturity securities in an unrealized loss position at June 30, 2023 and December 31, 2022, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
June 30, 2023
Fixed maturity securities:
United States Government securities58$1,019 $(29)48$278 $(46)
Government sponsored securities1863 (2)2918 (2)
Foreign government securities
9756 (2)224186 (39)
States, municipalities and political subdivisions, tax-exempt7021,278 (20)9251,598 (187)
Corporate securities2,0514,323 (129)3,2166,910 (868)
Residential mortgage-backed securities6421,251 (38)1,2861,714 (275)
Commercial mortgage-backed securities246701 (28)5531,316 (152)
Other asset-backed securities3481,258 (62)8272,265 (146)
Total fixed maturity securities4,162$9,949 $(310)7,108$14,285 $(1,715)
December 31, 2022
Fixed maturity securities:
United States Government securities61$701 $(40)38$442 $(63)
Government sponsored securities3973 (4)65 (1)
Foreign government securities
150100 (10)198142 (36)
States, municipalities and political subdivisions, tax-exempt1,3982,615 (147)396652 (118)
Corporate securities3,5517,826 (549)2,2043,521 (669)
Residential mortgage-backed securities
1,3411,435 (121)496982 (203)
Commercial mortgage-backed securities
4571,082 (76)324719 (100)
Other asset-backed securities7842,203 (124)3981,074 (117)
Total fixed maturity securities7,781$16,035 $(1,071)4,060$7,537 $(1,307)
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of June 30, 2023, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amounts of $7 and $9 at June 30, 2023 and December 31, 2022, respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest.


-14-

The amortized cost and fair value of fixed maturity securities at June 30, 2023, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$1,127 $1,118 
Due after one year through five years8,193 7,810 
Due after five years through ten years9,466 8,883 
Due after ten years6,059 5,588 
Mortgage-backed securities5,879 5,397 
Total fixed maturity securities$30,724 $28,796 
During the three and six months ended June 30, 2023, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $9,675 and $15,085, respectively. During the three and six months ended June 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $7,026 and $10,672, respectively.
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at June 30, 2023 and December 31, 2022 is as follows:
 June 30, 2023December 31, 2022
Equity securities:
Exchange traded funds$166 $822 
Common equity securities31 43 
Private equity securities75 88 
Total$272 $953 
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three month lag due to the timing of when we receive financial information from the companies.
-15-

Investment Gains and Losses
Net investment (losses) gains for the three and six months ended June 30, 2023 and 2022 are as follows:
Three Months Ended June 30Six Months Ended June 30
2023202220232022
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$11 $16 $21 $36 
Gross realized losses from sales(99)(176)(214)(254)
Impairment losses recognized in income(3)(1)(10)(21)
Net realized losses from sales of fixed maturity securities(91)(161)(203)(239)
Equity securities:
Unrealized gains (losses) recognized on equity securities still held at the end of the period2 (83)(2)(154)
Net realized gains (losses) recognized on equity securities sold during the period1 (5)4 (19)
Net gains (losses) on equity securities3 (88)2 (173)
Other investments:
Gross gains2 10 20 33 
Gross losses(16)(15)(9)(44)
Impairment losses recognized in income(26)(1)(29)(5)
Net losses on other investments(40)(6)(18)(16)
Net losses on investments$(128)$(255)$(219)$(428)
Accrued Investment Income
At June 30, 2023 and December 31, 2022, accrued investment income totaled $266 and $245, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,311 and $2,457 at June 30, 2023 and December 31, 2022, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of June 30, 2023 and December 31, 2022. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
At June 30, 2023 and December 31, 2022, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,237 and $2,221, respectively, of United States Government securities for $73 and $224, respectively, and of Residential Mortgage-Backed securities for $1 and $12, respectively.
5.    Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
-16-

We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $214 and $229 at June 30, 2023 and December 31, 2022, respectively.
During the three and six months ended months ended June 30, 2023, we recognized net gains of $7 and net losses of $15, respectively, on non-hedging derivatives. During the three and six months ended months ended June 30, 2022, we recognized net gains on non-hedging derivatives of $24 and $46, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,” of this Form 10-Q.
6.    Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level InputInput Definition
Level IInputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level IIInputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level IIIUnobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.
-17-

Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty.
-18-

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 is as follows:
Level ILevel IILevel IIITotal
June 30, 2023
Assets:
Cash equivalents$6,100 $— $— $6,100 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,883 — 1,883 
Government sponsored securities— 91 — 91 
Foreign government securities— 297 — 297 
States, municipalities and political subdivisions, tax-exempt— 3,772 — 3,772 
Corporate securities— 13,222 103 13,325 
Residential mortgage-backed securities— 3,315 — 3,315 
Commercial mortgage-backed securities— 2,082 — 2,082 
Other asset-backed securities— 3,665 366 4,031 
Total fixed maturity securities, available-for-sale— 28,327 469 28,796 
Equity securities:
Exchange traded funds166 — — 166 
Common equity securities12 19 — 31 
Private equity securities— — 75 75 
Total equity securities178 19 75 272 
Other invested assets - common equity securities121 — — 121 
Securities lending collateral— 2,312 — 2,312 
Derivatives - other assets— 3 — 3 
Total assets$6,399 $30,661 $544 $37,604 
Liabilities:
Derivatives - other liabilities$— $(69)$— $(69)
Total liabilities$— $(69)$— $(69)
December 31, 2022
Assets:
Cash equivalents$3,567 $— $— $3,567 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,401 — 1,401 
Government sponsored securities— 78 — 78 
Foreign government securities— 274 — 274 
States, municipalities and political subdivisions, tax-exempt— 4,143 — 4,143 
Corporate securities— 12,392 137 12,529 
Residential mortgage-backed securities— 2,663 — 2,663 
Commercial mortgage-backed securities— 1,878 — 1,878 
Other asset-backed securities— 3,382 356 3,738 
Total fixed maturity securities, available-for-sale— 26,211 493 26,704 
Equity securities:
Exchange traded funds822 — — 822 
Common equity securities2 41 — 43 
Private equity securities— — 88 88 
Total equity securities824 41 88 953 
Other invested assets - common equity securities103 — — 103 
Securities lending collateral— 2,457 — 2,457 
Derivatives - other assets— 3 — 3 
Total assets$4,494 $28,712 $581 $33,787 
Liabilities:
Derivatives - other liabilities$— $(60)$— $(60)
Total liabilities$— $(60)$— $(60)
-19-

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended June 30, 2023 and 2022 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other Asset-
backed
Securities		Equity
Securities		Total
Three Months Ended June 30, 2023
Beginning balance at April 1, 2023$142 $— $390 $78 $610 
Total gains (losses):
Recognized in net income(2)— 1 2 1 
Recognized in accumulated other comprehensive loss1 — (9)— (8)
Purchases2 — 7 — 9 
Sales(10)— (5)(5)(20)
Settlements(4)— — — (4)
Transfers into Level III— — 6 — 6 
Transfers out of Level III(26)— (24)— (50)
Ending balance at June 30, 2023$103 $— $366 $75 $544 
Change in unrealized losses included in net income related to assets still held at June 30, 2023
$— $— $— $1 $1 
Three Months Ended June 30, 2022
Beginning balance at April 1, 2022$341 $4 $37 $99 $481 
Total gains (losses):
Recognized in net income(5)— — (2)(7)
Purchases11 — 190 11 212 
Sales(188)— — (14)(202)
Settlements(5)— — — (5)
Transfers into Level III14 — — — 14 
Transfers out of Level III(13)(4)(9)— (26)
Ending balance at June 30, 2022$155 $— $218 $94 $467 
Change in unrealized gains included in net income related to assets still held at June 30, 2022
$— $— $— $(3)$(3)
-20-

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the six months ended June 30, 2023 and 2022 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other Asset-
backed
Securities		Equity
Securities		Total
Six Months Ended June 30, 2023
Beginning balance at January 1, 2023$137 $— $356 $88 $581 
Total losses:
Recognized in net income(3)— 1 (5)(7)
Recognized in accumulated other comprehensive loss2 — (4)— (2)
Purchases4 — 18 1 23 
Sales(10)— (11)(9)(30)
Settlements(6)— — — (6)
Transfers into Level III— — 6 — 6 
Transfers out of Level III(21)— — — (21)
Ending balance at June 30, 2023$103 $— $366 $75 $544 
Change in unrealized gains included in net income related to assets still held at June 30, 2023
$— $— $— $(6)$(6)
Six Months Ended June 30, 2022
Beginning balance at January 1, 2022$336 $5 $19 $89 $449 
Total gains:
Recognized in net income(4)— — 1 (3)
Recognized in accumulated other comprehensive loss(2)— — — (2)
Purchases35 — 205 20 260 
Sales(175)— — (16)(191)
Settlements(39)— — — (39)
Transfers into Level III14 — — — 14 
Transfers out of Level III(10)(5)(6)— (21)
Ending balance at June 30, 2022$155 $— $218 $94 $467 
Change in unrealized gains included in net income related to assets still held at June 30, 2022
$— $— $— $1 $1 
There were no individually material transfers into or out of Level III during the three and six months ended June 30, 2023 or 2022.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of BioPlus in the first quarter of 2023 and Integra during the second quarter of 2022. The net assets acquired in our acquisitions of BioPlus and Integra and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of tangible assets acquired and liabilities assumed were recorded at their carrying values as of the acquisition date, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of BioPlus and Integra were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of BioPlus and Integra described above, there were no
-21-

material assets or liabilities measured at fair value on a nonrecurring basis during the three and six months ended June 30, 2023 or 2022.
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and six months ended June 30, 2023 or 2022.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets:
Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities. The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.
-22-

A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at June 30, 2023 and December 31, 2022 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
June 30, 2023
Assets:
Other invested assets$5,872 $— $— $5,872 $5,872 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Notes24,859 — 22,872 — 22,872 
December 31, 2022
Assets:
Other invested assets$5,582 $— $— $5,582 $5,582 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Notes23,786 — 21,861 — 21,861 
Convertible debentures63 — 463 — 463 
7.     Income Taxes
During the three months ended June 30, 2023 and 2022, we recognized income tax expense of $585 and $488 (restated), respectively, which represent effective income tax rates of 24.0% and 23.0% (restated), respectively. The increase in our effective income tax rate from the three months ended June 30, 2022 is primarily due to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits.
During the six months ended June 30, 2023 and 2022, we recognized income tax expense of $1,200 and $1,015 (restated), respectively, which represent effective income tax rates of 23.7% and 22.9% (restated), respectively. The increase in our effective income tax rate from the six months ended June 30, 2022 is primarily related to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits.
Income taxes receivable totaled $48 and $440 at June 30, 2023 and December 31, 2022, respectively. We recognize the income receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.
-23-

8. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2023 and 2022 is as follows:
20232022
Gross medical claims payable, beginning of period$15,348 $13,282 
Ceded medical claims payable, beginning of period(6)(21)
Net medical claims payable, beginning of period15,342 13,261 
Business combinations and purchase adjustments— 133 
Net incurred medical claims:
Current period61,290 55,737 
Prior periods redundancies(1,112)(972)
Total net incurred medical claims60,178 54,765 
Net payments attributable to:
Current period medical claims48,217 42,882 
Prior periods medical claims11,409 10,401 
Total net payments59,626 53,283 
Net medical claims payable, end of period15,894 14,876 
Ceded medical claims payable, end of period8 13 
Gross medical claims payable, end of period$15,902 $14,889 
At June 30, 2023, the total of net incurred but not reported liabilities plus expected development on reported claims was $597, $2,224 and $13,073 for the claim years 2021 and prior, 2022 and 2023, respectively.
The favorable development recognized in the six months ended June 30, 2023 and 2022 resulted primarily from trend factors in late 2022 and late 2021, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2022 developing faster than expected also contributed to the favorable development in the six months ended June 30, 2023.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2023 is as follows:
Three Months Ended Six Months Ended June 30, 2023
March 31, 2023June 30, 2023
Total net incurred medical claims$29,683 $30,495 $60,178 
Quality improvement and other claims expense1,103 1,109 2,212 
Benefit expense$30,786 $31,604 $62,390 
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2022 is as follows:
Three Months Ended Six Months Ended June 30, 2022
March 31, 2022June 30, 2022
(Restated)(Restated)(Restated)
Total net incurred medical claims$27,131 $27,634 $54,765 
Quality improvement and other claims expense1,100 1,161 2,261 
Benefit expense$28,231 $28,795 $57,026 
-24-

The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of June 30, 2023 and December 31, 2022, is as follows:
June 30, 2023December 31, 2022
Net medical claims payable, end of period$15,894 $15,342 
Ceded medical claims payable, end of period8 6 
Insurance lines other than short duration263 248 
Gross medical claims payable, end of period$16,165 $15,596 
9.     Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At June 30, 2023 and December 31, 2022, we had $24,834 and $23,761, respectively, outstanding under these notes.
On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the “2026 Notes”), $1,000 aggregate principal amount of 4.750% Notes due 2033 (the “2033 Notes”), and $1,100 aggregate principal amount of 5.125% Notes due 2053 (the “2053 Notes”) under our shelf registration statement. Interest on the 2026 Notes is payable semi-annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and 2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023. We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.
On January 17, 2023, we repaid, at maturity, the $1,000 outstanding balance of our 3.300% senior unsecured notes. On March 15, 2023, we repaid, at maturity, the $500 outstanding balance of our 0.450% senior unsecured notes.
We have an unsecured surplus note with an outstanding principal balance of $25 at both June 30, 2023 and December 31, 2022.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of June 30, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.6%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of June 30, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the six months ended June 30, 2023 or the year ended December 31, 2022.
Through certain subsidiaries, we had previously entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provided combined credit of up to $200. As of June 30, 2023, the Subsidiary Credit Facilities have been terminated.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. At June 30, 2023 and December 31, 2022, we had $90 and $0, respectively, outstanding under this program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.
-25-

On March 15, 2023, we redeemed all of our outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), pursuant to the indenture dated as of October 9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The Debentures were redeemed at a redemption price equal to 100% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption, for cash totaling $5. During the three months ended March 31, 2023, $59 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and conditions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three months ended March 31, 2023 of $404.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $175 and $265 of outstanding short-term borrowings from the FHLBs at June 30, 2023 and December 31, 2022, respectively.
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLBs borrowings.
10.     Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint, or in other court filings, the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at June 30, 2023. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in 28 states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.
-26-

In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which amount was accrued in 2020.
Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit, which has scheduled oral argument on the appeals for September 2023. In the event that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that Ohio v. American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In November 2022, the Court issued an order requiring the parties to submit supplemental briefs on certain questions related to the providers’ renewed motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.) ("Alaska Air"); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.) ("Jet Blue"); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.) ("Bed Bath & Beyond"); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.). In February 2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in Alaska Air and Jet Blue. In March 2023, pursuant to a stipulation by the parties, the Court denied the
-27-

defendants’ motion to dismiss also based on a statute of limitations defense in Bed Bath & Beyond. We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.
Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.
In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit. In November 2021, the plaintiff appealed the summary judgment order. In March 2023, the appeal was argued before the California Second District Court of Appeal (the "Second District"). The Second District affirmed the Superior Court's summary judgment order in April 2023. The plaintiff filed a petition for review with the California Supreme Court in June 2023, and BCC filed its answer to the petition in the same month. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.

Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for pharmacy benefit management services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express
-28-

Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed, and the District Court denied in March 2023, allowing our operational breach claim to proceed. A trial date has been set for December 2023. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be complete by February 2025. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We have submitted corrected data to CMS related to these investigations. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the indemnity claims were resolved in the fourth quarters of 2021 and 2022, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our
-29-

business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The agreement superseded certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at June 30, 2023 is approximately $621. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.
We formed CarelonRx, formerly known as IngenioRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own, starting in the second quarter of 2019. The comprehensive pharmacy services portfolio includes, but is not limited to, formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services. CarelonRx delegates certain pharmacy services, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.

11.     Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the six months ended June 30, 2023 and 2022 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Six Months Ended June 30, 2023
January 24, 2023March 10, 2023March 24, 2023$1.48$351 
April 18, 2023June 9, 2023June 23, 2023$1.48$350 
Six Months Ended June 30, 2022
January 25, 2022March 10, 2022March 25, 2022$1.28$309 
April 19, 2022June 10, 2022June 24, 2022$1.28$309 
On July 18, 2023, our Audit Committee declared a third quarter 2023 dividend to shareholders of $1.48 per share, payable on September 22, 2023 to shareholders of record at the close of business on September 8, 2023.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
-30-

A summary of common stock repurchases for the six months ended June 30, 2023 and 2022 is as follows:
Six Months Ended June 30
 20232022
Shares repurchased2.7 2.5 
Average price per share$466.62 $471.72 
Aggregate cost$1,268 $1,169 
Authorization remaining at the end of the period$5,608 $3,022 
For additional information regarding the use of capital for debt security repurchases, see Note 9, “Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
Stock Incentive Plans
A summary of stock option activity for the six months ended June 30, 2023 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20232.8 $293.28 
Granted0.6 469.05 
Exercised(0.2)268.35 
Forfeited or expired— 391.44 
Outstanding at June 30, 20233.2 323.85 6.51$402 
Exercisable at June 30, 20232.1 265.51 5.31$376 
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the six months ended June 30, 2023 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20231.2 $357.21 
Granted0.6 469.60 
Vested(0.6)301.18 
Forfeited— 405.25 
Nonvested at June 30, 20231.2 422.67 
During the six months ended June 30, 2023, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three-year period from 2023 to 2025. These grants have been included in the activity shown above but will be subject to adjustment at the end of 2025 based on results in the three-year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
-31-

The following weighted-average assumptions were used to estimate the fair values of options granted during the six months ended June 30, 2023 and 2022:
Six Months Ended June 30
20232022
Risk-free interest rate3.95 %1.97 %
Volatility factor29.00 %29.00 %
Quarterly dividend yield0.316 %0.282 %
Weighted-average expected life (years)4.405.10
The following weighted-average fair values per option or share were determined for the six months ended June 30, 2023 and 2022: 
Six Months Ended June 30
20232022
Options granted during the period$127.13 $116.80 
Restricted stock awards granted during the period469.60 452.78 
-32-

12.     Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at June 30, 2023 and 2022 is as follows:
Three Months Ended
June 30		Six Months Ended
June 30
2023202220232022
(Restated)(Restated)
Net unrealized investment (losses) gains:
Beginning of period balance$(1,330)$(570)$(1,755)$494 
Other comprehensive (loss) gain before reclassifications, net of tax benefit (expense) of $61, $323, $(25) and $677, respectively
(191)(1,050)146 (2,196)
Amounts reclassified from accumulated other comprehensive loss, net of tax expense of $(23), $(34), $(51) and $(55), respectively
72 128 162 205 
Other comprehensive (loss) income(119)(922)308 (1,991)
Other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0 and $(3), respectively
— 3 (2)8 
End of period balance(1,449)(1,489)(1,449)(1,489)
Non-credit components of impairments on investments:
Beginning of period balance(5)(1)(3)— 
Other comprehensive loss, net of tax benefit of $0, $0, $1 and $1, respectively
(1)(1)(3)(2)
End of period balance(6)(2)(6)(2)
Net cash flow hedges:
Beginning of period balance(218)(236)(229)(239)
Other comprehensive income, net of tax (expense) of $(1), $(1), $7 and $(2), respectively
4 3 15 6 
End of period balance(214)(233)(214)(233)
Pension and other postretirement benefits:
Beginning of period balance(497)(422)(499)(429)
Other comprehensive income, net of tax expense of $(1), $(4), $(2) and $(6), respectively
3 9 5 16 
End of period balance(494)(413)(494)(413)
Future policy benefits:
Beginning of period balance15 (10)13 (19)
Other comprehensive (loss) income, net of tax expense of $1, $0, $1 and $0, respectively
(3)8 (1)17 
End of period balance12 (2)12 (2)
Foreign currency translation adjustments:
Beginning of period balance(15)(7)(17)(4)
Other comprehensive income (loss), net of tax benefit of $(5), $1, $(3) and $2, respectively
— (5)2 (8)
End of period balance(15)(12)(15)(12)
Total:
Total beginning of period accumulated other comprehensive loss(2,050)(1,246)(2,490)(197)
Total other comprehensive (loss) income, net of tax benefit (expense) of $32, $285, $(72), and $617, respectively
(116)(908)326 (1,962)
Total other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0and $(3) respectively
— 3 (2)8 
Total end of period accumulated other comprehensive loss$(2,166)$(2,151)$(2,166)$(2,151)

-33-

13.     Earnings per Share
The denominator for basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
Denominator for basic earnings per share – weighted-average shares
236.6 240.7 237.0 241.0 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
1.2 2.7 1.7 2.9 
Denominator for diluted earnings per share
237.8 243.4 238.7 243.9 
During the three months ended June 30, 2023 and 2022, weighted-average shares related to certain stock options of 1.0 and 0.5 respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the six months ended June 30, 2023 and 2022, weighted-average shares related to certain stock options of 0.7 and 0.4, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options were anti-dilutive.
During the three and six months ended June 30, 2023, we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2023 through 2025. During the three and six months ended months ended June 30, 2022, we issued approximately 0.0 and 0.5 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2022 through 2024. The contingent restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if and when the contingency is met.
14.     Segment Information
As discussed in Note 1 “Organization”, we are reorganizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business and the products in each of our operating segments, which has resulted in restructurings between some of our operating segments. As a result of these changes, we have changed our reportable segment presentation and its composition to reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources beginning on January 1, 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other. In 2022, we managed and presented our operations through the following four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx and Other. Previously reported information throughout this Form 10-Q has been reclassified to conform to the new presentation.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes services such as formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services.

Our Carelon Services segment is focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic
-34-

conditions. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as corporate expenses not allocated to our other reportable segments.
We define operating revenues to include premium income, product revenue and service fees. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense.
Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, in addition to certain back-office services provided by our international businesses, which are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.
Financial data by reportable segment for the three months ended June 30, 2023 and 2022 is as follows:
Carelon
Health
Benefits		CarelonRxCarelon
Services		TotalCorporate
& Other		EliminationsTotal
Three Months Ended June 30, 2023
Premiums$36,233 $— $429 $429 $— $(73)$36,589 
Product revenue— 4,859 — 4,859 — — 4,859 
Service fees1,767 — 201 201 (39)— 1,929 
Operating revenue - unaffiliated38,000 4,859 630 5,489 (39)(73)43,377 
Operating revenue - affiliated— 3,607 2,811 6,418 326 (6,744)— 
Operating revenue - total$38,000 $8,466 $3,441 $11,907 $287 $(6,817)$43,377 
Operating gain (loss)$2,148 $496 $136 $632 $(152)$— $2,628 
Three Months Ended June 30, 2022
Premiums$32,787 $— $327 $327 $— $(38)$33,076 
Product revenue— 3,568 — 3,568 — — 3,568 
Service fees1,609 — 220 220 9 — 1,838 
Operating revenue - unaffiliated34,396 3,568 547 4,115 9 (38)38,482 
Operating revenue - affiliated— 3,503 2,436 5,939 306 (6,245)— 
Operating revenue - total$34,396 $7,071 $2,983 $10,054 $315 $(6,283)$38,482 
Operating gain (loss) (restated)$1,781 $479 $113 $592 $(27)$— $2,346 
-35-

Financial data by reportable segment for the six months ended June 30, 2023 and 2022 is as follows:
Carelon
Health
Benefits		CarelonRxCarelon
Services		TotalCorporate
& Other		EliminationsTotal
Six Months Ended June 30, 2023
Premiums$71,767 $— $839 $839 $— $(149)$72,457 
Product revenue— 8,881 — 8,881 — — 8,881 
Service fees3,513 — 408 408 16 — 3,937 
Operating revenue - unaffiliated75,280 8,881 1,247 10,128 16 (149)85,275 
Operating revenue - affiliated— 7,609 5,506 13,115 522 (13,637)— 
Operating revenue - total$75,280 $16,490 $6,753 $23,243 $538 $(13,786)$85,275 
Operating gain (loss)$4,307 $1,008 $345 $1,353 (201)— 5,459 
Six Months Ended June 30, 2022
Premiums$65,250 $— $693 $693 $— $(82)$65,861 
Product revenue— 6,869 — 6,869 — — 6,869 
Service fees3,173 — 446 446 19 — 3,638 
Operating revenue - unaffiliated68,423 6,869 1,139 8,008 19 (82)76,368 
Operating revenue - affiliated— 6,885 4,792 11,677 569 (12,246)— 
Operating revenue - total$68,423 $13,754 $5,931 $19,685 $588 $(12,328)$76,368 
Operating gain (loss) (restated)$3,632 $877 $313 $1,190 $(49)$— $4,773 
For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated eliminations.
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
Reportable segments’ operating revenue43,377 $38,482 $85,275 $76,368 
Net investment income416 381 803 741 
Net losses on financial instruments(121)(231)(234)(382)
Total revenues$43,672 $38,632 $85,844 $76,727 
-36-

A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
(Restated)(Restated)
Income before income tax expense$2,441 $2,122 $5,060 $4,428 
Net investment income(416)(381)(803)(741)
Net losses on financial instruments121 231 234 382 
Interest expense261 208 512 409 
Amortization of other intangible assets221 166 456 295 
Reportable segments’ operating gain$2,628 $2,346 $5,459 $4,773 
15.     Leases
We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases have remaining lease terms of 1 year to 11 years.
The information related to our leases is as follows:
Balance Sheet LocationJune 30, 2023December 31, 2022
Operating Leases
Right-of-use assetsOther noncurrent assets$605 $604 
Lease liabilities, currentOther current liabilities178 181 
Lease liabilities, noncurrentOther noncurrent liabilities717 751 
Three Months Ended 
 June 30		Six Months Ended 
 June 30
2023202220232022
Lease Expense
Operating lease expense$32 $33 $57 $65 
Short-term and variable lease expense16 11 29 24 
Sublease income(1)(1)(2)(2)
Total lease expense$47 $43 $84 $87 
Other information
 Operating cash paid for amounts included in the measurement of lease liabilities, operating leases$54 $53 $105 $105 
Right-of-use assets obtained in exchange for new lease liabilities, operating leases$18 $29 $40 $37 
As of June 30, 2023 and December 31, 2022, the weighted average remaining lease term of our operating leases was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 3.28% at June 30, 2023 and 2.98% at December 31, 2022.
-37-

Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:
2023 (excluding the six months ended June 30, 2023)$110 
2024195 
2025162 
2026128 
202793 
Thereafter329 
Total future minimum payments 1,017 
Less imputed interest122 
Total lease liabilities$895 

-38-


ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the accompanying consolidated financial statements and notes, our consolidated financial statements and notes as of and for the year ended December 31, 2022 and the MD&A included in our 2022 Annual Report on Form 10-K. References to the terms “we,” “our,” “us,” or “Elevance Health” used throughout this MD&A refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
Results of operations, cost of care trends, investment yields and other measures for the three and six months ended June 30, 2023 are not necessarily indicative of the results and trends that may be expected for the full year ending December 31, 2023, or any other period.
Overview
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 48 million medical members through our affiliated health plans as of June 30, 2023. We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans, and serve members as the Blue Cross or Blue Cross and Blue Shield licensee in 14 states. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services and other healthcare-related services.
As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans; and
•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Form 10-Q has been reclassified to conform to the new presentation. For additional information, see Note 14, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our 2022 Annual Report on Form 10-K.
-39-

Business Trends
In 2022, we made the decision to modestly expand our participation in the Individual state- or federally-facilitated marketplaces (the “Public Exchange”) for 2023, after also modestly expanding in 2022. As a result, for 2023, we are offering Individual Public Exchange products in 138 of the 143 rating regions in which we operate, in comparison to 122 of 143 rating regions in 2022. Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment and underlying market characteristics. Changes to our business environment are likely to continue as elected officials at the national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and fees. In addition, the continuing growth in our government-sponsored business exposes us to increased regulatory oversight.
Our CarelonRx subsidiary markets and offers pharmacy services to our affiliated health plan customers throughout the country, as well as to customers outside of the health plans we own. Our comprehensive pharmacy services portfolio includes features such as formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services. CarelonRx delegates certain pharmacy services, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.

Pricing Trends: We strive to price our health benefit products consistent with anticipated underlying medical cost trends. We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing competitors and new market entrants. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments. Product pricing remains competitive.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of these services. We work to mitigate these trends through various medical management programs such as care and condition management, program integrity and specialty pharmacy management and utilization management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical technology, new high-cost prescription drugs, provider contracting inflation, labor costs and healthcare provider or member fraud.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our 2022 Annual Report on Form 10-K.
Regulatory Trends and Uncertainties
Under the Consolidated Appropriations Act of 2023 (the “2023 Appropriations Act”), Congress decoupled Medicaid eligibility redeterminations from the Public Health Emergency initially declared in January 2020 relating to COVID-19 (the “PHE”). As a result, states were permitted to begin removing ineligible beneficiaries from their Medicaid programs starting April 1, 2023, and the majority of our Medicaid markets began doing so as of June 30, 2023. As redeterminations have resumed, we have experienced a decline in our Medicaid membership. Over time, we expect growth in our commercial plans, including through the Public Exchanges, as members who do not qualify for redetermination exit the Medicaid program in our 14 commercial states and seek coverage elsewhere. On May 11, 2023, the PHE ended in accordance with the Biden Administration’s January 30, 2023 announcement. Some states such as California have extended their COVID-19 related policies beyond the PHE.
-40-

The Inflation Reduction Act of 2022, which was signed into law in August 2022, contains a variety of provisions that impact our business including an extension of the American Rescue Plan Act of 2021’s enhanced Premium Tax Credits (“PTC”) through 2025; imposing a new corporate alternative minimum tax; providing a one percent excise tax on repurchases of stock made after December 31, 2022; allowing Centers for Medicare and Medicaid Services (“CMS”) to negotiate prices on a limited set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts B and D; redesigning of the Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices increase beyond inflation; and delaying the implementation of the Trump Administration Medicare drug rebate rule until 2032. The extension of the enhanced PTC has allowed for growth in Individual exchange market enrollment as Medicaid eligibility redeterminations have resumed, supporting continuity of coverage for more people.
The Consolidated Appropriations Act of 2021 (the “Appropriations Act”) has impacted and in the future may have a material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health parity reporting, and reporting on pharmacy benefits and drug costs. The requirements of the Appropriations Act applicable to us have varying effective dates, some of which were effective in December 2021 and others that have been extended into 2023 since the enactment of the Appropriations Act.
The health plan price transparency regulations issued by the U.S. Departments of Health and Human Services, Labor and Treasury required us in 2022 to begin disclosing detailed pricing information regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we are now required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for 500 covered healthcare items and services, including prescription drugs. In 2024, this requirement will expand to all items and services.
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”), continues to impact our business and results of operations, including pricing, minimum medical loss ratios and the geographies in which our products are available. We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving methodology for ratings and quality bonus payments. CMS also frequently proposes changes to its program that audits data submitted under the risk adjustment programs in ways that could increase financial recoveries from plans.
For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business – Regulation”, Part I, Item 1A, “Risk Factors”, and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2022 Annual Report on Form 10-K.
Other Significant Items
Business and Operational Matters
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected to close by the end of the first quarter of 2024 and is subject to standard closing conditions and customary approvals.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health solutions to BCBSLA’s members. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition
-41-

aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve.
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes.
For additional information, see Note 3, “Business Acquisitions and Divestitures,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Litigation Matters
In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the “Court”) captioned In re Blue Cross Blue Shield Antitrust Litigation (“BCBSA Litigation”), the BCBSA and Blue Cross and/or Blue Shield licensees, including us (the “Blue plans”) previously approved a settlement agreement and release with the plaintiffs representing a putative nationwide class of health plan subscribers (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. Generally, the lawsuits in the BCBSA Litigation challenge elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Subscriber Settlement Agreement applies only to the subscriber class. The defendants continue to contest the consolidated cases brought by the provider plaintiffs.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which amount was accrued in 2020. Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit, which has scheduled oral argument on the appeals for September 2023. In the event all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement. For additional information regarding the BCBSA Litigation, see Note 10, “Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Selected Operating Performance
For the twelve months ended June 30, 2023, total medical membership increased by 0.9 million, or 2.0%. Our membership increase was primarily driven by growth in our Medicaid business, increased BlueCard sales and growth in both our Individual Public Exchange and Medicare Advantage products, partially offset by attrition in our Employer Group risk-based business.
Operating revenue for the three months ended June 30, 2023 was $43,377, an increase of $4,895, or 12.7%, from the three months ended June 30, 2022. Operating revenue for the six months ended June 30, 2023 was $85,275, an increase of $8,907, or 11.7%, from the six months ended June 30, 2022. This increase in operating revenue for both periods was primarily driven by higher premium revenues due to premium rate increases in our Health Benefits business to more accurately reflect cost of care and membership growth in our Medicaid and Medicare Advantage businesses. The increase in operating revenue was further attributable to growth in CarelonRx pharmacy product revenue driven by growth in external pharmacy members and the acquisition of BioPlus in the first quarter of 2023.
Net income for the three months ended June 30, 2023 was $1,856, an increase of $222, or 13.6%, from the three months ended June 30, 2022. Net income for the six months ended June 30, 2023 was $3,860, an increase of $447, or 13.1%, from the six months ended June 30, 2022. The increase in net income for both periods was primarily due to operating gain increases in our Health Benefits, CarelonRx and Carelon Services business segments, lower net losses on financial instruments and higher net investment income. These increases were partially offset by higher income taxes, additional amortization of other intangible assets and increased interest expense.
-42-

Our fully-diluted shareholders’ earnings per share (“EPS”) was $7.79 for the three months ended June 30, 2023, which represented a 15.8% increase from EPS of $6.73 for the three months ended June 30, 2022. Our fully-diluted EPS was $16.10 for the six months ended June 30, 2023, which represented a 14.6% increase from fully-diluted EPS of $14.05 for the six months ended June 30, 2022. The increase in EPS for both periods resulted primarily from higher net income.
Operating cash flow for the six months ended June 30, 2023 and 2022 was $8,419 and $4,993, respectively. The increase was primarily due to the timing of CMS payments received in the current year and higher net income for the six months ended June 30, 2023, partially offset by the timing of working capital changes.

Membership and Other Metrics
The following table presents our medical membership by customer type as of June 30, 2023 and 2022. Also included below are other membership by product and other metrics. The membership data and other metrics presented are unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the period. The CarelonRx Quarterly Adjusted Scripts metric represents adjusted script volume based on the number of days a prescription covers. On an adjusted basis, one 90-day script counts the same as three 30-day scripts. The Carelon Services Consumers Served metric represents the number of consumers receiving one or more healthcare-related services from Carelon Services who are members of our affiliated health plans as well as those who are members of non-affiliated health plans. For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2022 Annual Report on Form 10-K.
  
June 30  
20232022Change% Change
Medical Membership (in thousands)
Individual949 803 14618.2 %
Employer Group Risk-Based3,765 4,020 (255)(6.3)%
Commercial Risk-Based4,714 4,823 (109)(2.3)%
BlueCard®
6,737 6,445 2924.5 %
Employer Group Fee-Based20,160 20,086 740.4 %
Commercial Fee-Based26,897 26,531 3661.4 %
Medicare Advantage2,059 1,946 1135.8 %
Medicare Supplement926 942 (16)(1.7)%
Total Medicare2,985 2,888 973.4 %
Medicaid11,759 11,181 5785.2 %
Federal Employees Health Benefits (“FEHB”)1,634 1,628 60.4 %
Total Medical Membership47,989 47,051 9382.0 %
Other Membership (in thousands)
Life and Disability Members4,686 4,779 (93)(1.9)%
Dental Members6,728 6,620 108 1.6 %
Dental Administration Members1,694 1,589 105 6.6 %
Vision Members9,850 9,385 465 5.0 %
Medicare Part D Standalone Members263 276 (13)(4.7)%
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts77.4 76.4 1.0 1.3 %
Carelon Services Consumers Served103.6 104.7 (1.1)(1.1)%
-43-

Medical Membership
Medical membership increased primarily due to growth in our Medicaid business, increased BlueCard sales and growth in both our Individual Public Exchange and Medicare Advantage products, partially offset by attrition in our Employer Group risk-based business.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to our health business. Life and disability membership decreased primarily due to lapses associated with our Employer Group risk-based accounts. Dental membership increased primarily due to greater penetration in our Employer Group risk-based accounts and increases in our FEHB program. Dental administration membership increased primarily due to favorable in-group-change with other BCBSA plans associated with the FEHB program. Vision membership increased due to sales exceeding lapses in our Employer Group risk-based accounts and increases associated with Medicare Advantage plans.
Other Metrics
CarelonRx quarterly adjusted scripts increased due to growth in our standalone pharmacy customers.
-44-

Consolidated Results of Operations
Our consolidated summarized results of operations and other financial information for the three and six months ended June 30, 2023 and 2022 are as follows: 
Three Months Ended 
 June 30		Six Months Ended 
 June 30		Change
Three Months Ended 
 June 30		Six Months Ended 
 June 30
2023 vs. 20222023 vs. 2022
2023202220232022$%$%
(Restated)(Restated)
Total operating revenue$43,377$38,482$85,275$76,368$4,895 12.7 %$8,907 11.7 %
Net investment income41638180374135 9.2 %62 8.4 %
Net losses on financial instruments(121)(231)(234)(382)110 (47.6)%148 (38.7)%
Total revenues43,67238,63285,84476,7275,040 13.0 %9,117 11.9 %
Benefit expense31,60428,79562,39057,0262,809 9.8 %5,364 9.4 %
Cost of products sold4,3273,0697,8085,9521,258 41.0 %1,856 31.2 %
Operating expense
4,8184,2729,6188,617546 12.8 %1,001 11.6 %
Other expense1 
482374968704108 28.9 %264 37.5 %
Total expenses41,23136,51080,78472,2994,721 12.9 %8,485 11.7 %
Income before income tax expense2,4412,1225,0604,428319 15.0 %632 14.3 %
Income tax expense5854881,2001,01597 19.9 %185 18.2 %
Net income$1,856$1,634$3,860$3,413$222 13.6 %$447 13.1 %
Net (income) loss attributable to noncontrolling interests(3)3(18)13(6)NM(31)NM
Shareholders’ net income$1,853$1,637$3,842$3,426$216 13.2 %$416 12.1 %
Average diluted shares outstanding237.8243.4238.7243.9(5.6)(2.3)%(5.2)(2.1)%
Diluted shareholders’ net income per share$7.79$6.73$16.10$14.05$1.06 15.8 %$2.05 14.6 %
Effective tax rate24.0 %23.0 %23.7 %22.9 %
100 bp3
80 bp3
Benefit expense ratio2
86.4 %87.1 %86.1 %86.6 %
(70) bp3
(50) bp3
Operating expense ratio4
11.1 %11.1 %11.3 %11.3 %
0 bp3
0 bp3
Income before income tax expense as a percentage of total revenues5.6 %5.5 %5.9 %5.8 %
10 bp3
10 bp3
Shareholders’ net income as a percentage of total revenues4.2 %4.2 %4.5 %4.4 %
0 bp3
10 bp3
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM    Not meaningful.
1    Includes interest expense and amortization of other intangible assets.
2    Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the three months ended June 30, 2023 and 2022 were $36,589 and $33,076, respectively. Premiums for the six months ended June 30, 2023 and 2022 were $72,457 and $65,861, respectively.
3    bp = basis point; one hundred basis points = 1%.
4    Operating expense ratio represents operating expense as a percentage of total operating revenue.
Three Months Ended June 30, 2023 Compared to the Three Months Ended June 30, 2022
Total operating revenue increased primarily as a result of higher premium revenues due to premium rate increases in our Health Benefits business to more accurately reflect cost of care and membership growth in our Medicaid and Medicare Advantage businesses. The increase in operating revenue was further attributable to growth in CarelonRx pharmacy product revenue driven by growth in external pharmacy members and the acquisition of BioPlus in the first quarter of 2023.
Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by reduced investment income from alternative investments.
-45-

Net losses on financial instruments decreased primarily due to lower mark-to-market losses on equity securities still held at the period end date and reduced net losses on the sale of fixed maturity securities, partially offset by lower net gains on other invested assets.
Benefit expense increased primarily due to medical cost trends as well as healthcare costs associated with membership growth.
Our benefit expense ratio decreased, driven by premium rate increases to more accurately reflect cost of care.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated customers. Cost of products sold increased as the corresponding pharmacy product revenues increased.
Operating expense increased primarily due to increased costs to support growth.
Our operating expense ratio remained unchanged primarily due to continued expense leverage associated with our growth in operating revenue, offset by increased spend to support growth.
Other expense increased primarily due to additional amortization of other intangible assets as well as increased interest expense.
Our effective income tax rate increased in 2023 primarily due to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits.
Our shareholders’ net income as a percentage of total revenues remained constant in 2023 as compared to 2022 as a result of all factors discussed above.
Six Months Ended June 30, 2023 Compared to the Six Months Ended June 30, 2022
Total operating revenue increased primarily as a result of higher premium revenues due to premium rate increases in our Health Benefits business to more accurately reflect cost of care and membership growth in our Medicaid and Medicare Advantage businesses. The increase in operating revenue was further attributable to growth in CarelonRx pharmacy product revenue driven by growth in external pharmacy members and the acquisition of BioPlus in the first quarter of 2023.
Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by reduced investment income from alternative investments.
Net losses on financial instruments decreased primarily due to lower mark-to-market losses on equity securities still held at the period end date and reduced net losses on the sale of fixed maturity securities, partially offset by lower net gains on other invested assets.
Benefit expense increased primarily due to medical cost trends as well as healthcare costs associated with membership growth.
Our benefit expense ratio decreased, driven by premium rate increases to more accurately reflect cost of care.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated customers. Cost of products sold increased as the corresponding pharmacy product revenues increased.
Operating expense increased primarily due to increased costs to support growth.
Our operating expense ratio remained unchanged primarily due to continued expense leverage associated with our growth in operating revenue, offset by increased spend to support growth.
Other expense increased primarily due to additional amortization of other intangible assets as well as increased interest expense.
Our effective income tax rate increased in 2023 primarily due to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits.
-46-

Our shareholders’ net income as a percentage of total revenues increased in 2023 as compared to 2022 as a result of all factors discussed above.
Reportable Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted accounting principles (“GAAP”). We also calculate operating gain and operating margin to further aid investors in understanding and analyzing our core operating results and comparing them among periods. We define operating revenue as premium income, product revenue and service fees. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net losses on financial instruments, interest expense, amortization of other intangible assets or income taxes, as these items are managed in our corporate shared service environment and are not the responsibility of operating segment management. Operating margin is calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, shareholders’ net income or EPS prepared in accordance with GAAP, and may not be comparable to similarly titled measures reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total revenue included in the consolidated statements of income and a reconciliation of income before income tax expense to reportable segments’ operating gain, see Note 14, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
As discussed in Note 1 “Organization,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q, we are reorganizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and our reportable segment presentation and its composition as of January 1, 2023 reflects changes associated with this evolution and new branding strategy. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Form 10-Q has been reclassified to conform to the new presentation. For additional information, see Note 14, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-47-

The following table presents a summary of the reportable segment financial information for the three and six months ended June 30, 2023 and 2022:
 Six Months Ended 
 June 30		Change
 Three Months Ended 
 June 30		Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023 vs. 20222023 vs. 2022
2023202220232022$%$%
Operating Revenue
Health Benefits$38,000$34,396$75,280$68,423$3,604 10.5 %$6,857 10.0 %
CarelonRx8,4667,07116,49013,7541,395 19.7 %2,736 19.9 %
Carelon Services3,4412,9836,7535,931458 15.4 %822 13.9 %
Corporate & Other287315538588(28)(8.9)%(50)(8.5)%
Eliminations (6,817)(6,283)(13,786)(12,328)(534)8.5 %(1,458)11.8 %
Total operating revenue$43,377$38,482$85,275$76,368$4,895 12.7 %$8,907 11.7 %
Operating Gain (Loss)(Restated)(Restated)
Health Benefits$2,148$1,781$4,307$3,632$367 20.6 %$675 18.6 %
CarelonRx4964791,00887717 3.5 %131 14.9 %
Carelon Services13611334531323 20.4 %32 10.2 %
Corporate & Other(152)(27)(201)(49)(125)463 %(152)310 %
Operating Margin
Health Benefits5.7 %5.2 %5.7 %5.3 %50 bp40 bp
CarelonRx5.9 %6.8 %6.1 %6.4 %(100) bp(30) bp
Carelon Services4.0 %3.8 %5.1 %5.3 %20 bp(20) bp
bp = basis point; one hundred basis points = 1%.
Three Months Ended June 30, 2023 Compared to the Three Months Ended June 30, 2022
Health Benefits
Operating revenue increased primarily due to higher premium revenues due to premium rate increases to more accurately reflect cost of care and membership growth in our Medicaid and Medicare Advantage businesses.
Operating gain increased primarily due to higher premium revenues due to premium rate increases to more accurately reflect cost of care and membership growth in our Medicaid business, partially offset by a charge associated with a court ruling impacting health plans in a certain state related to prior years’ COVID-19 costs.
CarelonRx
Operating revenue and operating gain increased primarily as a result of growth in external pharmacy members and the acquisition of BioPlus in the first quarter of 2023, partially offset by the impact of a favorable out-of-period adjustment in the second quarter of 2022 that did not recur in the second quarter of 2023.
Carelon Services
Operating revenue increased primarily due to higher revenue for post-acute care services performed for our Medicare business and behavioral health services performed for our Medicaid business.
The increase in operating gain was primarily driven by improved performance in our medical management businesses and the expansion of our post-acute care services, partially offset by medical cost trends.
-48-

Corporate & Other
Operating revenue decreased primarily due to an unfavorable out-of-period adjustment in our international operations.
Operating loss increased primarily due to an increase in unallocated corporate expenses.
Six Months Ended June 30, 2023 Compared to the Six Months Ended June 30, 2022
Health Benefits
Operating revenue increased primarily due to premium rate increases to more accurately reflect cost of care and membership growth in our Medicaid and Medicare Advantage businesses.
Operating gain increased primarily due to premium rate increases to more accurately reflect cost of care and membership growth in our Medicaid businesses, partially offset by a charge associated with a court ruling impacting health plans in a certain state related to prior years’ COVID-19 costs.
CarelonRx
Operating revenue and operating gain increased primarily as a result of growth in external pharmacy members and the acquisition of BioPlus in the first quarter of 2023, partially offset by the impact of a favorable out-of-period adjustment in the second quarter of 2022 that did not recur in the second quarter of 2023.
Carelon Services
Operating revenue increased primarily due to higher revenue for post-acute care services performed for our Medicare business and behavioral health services performed for our Medicaid business.
The increase in operating gain was primarily driven by the expansion of our post-acute care services and improved performance in our medical management businesses, partially offset by medical cost trends.
Corporate & Other
Operating revenue decreased primarily due to lower affiliated revenues in our international operations.
Operating loss increased primarily due to an increase in unallocated corporate expenses.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes, goodwill and other intangible assets, investments and retirement benefits. Our accounting policies related to these items are discussed in our 2022 Annual Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,” to our audited consolidated financial statements as of and for the year ended December 31, 2022, as well as in the “Critical Accounting Policies and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” As of June 30, 2023, our critical accounting policies and estimates have not changed from those described in our 2022 Annual Report on Form 10-K.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. Our accounting policies related to medical claims payable are discussed in the references cited above. As of June 30, 2023, our critical accounting policies and estimates related to medical claims payable have not changed from those described in our 2022 Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical claims payable for the six months ended June 30, 2023 and 2022, see Note 8, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-49-

The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the six months ended June 30, 2023 and 2022, which are the trend and completion factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.
Favorable Developments by 
Changes in Key Assumptions
Six Months Ended 
 June 30
20232022
Assumed trend factors$709 $967 
Assumed completion factors403 5 
Total$1,112 $972 
The favorable development recognized in the six months ended June 30, 2023 and 2022 resulted primarily from trend factors in late 2022 and late 2021, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter part of 2022 developing faster than expected also contributed to the favorable development for the six months ended June 30, 2023.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 78.7% and 76.9% for the six months ended June 30, 2023 and 2022, respectively. This ratio serves as an indicator of claims processing speed whereby speed for claims payments was slightly higher during the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims payable less prior year redundancies in the current period in order to demonstrate the development of prior year reserves. For the six months ended June 30, 2023, this metric was 7.8%, largely driven by favorable trend factor development at the end of 2022 as well as favorable completion factor development from 2022. For the six months ended June 30, 2022, this metric was 7.9%, largely driven by favorable trend factor development at the end of 2021.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims and the consistency in our methodology. For the six months ended June 30, 2023, this metric was 1.0%, which was calculated using the redundancy of $1,112. For the six months ended June 30, 2022, the comparable metric was also 1.0%, which was calculated using the redundancy of $972. We believe these metrics demonstrate an appropriate level of reserve conservatism.
New Accounting Pronouncements
We adopted accounting standard amendments on long-duration insurance accounting which became effective for us on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our adoption as required by the new standard. For more information regarding this new accounting pronouncement that was adopted, see the “Recently Adopted Accounting Guidance” sections of Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily from premiums, product revenue, service fees, investment income, proceeds from the sale or maturity of our investment securities, proceeds from borrowings and proceeds from the issuance of common stock under our employee stock plans. Cash disbursements result mainly from claims payments, operating expenses, taxes,
-50-

purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included in the “Liquidity and Capital Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2022 Annual Report on Form 10-K.
For additional information regarding our sources and uses of capital during the three and six months ended June 30, 2023, see Note 5, “Derivative Financial Instruments,” Note 9, “Debt,” and Note 11, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Liquidity
A summary of our major sources and uses of cash and cash equivalents for the six months ended June 30, 2023 and 2022 is as follows:
 Six Months Ended 
 June 30
 20232022Change
Sources of Cash:
Net cash provided by operating activities$8,419 $4,993 $3,426 
Issuances of short- and long-term debt, net of repayments666 507 159 
Changes in securities lending payable145 — 145 
Proceeds from issuance of common stock under employee stock plans81 116 (35)
Other sources of cash, net— 681 (681)
Total sources of cash9,311 6,297 3,014 
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and redemptions(1,653)(1,766)113 
Purchases of subsidiaries, net of cash acquired(1,651)(609)(1,042)
Repurchase and retirement of common stock(1,268)(1,169)(99)
Purchases of property and equipment(651)(549)(102)
Cash dividends(701)(618)(83)
Changes in securities lending payable(145)— (145)
Other uses of cash, net(640)— (640)
Total uses of cash(6,709)(4,711)(1,998)
Effect of foreign exchange rates on cash and cash equivalents2 (10)12 
Net increase in cash and cash equivalents$2,604 $1,576 $1,028 
The increase in net cash provided by operating activities was primarily due to the timing of CMS payments received in the current year and higher net income for the six months ended June 30, 2023, partially offset by the timing of working capital changes.
Other significant changes in sources or uses of cash year-over-year included a decline in bank overdrafts outstanding (included in Other uses and sources of cash, net), higher amounts for purchases of subsidiaries, net of cash acquired and an increase in the purchase of property and equipment. These additional uses of cash were partially offset by increased issuances of short- and long-term debt, net of repayments, and reduced purchases of investments, net of proceeds from sales, maturities, calls and redemptions.
-51-

We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity securities of $39,059 at June 30, 2023. Since December 31, 2022, total cash, cash equivalents and investments in fixed maturity and equity securities increased by $4,015, primarily due to cash generated from operations and an increase in the market value of our fixed maturity securities. These increases were partially offset by cash used for the purchase of subsidiaries, cash used for common stock repurchases, dividends paid to shareholders and the purchase of property and equipment.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our subsidiaries.
At June 30, 2023, we held $1,043 of cash, cash equivalents and investments at the parent company, which are available for general corporate use, including investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.
Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more information on our debt, including redemptions and issuances, see Note 9, “Debt,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our consolidated balance sheets included in Part I, Item 1 of this Form 10-Q. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders’ equity. Total debt is the sum of short-term borrowings, current portion of long-term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated debt-to-capital ratio was 39.6% and 39.9% as of June 30, 2023 and December 31, 2022, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Capital Resources
We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries, the financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides for a credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. We had no amounts outstanding under the 5-Year Facility as of June 30, 2023 or December 31, 2022. As of June 30, 2023, we were in compliance with all of the debt covenants under the 5-Year Facility.
-52-

Through certain subsidiaries, we had previously entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provided combined credit up to $200. As of June 30, 2023, the Subsidiary Credit Facilities have been terminated.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash on hand and/or our 5-Year Facility to redeem any outstanding commercial paper upon maturity. At June 30, 2023 and December 31, 2022, we had $90 and $0, respectively, outstanding under our commercial paper program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.
While there is no assurance in the current economic environment, we believe the lenders participating in our 5-Year Facility, if market conditions allow, would be willing to provide financing in accordance with their legal obligations.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $175 and $265 of outstanding short-term borrowings from the FHLBs at June 30, 2023 and December 31, 2022, respectively.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
For additional information regarding our sources and uses of capital at June 30, 2023, see Note 4, “Investments,” Note 5, “Derivative Financial Instruments,” Note 9, “Debt,” and Note 11, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and health maintenance organizations largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital (RBC) for Health Organizations Model Act (the “RBC Model Act”). These RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual insurance company’s business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of December 31, 2022, which was the most recent date for which reporting was required, were in excess of all applicable mandatory RBC requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our California subsidiaries. For additional information, see Note 22, “Statutory Information,” in our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
Future Sources and Uses of Liquidity
We believe that cash on hand, future operating cash receipts, investments and funds available under our commercial paper program, our 5-Year Facility and borrowings available from the FHLBs will be adequate to fund our expected cash disbursements over the next twelve months.
There have been no material changes to our long-term liquidity requirements as disclosed in our 2022 Annual Report on Form 10-K. For additional updates regarding our estimated long-term liquidity requirements, see Note 5, “Derivative Financial Instruments,” Note 9, “Debt,” and the “Other Contingencies” and “Contractual Obligations and Commitments” sections of Note 10 “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q. We believe that funds from future operating cash flows, cash and investments and funds available
-53-

under our 5-Year Facility and/or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.
-54-

FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including healthcare laws and regulations, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to comply with any privacy or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated with providing pharmacy, healthcare and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.
-55-

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our 2022 Annual Report on Form 10-K. There have been no material changes to any of these risks since December 31, 2022.

ITEM 4.    CONTROLS AND PROCEDURES
We carried out an evaluation as of June 30, 2023, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
There have been no changes in our internal control over financial reporting that occurred during the six months ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS
For information regarding legal proceedings at June 30, 2023, see the “Litigation and Regulatory Proceedings,” and “Other Contingencies” sections of Note 10, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q, which information is incorporated herein by reference.

ITEM 1A.    RISK FACTORS
There have been no material changes to the risk factors disclosed in our 2022 Annual Report on Form 10-K.
-56-

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Period
Total Number
of Shares
Purchased1 
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)    
April 1, 2023 to April 30, 2023393,124 $468.66 392,648 $6,070 
May 1, 2023 to May 31, 2023533,173 457.79 531,807 5,827 
June 1, 2023 to June 30, 2023489,418 447.84 487,719 5,608 
1,415,715 1,412,174 
1    Total number of shares purchased includes 3,541 shares delivered to or withheld by us in connection with employee payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated changes in equity are shown net of these shares purchased.
2    Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of Directors evaluates periodically. During the three months ended June 30, 2023, we repurchased 1,412,174 shares at a total cost of $646 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The most recent authorized increase to the program was $5,000 on January 24, 2023 by our Audit Committee, pursuant to authorization granted by the Board of Directors. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time.

ITEM 3.    DEFAULTS UPON SENIOR SECURITIES
None.

ITEM 4.    MINE SAFETY DISCLOSURES
None.

ITEM 5.    OTHER INFORMATION

Rule 10b5-1 Trading Plans
Ramiro Peru, a member of our Board of Directors, adopted a stock trading plan on May 3, 2023, pursuant to which he may sell up to 753 shares of the Company’s common stock prior to April 22, 2024. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in our securities.

-57-

ITEM 6.    EXHIBITS
Exhibit
Number
 Exhibit
3.1 
3.2 
4.7 Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
10.7
31.1 
31.2 
32.1 
32.2 
101 The following material from Elevance Health, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Changes in Equity; and (vi) Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104 Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
*Indicates management contracts or compensatory plans or arrangements.

-58-

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
ELEVANCE HEALTH, INC.
Registrant
July 19, 2023By: 
/S/  JOHN E. GALLINA
 John E. Gallina
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
July 19, 2023By: 
/S/  RONALD W. PENCZEK
 Ronald W. Penczek
Chief Accounting Officer and Controller
(Principal Accounting Officer)
-59-
 EX-10.7 2 exhibit107directorcompensa.htm EX-10.7 Document
Exhibit 10.7
ELEVANCE HEALTH, INC.
BOARD OF DIRECTORS COMPENSATION PROGRAM
(AS AMENDED EFFECTIVE MAY 10, 2023)

Directors who are employed by Elevance Health, Inc. or its subsidiaries do not receive compensation for serving as Directors. However, Directors who are not employees of Elevance Health, Inc. or its subsidiaries are entitled to receive the following compensation:

CASH COMPENSATION—Retainers

Annual Board Retainer:

• $125,000 for all Directors paid quarterly in advance (in four equal installments of $31,250) on January 1, April 1, July 1 and October 1.

Annual Retainer for Non-Executive Chair of Board:

• $260,000 for the Non-Executive Chair of the Board, if any, paid quarterly in advance (in four equal installments of $65,000) on January 1, April 1, July 1 and October 1.

Annual Retainer for Lead Director:

•$50,000 for the Lead Director of the Board, if any, paid quarterly in advance (in four equal installments of $12,500) on January 1, April 1, July 1 and October 1.

Annual Retainer for Committee Chairs:

• $30,000 for the Chair of each of the Committees of the Board of Directors paid quarterly in advance (in four equal installments of $7,500) on January 1, April 1, July 1 and October 1.

If a Director is elected to the Board or becomes the Non-Executive Chair or Lead Director of the Board or a Committee Chair on a date other than the first day of a calendar quarter, the retainers described above will be pro-rated based on days served in the applicable position.

STOCK COMPENSATION

Annual Full Value Share Grant:

Each Director will receive on the date of the Elevance Health, Inc. annual meeting of shareholders, subject to the deferral described below, an annual grant of a number of shares equal in value to $210,000 (the “Annual Full Value Share Grant”). The exact number of shares for each Annual Full Value Share Grant will be calculated using the following formula:

[$210,000] ÷ [the closing price of the Elevance Health, Inc. common stock as reported on the New York Stock Exchange on the date of the annual meeting of shareholders] = Number of shares of the Annual Full Value Share Grant.

Partial Value Share Grants:

Any Director who joins the Board of Directors after the date of the Elevance Health, Inc. annual meeting of shareholders (the “Effective Date”) shall receive a pro-rated share grant (the “Partial Value Share Grant”) on the first business day of the month following the Effective Date (unless the Effective Date is on the first business day of a month, in which case, the grant shall be made on the Effective Date). The Partial Value Share Grant shall be subject
1
Exhibit 10.7
to the deferral described below. The exact number of shares of the Partial Value Share Grant will be calculated using the following formula:

[$210,000 x (the number of days from the Effective Date to the first annual meeting of shareholders after the Effective Date ÷ 365)] ÷ the closing price of the Elevance Health, Inc. common stock as reported on the New York Stock Exchange on the first business day of the month following the Effective Date (unless the Effective Date is on the first business day of a month, in which case, the closing price on the Effective Date shall be used) = Number of shares of the Partial Value Share Grant.

Deferral of Share Grants:

Share grants will be deferred for a minimum period of five years from the (1) grant date for Annual Full Value Share Grants and (2) the date of the annual meeting of shareholders that immediately precedes the Effective Date for Partial Value Share Grants (each a “Deferral Period”) in accordance with the terms of the Director Deferred Compensation Plan. Such grants shall not be distributed to the Directors until the earlier of the expiration of the Deferral Period or the date on which a Director ceases to be a member of the Board of Directors.

Director Ownership Guidelines:

Each Director shall have the obligation to own at least $625,000 of Elevance Health, Inc. common stock (including deferred shares and phantom stock, but not options) commencing on the fifth anniversary of the date such Director became a member of the Board of Directors.

MISCELLANEOUS

Annual Physical Exam:

Elevance Health, Inc. will pay the cost of an annual physical examination for each Director.

Expenses:

Elevance Health, Inc. will reimburse each Director for all travel, lodging and other expenses incurred in connection with attendance at and/or participation in any and all Board of Directors and Committee meetings and related matters.


2
 EX-31.1 3 exhibit311-20230630q22023.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1.I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
July 19, 2023 /s/ GAIL K. BOUDREAUX
 President and Chief Executive Officer


 EX-31.2 4 exhibit312-20230630q22023.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John E. Gallina, certify that:
1.I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
July 19, 2023 /s/ JOHN E. GALLINA
      Executive Vice President and
     Chief Financial Officer


 EX-32.1 5 exhibit321-20230630q22023.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gail K. Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
July 19, 2023


 EX-32.2 6 exhibit322-20230630q22023.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John E. Gallina, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
July 19, 2023


 EX-101.SCH 7 elv-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document And Entity Information Document link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements Of Income link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements Of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis Of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Medical Claims Payable link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Medical Claims Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Capital Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Investments (Current Equity Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Investments (Net Investment Gains/Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Investments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Derivative Financial Instruments (Financial Statement Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - Fair Value (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details) link:presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 9954727 - Disclosure - Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) link:presentationLink link:calculationLink link:definitionLink 9954728 - Disclosure - Medical Claims Payable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954729 - Disclosure - Debt (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954730 - Disclosure - Commitments And Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954731 - Disclosure - Capital Stock (Summary of Cash Dividend Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 9954732 - Disclosure - Capital Stock (Summary of Share Repurchases) (Details) link:presentationLink link:calculationLink link:definitionLink 9954733 - Disclosure - Capital Stock (Summary of Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 9954734 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 9954735 - Disclosure - Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 9954736 - Disclosure - Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) link:presentationLink link:calculationLink link:definitionLink 9954737 - Disclosure - Capital Stock (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954738 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954739 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 9954740 - Disclosure - Earnings Per Share (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954741 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954742 - Disclosure - Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) link:presentationLink link:calculationLink link:definitionLink 9954743 - Disclosure - Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) link:presentationLink link:calculationLink link:definitionLink 9954744 - Disclosure - Segment Information Segment Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954745 - Disclosure - Leases (Lease and Other Information) (Details) link:presentationLink link:calculationLink link:definitionLink 9954746 - Disclosure - Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954747 - Disclosure - Leases (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 elv-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 elv-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 elv-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Net (income) loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Proceeds from Sale of Available-for-sale Securities Proceeds from Sale of Debt Securities, Available-for-Sale Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Award Type [Domain] Award Type [Domain] Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Nonvested at Beginning Balance, Restricted Stock Shares and Units Nonvested at Ending Balance, Restricted Stock Shares and Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Repayments of Short-term Debt Repayments of Short-Term Debt Debt Debt Disclosure [Text Block] Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items] Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Other invested assets Other invested assets Other Long-Term Investments Revolving Credit Facility [Member] Revolving Credit Facility [Member] Current and Long-Term Investments, Available-For-Sale Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Commercial paper authorized Commercial Paper Maximum Borrowing Capacity Commercial Paper, Maximum Borrowing Capacity Effect of foreign exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations AOCI, Defined Benefit Plan, Beginning Balance AOCI, Defined Benefit Plan, Ending Balance Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Deferred tax liabilities, net Deferred Income Tax Liabilities, Net Senior Unsecured Notes [Member] Senior Unsecured Notes [Member] Senior Unsecured Notes [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Exercisable at end of period, Weighted-Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Transfers out of Level III Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Mortgage-backed securities, Estimated Fair Value Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value Fixed Maturities [Member] Fixed Maturities [Member] Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Expense) Benefit Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Corporate Securities [Member] Corporate Debt Securities [Member] Purchases of investments Payments to Acquire Investments Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Commitments and contingencies – Note 10 Commitments and Contingencies Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Exercisable at end of period, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Operating lease payments, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Long-term purchase commitment, amount Long-Term Purchase Commitment, Amount Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract] Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract] Capital Stock Equity [Text Block] Income Taxes Income Tax Disclosure [Text Block] Medical claims payable Gross medical claims payable, end of period Liability for Claims and Claims Adjustment Expense Equity Securities Equity Securities Fair value of investments in equity securities. Number of Medical Members Number Of Medical Members Served Number of medical members served Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax Quarterly dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Self-funded receivables Self-Funded Receivables, Net The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts. Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense -- None. No documentation exists for this element. -- Total liabilities Financial Liabilities Fair Value Disclosure Revenue Recognition Revenue [Policy Text Block] Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Customer [Axis] Customer [Axis] Change in unrealized gains (losses) included in net income related to assets still held Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) Current Liabilities: Liabilities, Current [Abstract] Short-duration Insurance Contracts, Claim Year [Axis] Short-Duration Insurance Contracts, Accident Year [Axis] Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted-Average Grant Date Fair Value Per Share [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Proceeds originally received at time of divestiture Proceeds from Divestiture of Businesses Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Forfeited or expired, Weighted-Average Option Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Diluted net income per share Earnings Per Share, Diluted Hedging Relationship [Axis] Hedging Relationship [Axis] Number of counties in the Kansas City area the Company does not serve Number Of Counties In State Of Kansas Company Does Not Serve Number Of Counties In The State Of Kansas Company Does Not Serve Level III [Member] Fair Value, Inputs, Level 3 [Member] Subsidiary Credit Facilities [Member] Line of Credit [Member] Claims Development [Line Items] Claims Development [Line Items] Investment [Table] Schedule of Gain (Loss) on Securities [Table] Outstanding at beginning of period, Number of Shares Outstanding at end of period, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Litigation Case [Axis] Litigation Case [Axis] Due after five years through ten years, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Issuance of common stock under employee stock plans, net of related tax benefits Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol United States Government Securities [Member] US Government Agencies Debt Securities [Member] Granted, Weighted-Average Option Price per Share Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Options granted during the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Shareholders’ net income Shareholders' net income Net Income (Loss) Total current liabilities Liabilities, Current Integra Managed Care [Member] Integra Managed Care [Member] Integra Managed Care Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Due after one year through five years, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Leases Lessee, Operating Leases [Text Block] Gross medical claims payable, beginning of period Gross medical claims payable, end of period Short Duration Contract Liability For Claims Adjustment Expense The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration. Commercial paper Commercial Paper Damages for Pharmacy Pricing [Member] Pharmacy pricing [Member] Pharmacy pricing [Member] Liabilities and shareholders' equity Liabilities and Equity [Abstract] Fixed maturities, amortized cost, current Debt Securities, Available-for-Sale, Amortized Cost, Current Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Shareholders' equity Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Exercised, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Receivables, net Increase (Decrease) in Receivables Denominator for Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Receivable Receivable [Policy Text Block] Cost of products sold Cost of Goods and Services Sold Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] AOCI, Other than Temporary Impairment, Not Credit Loss, Beginning Balance AOCI, Other than Temporary Impairment, Not Credit Loss, Ending Balance Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities Restricted Stock Shares and Units [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised, Weighted-Average Option Price per Share Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level I [Member] Fair Value, Inputs, Level 1 [Member] Four Point Seven Five Zero Percent Due Two Thousand Thirty Three Four Point Seven Five Zero Percent Due Two Thousand Thirty Three [Member] Four Point Seven Five Zero Percent Due Two Thousand Thirty Three Goodwill Goodwill Statement, Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Hedging Relationship [Domain] Hedging Relationship [Domain] Investment Type [Axis] Investment Type [Axis] Net payments attributable to current period medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Lessee, Leases Lessee, Lease, Description [Table] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Entity Small Business Entity Small Business Investments [Domain] Investments [Domain] Net payments attributable to prior periods medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Dividends per share Common Stock, Dividends, Per Share, Declared OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Foreign Government Securities [Member] Foreign Government Debt [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Noncontrolling Interest, Period Increase (Decrease) Noncontrolling Interest, Period Increase (Decrease) Accrued investment income receivable Accrued Investment Income Receivable Capital [Abstract] Banking Regulation, Total Capital [Abstract] Change in non-credit component of impairment losses on investments Change in non-credit component of impairment losses on investments net of tax Change in non-credit component of impairment losses on investments, net of tax effect. Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures Weighted Average Number of Shares Outstanding, Diluted, Adjustment Damages for Operational Breaches [Member] Operational [Member] Operational [Member] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Insurance lines other than short duration Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item Due after ten years, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 Total revenues Revenues Allowance for doubtful accounts, other receivables Allowance for Credit Loss, Receivable, Other, Current Product and Service [Domain] Product and Service [Domain] Commercial Mortgage-Backed Securities [Member] Commercial Mortgage-Backed Securities [Member] Net medical claims payable, end of period Liability for Unpaid Claims and Claims Adjustment Expense, Net Lessee, Operating Lease, Disclosure [Table Text Block] Lease, Cost [Table Text Block] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Granted, Restricted Stock Shares and Units Restricted stock units issued under stock incentive plan Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Income taxes receivable Income Taxes Receivable, Current Interest expense Interest Expense Dividends and dividend equivalents Dividends, Common Stock Total net payments Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Finite-lived Intangible Assets Acquired Finite-Lived Intangible Assets Acquired Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Carelon Total Carelon Total [Member] Carelon Total Outstanding at end of period, Weighted-Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Summary of Cash Dividend Activity Dividends Declared [Table Text Block] Imputed Interest, Leases Lessee, Operating Lease, Liability, Undiscounted Excess Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Weighted-Average Fair Values Determined for the Periods Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Operating lease payments, Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Operating Lease, Liability, Current Operating Lease, Liability, Current Product revenue Product Revenue Amount of revenue recognized from goods sold. Short-Duration Insurance Contract, Accident Year 2021 [Member] Short-Duration Insurance Contract, Accident Year 2021 [Member] Debt Securities, Available-for-Sale, Allowance for Credit Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Income taxes Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Amortization of other intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Operating lease payments, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Unearned income Unearned Premiums New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Operating lease payments, 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Insurance [Abstract] Insurance [Abstract] Net medical claims payable, beginning of period Net medical claims payable, end of period Short duration contract liability for unpaid claims and adjustment expense, Net Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims. Government Sponsored Securities [Member] US Government-sponsored Enterprises Debt Securities [Member] Increase In Stock Repurchase Program Authorization Increase In Stock Repurchase Program Authorization The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program. Changes in securities lending collateral Increase (Decrease) in Collateral Held under Securities Lending Operating Lease, Cost Operating Lease, Cost Estimated fair value, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued Common Stock, Shares, Issued Vested, Restricted Stock Shares And Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Exchange Traded Funds [Member] Exchange Traded Funds [Member] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Total assets Assets, Fair Value Disclosure Long-term Debt Senior revolving credit facility Long-Term Debt Repurchase Agreements and Similar Transactions, Maturity Periods [Axis] Repurchase Agreements and Similar Transactions, Maturity Periods [Axis] Investment Income [Table] Investment Income [Table] Number of securities, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Operating expense Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Loss, Beginning Balance Accumulated Other Comprehensive Loss, Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Investment, Policy Investment, Policy [Policy Text Block] Other, net Proceeds from (Payments for) Other Financing Activities Debt instruments, repurchased face amount Debt Instrument, Repurchased Face Amount Maximum [Member] Maximum [Member] Total shareholders’ comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Other invested assets Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI Depreciation and amortization Depreciation, Amortization and Accretion, Net Document Type Document Type Goodwill, Acquired During Period Goodwill, Acquired During Period Total expenses Benefits, Losses and Expenses Short-term Lease, Cost Short-Term Lease, Cost Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies [Table]. Type of Adoption [Domain] Accounting Standards Update [Domain] Entity Address, Address Line One Entity Address, Address Line One Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned Securities Lending Transactions Ratio of Fair Value of Collateral Held To Securities On Loan Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions. Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] CarelonRx Segment [Member] CarelonRx Segment [Member] CarelonRx Segment [Member] Policy liabilities Increase (Decrease) in Insurance Liabilities Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Changes in bank overdrafts Increase (Decrease) in Outstanding Checks, Financing Activities Weighted-Average Option Price Per Share [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Reconciliation Of The Claims Development To The Claims Liability [Abstract] Reconciliation Of The Claims Development To The Claims Liability [Abstract] Reconciliation Of The Claims Development To The Claims Liability [Abstract] Convertible debentures Convertible Debt, Noncurrent Expenses Benefits, Losses and Expenses [Abstract] Subsequent Event [Member] Subsequent Event [Member] 2022 to 2024 [Member] 2022 to 2024 [Member] 2022 to 2024 Other current liabilities Other Liabilities, Current Cash [Member] Cash [Member] Income Statement [Abstract] Income Statement [Abstract] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Net investment income Net investment income Net Investment Income Title of 12(b) Security Title of 12(b) Security Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Performance measurement period [Domain] Performance measurement period [Domain] Performance measurement period [Domain] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Sublease Income Sublease Income Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Gross losses Gross Losses From Other Investments Gross Losses From Other Investments Other comprehensive loss (income) attributable to noncontrolling interests Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Nonvested at Beginning Balance, Weighted-Average Grant Date Fair Value per Share Nonvested at Ending Balance, Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Short-Duration Insurance Contract, Accident Year 2022 [Member] Short-Duration Insurance Contract, Accident Year 2022 [Member] Lease, Cost Lease, Cost Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest Collateral received for securities loaned, at carrying value Deposits Received for Securities Loaned, at Carrying Value Statistical Measurement [Axis] Statistical Measurement [Axis] Other Investments [Member] Other Investments [Member] Financial Instrument [Axis] Financial Instrument [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Entity Interactive Data Current Entity Interactive Data Current Derivatives [Member] Derivative [Member] Common Equity Securities [Member] Common Equity Securities [Member] Common Equity Securities [Member] Available-for-sale Securities Debt Securities, Available-for-Sale [Table] Repurchase and retirement of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Investment [Line Items] Gain (Loss) on Securities [Line Items] Business Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Transfers into Level III Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Other Asset-backed Securities [Member] Other Debt Obligations [Member] Debt Instrument, Face Amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Short-duration Insurance Contracts, Claims Development [Table] Short-Duration Insurance Contracts, Claims Development [Table] Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Prior periods redundancies Prior Year Claims and Claims Adjustment Expense Entity Address, State or Province Entity Address, State or Province Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Residential Mortgage-Backed Securities [Member] Residential Mortgage-Backed Securities [Member] Operating Lease, Payments Operating Lease, Payments Change in net unrealized losses/gains on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding Common Stock, Shares, Outstanding Maturities, calls and redemptions from investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Dividends Dividends Health Benefits Segment Health Benefits Segment [Member] Health Benefits Segment Aggregate settlement amount Loss Contingency, Estimate of Possible Loss Other receivables Other Receivables Proceeds from short-term borrowings Proceeds from Short-Term Debt Long-term investments: Long-Term Investments [Abstract] Reserves for future policy benefits, noncurrent Liability for Future Policy Benefit, before Reinsurance Notes Notes Payable Balance (in shares), Beginning Balance (in shares), Ending Shares, Outstanding Medical Claims Payable [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Common stock, par value Common Stock, Par or Stated Value Per Share Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Class of Stock [Domain] Class of Stock [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Equity securities Equity Securities, FV-NI, Current Customer [Domain] Customer [Domain] Accounting Policies [Line Items] Accounting Policies [Line Items] Accounting Policies [Line Items] Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Quality improvement and other claims expense SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense Debt Instrument [Axis] Debt Instrument [Axis] Repurchase and retirement of common stock Aggregate cost Stock Repurchased and Retired During Period, Value Effective tax rate Effective Income Tax Rate Reconciliation, Percent Operating Lease Liabilities Operating Lease, Liability Exercisable at end of period, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Volatility factor Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Investments In Equity Securities Investments in equity securities [Table Text Block] Investments in equity securities [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Cumulative Effect, Period of Adoption, Adjusted Balance Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Accumulated Other Comprehensive (Loss) Income [Member] AOCI Attributable to Parent [Member] Net proceeds from commercial paper borrowings Proceeds from (Repayments of) Commercial Paper Measurement Frequency [Domain] Measurement Frequency [Domain] Covenant compliance Debt Instrument, Covenant Compliance Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Debt Disclosure [Abstract] Debt Disclosure [Abstract] Assets and Liabilities, Lessee Assets and Liabilities, Lessee [Abstract] Medical Claims Payable Liability for Claims and Claims Adjustment Expense [Table] Number of Reportable Segments Number of Reportable Segments Shareholders’ net income per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 235,861,650 and 237,958,067 Common Stock, Value, Issued Estimated fair value, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Other Comprehensive Income (Loss), Tax (Expense) Benefit, Portion Attributable to Parent Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Due after one year through five years, Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Affiliated [Member] Affiliated [Member] Affiliated [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Gain Contingency, Nature [Axis] Gain Contingencies, Nature [Axis] Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position Schedule of Unrealized Loss on Investments [Table Text Block] Short-duration Insurance Contracts, Claim Year [Domain] Short-Duration Insurance Contracts, Accident Year [Domain] Balance sheet location of noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Total current assets Assets, Current AOCI, Liability for Future Policy Benefit, After Tax, Beginning Balance AOCI, Liability for Future Policy Benefit, After Tax, Ending Balance AOCI, Liability for Future Policy Benefit, after Tax Equity Securities [Member] Equity Securities [Member] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Litigation Case [Domain] Litigation Case [Domain] Entity Filer Category Entity Filer Category Summary of Share Repurchases Class of Treasury Stock [Table Text Block] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Reconciliation Of Components Of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accounting Standards Update 2020-06 [Member] Accounting Standards Update 2020-06 [Member] Preferred stock, shares authorized Preferred Stock, Shares Authorized Reconciliation of Net Incurred Medical Claims to Benefit Expense Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table Text Block] Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense. Granted, Weighted-Average Grant Date Fair Value per Share Restricted stock awards granted during the period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Zero Point Four Five Zero Percent Due Two Thousand Twenty Three Zero Point Four Five Zero Percent Due Two Thousand Twenty Three [Member] Zero Point Four Five Zero Percent Due Two Thousand Twenty Three Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Three Point Three Zero Zero Percent Due Two Thousand Twenty Three Three Point Three Zero Zero Percent Due Two Thousand Twenty Three [Member] Three Point Three Zero Zero Percent Due Two Thousand Twenty Three Equity Securities [Line Items] Marketable Securities [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Fair Value, Nonrecurring [Member] Fair Value, Nonrecurring [Member] Fixed maturities, current Debt Securities, Available-for-Sale, Current Total gains (losses) recognized in accumulated other comprehensive loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Service fees Other Income Organization Nature of Operations [Text Block] Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Restricted stock units excluded from the denominator for diluted earnings per share Potentially Dilutive Restricted Stock Units Contingent On Operating Results Potentially Dilutive Restricted Stock Units Contingent On Operating Results Debt instrument interest rate Debt Instrument, Interest Rate, Stated Percentage Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Information [Line Items] Entity Information [Line Items] Fixed maturities, allowance for credit loss, current Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current Short-Duration Insurance Contract, Accident Year 2023 [Member] Short-Duration Insurance Contract, Accident Year 2023 [Member] Total shareholders' equity Total shareholders' equity, Beginning Balance Total shareholders' equity, Ending Balance Equity, Attributable to Parent Debt Conversion Debt Principal Amount Debt Conversion Debt Principal Amount The aggregate principal amount of the original debt instrument that was surrendered for conversion. Debt Securities, Available-for-sale, Realized Gain Debt Securities, Available-for-Sale, Realized Gain Commercial Paper Commercial Paper [Member] Benefit expense Policyholder Benefits and Claims Incurred, Net Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Unearned income Increase (Decrease) in Deferred Revenue Premiums Premiums Earned, Net Net unrealized investment (losses) gains AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Foreign currency translation adjustments Foreign currency translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Weighted-average expected life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Anthem, Inc. v. Express Scripts, Inc. [Member] Anthem, Inc. v. Express Scripts, Inc. [Member] Anthem, Inc. v. Express Scripts, Inc. [Member] Income before income tax expense Income before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] States, Municipalities And Political Subdivisions [Member] US States and Political Subdivisions Debt Securities [Member] Future Policy Benefits Future Policy Benefits [Member] Future Policy Benefits Preferred stock, shares issued Preferred Stock, Shares Issued Level II [Member] Fair Value, Inputs, Level 2 [Member] Current period net incurred medical claims Current Year Claims and Claims Adjustment Expense Other Asset-Backed Securities [Member] Other Security Investments [Member] Entity Emerging Growth Company Entity Emerging Growth Company Securities lending collateral Securities Held as Collateral, at Fair Value Other intangible assets Intangible Assets, Net (Excluding Goodwill) Repurchase Agreements and Similar Transactions, Maturity Periods [Domain] Repurchase Agreements and Similar Transactions, Maturity Periods [Domain] Corporate & Other Segment Corporate & Other Segment [Member] Corporate & Other Segment Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Operating lease payments, 2023; excluding the six months ended June 30, 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Dividends Payable, Amount Per Share Dividends Payable, Amount Per Share Unaffiliated Unaffiliated [Member] Unaffiliated [Member] Gross premium tax rate, state of California Gross Premium Tax Rate Gross premium tax rate Securities lending transactions, initial collateral percentage value Securities Lending Transactions Initial Collateral Percentage Value Initial minimum percentage of cash and/or securities collateral accepted as compared to the value of securities on loan in a securities lending transaction. Operating lease payments, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity [Axis] Outstanding at beginning of period, Weighted-Average Option Price per Share Outstanding at end of period, Weighted-Average Option Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Share-Based Payment Arrangement, Noncash Expense Position [Domain] Position [Domain] Reconciliation of net incurred medical claims to benefit expense [Line Items] reconciliation of net incurred medical claims to benefit expense [Line Items] [Line Items] for Reconciliation of net incurred medical claims to benefit expense [Table] Common Stock [Member] Common Stock [Member] Granted, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Change in net periodic pension and postretirement costs Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Fixed maturities, long-term Debt Securities, Available-for-Sale, Noncurrent Five Point One Two Five Percent Due Two Thousand Fifty Three Five Point One Two Five Percent Due Two Thousand Fifty Three [Member] Five Point One Two Five Percent Due Two Thousand Fifty Three City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Non-credit components of impairments on investments [Member] Non-credit components of impairments on investments [Member] Non-credit components of impairments on investments Performance measurement period [Axis] Performance measurement period [Axis] Performance measurement period [Axis] Products and Services Product and Service [Axis] Earnings Per Share Earnings Per Share [Text Block] Medical Claims payable Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Equity Securities [Table] Marketable Securities [Table] Total equity Total equity, Beginning Balance Total equity, Ending Balance Equity, Including Portion Attributable to Noncontrolling Interest Derivative assets Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Cash flow hedges, holding gain (loss), tax (expense) benefit Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Investments [Abstract] Investments [Abstract] Minimum [Member] Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Share Repurchase Program [Domain] Share Repurchase Program [Domain] Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Cash dividends per share Common Stock, Dividends, Per Share, Cash Paid Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Change in future policy benefits Change in future policy benefits, net of tax OCI, Liability for Future Policy Benefit, Gain (Loss), after Reclassification Adjustment and Tax Assets Assets [Abstract] Total net incurred medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Due after ten years, Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Proceeds from long-term borrowings Proceeds from Issuance of Long-Term Debt BCBS Antitrust Litigation [Member] BCBS Antitrust Litigation [Member] BCBS Antitrust Litigation Taxes paid through withholding of common stock under employee stock plans Payment, Tax Withholding, Share-Based Payment Arrangement Balance sheet location of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Net income Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease and Other Information [Line Items] Lessee, Lease, Description [Line Items] Commitments And Contingencies Commitments and Contingencies Disclosure [Text Block] Other, net Payments for (Proceeds from) Other Investing Activities Retained Earnings [Member] Retained Earnings [Member] Retained Earnings [Member] Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet [Table Text Block] -- None. No documentation exists for this element. -- Current portion of long-term debt Long-Term Debt, Current Maturities Number of securities, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Total liabilities and shareholders' equity Liabilities and Equity Cost or Amortized Cost Available-for-sale securities, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other noncurrent assets Other Assets, Noncurrent Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Change in net unrealized gains/losses on cash flow hedges Cash flow hedges, holding gain (loss), net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Basic net income per share Earnings Per Share, Basic Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table] Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table] Other policyholder liabilities Other Policyholder Funds Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Class of Treasury Stock [Table] Class of Treasury Stock [Table] AOCI, Debt Securities, Beginning Balance AOCI, Debt Securities, Ending Balance AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Premium receivable, allowance for doubtful accounts Premium Receivable, Allowance for Credit Loss Proceeds from sale of investments Proceeds from sale of equity and fixed maturity securities Proceeds from sale of equity and fixed maturity securities. Entity Address, City or Town Entity Address, City or Town Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Private Equity Funds [Member] Private Equity Securities [Member] Private Equity Funds [Member] Financial Data By Reportable Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Mortgage-backed securities, Amortized Cost Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost Balance sheet location of current operating lease liabilities Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Impairment losses recognized in income Impairment (losses) reversals on investments Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income. Self-funded receivables, allowance for doubtful accounts Self-funded Receivables, Allowance For Doubtful Accounts The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value. Document Transition Report Document Transition Report Segment Eliminations [Member] Segment Eliminations [Member] Segment Eliminations [Member] Goodwill, Purchase Accounting Adjustments Goodwill, Purchase Accounting Adjustments Business Acquisitions [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Combinations [Abstract] Business Combinations [Abstract] Authorization remaining at the end of the period Stock Repurchase Program, Remaining Authorized Repurchase Amount Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] AOCI, Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Common stock, shares authorized Common Stock, Shares Authorized Change in future policy benefits, tax expense OCI, Liability for Future Policy Benefit, Gain (Loss), after Reclassification Adjustment, Tax Available-for-sale Securities Available-for-sale securities, Estimated Fair Value Debt Securities, Available-for-Sale Short-term borrowings Short-term borrowings Short-Term Debt Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Net gains (losses) on equity securities Equity Securities, FV-NI, Gain (Loss) Federal Home Loan Bank Advances [Member] Federal Home Loan Bank Advances [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Ceded medical claims payable, beginning of period Ceded medical claims payable, end of period Ceded medical claims payable end of period Reinsurance Recoverable for Unpaid Claims and Claims Adjustments Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss) Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss) Tax (expense) benefit of non-credit component of impairment loss on available-for-sale securities recognized in other comprehensive income Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six [Member] Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Due in one year or less, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Declaration date Dividends Payable, Date Declared Additional paid-in capital Additional Paid in Capital Due after five years through ten years, Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Forfeited, Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income taxes Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from issuance of common stock under employee stock plans Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Federal Home Loan Bank, advances, short-term Federal Home Loan Bank, Advances, Maturities Summary, Due in Next Rolling 12 Months Net losses on investments Investment Gains (Losses) Investment Gains (Losses) Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Senior Convertible Debenture [Member] Convertible Debt [Member] Business combinations and purchase adjustments Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions 2023 to 2025 2023 to 2025 [Member] 2023 to 2025 Forfeited, Restricted Stock Shares And Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Surplus Notes [Member] Surplus Notes [Member] Surplus Notes [Member] Net losses on financial instruments Net losses on financial instruments Net losses (gains) on financial instruments Net (losses) gains on financial instruments Net (losses) gains on financial instruments Outstanding at end of period, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Issuance of common stock under employee stock plans, net of related tax benefits, Shares Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Other assets Increase (Decrease) in Other Operating Assets Convertible debenture repurchases, conversions and tax adjustments Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Unrealized gains (losses) recognized on equity securities still held at the end of the period Equity Securities, FV-NI, Unrealized Gain (Loss) Carelon Services Segment Carelon Services Segment [Member] Carelon Services Segment Noncontrolling interests Noncontrolling interests, Beginning Balance Noncontrolling interests, Ending Balance Equity, Attributable to Noncontrolling Interest Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Period End Date Document Period End Date Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable at end of period, Weighted-Average Option Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Record date Dividends Payable, Date of Record Dividends Payable, Date of Record Repayments of long-term borrowings Repayments of Long-term Debt Repayments of Long-Term Debt Average price per share Stock Repurchased and Retired During Period Average Price Stock Repurchased and Retired During Period Average Price Entity Central Index Key Entity Central Index Key Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Payment date Dividends Payable, Date to be Paid Dividends Payable, Date to be Paid Derivative, Gain (Loss) Recognized Derivative, Gain (Loss) on Derivative, Net Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Total gains (losses) recognized in net income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Customer funds and cash and cash equivalents on deposit for regulatory requirements Restricted Cash and Investments, Current Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Income tax expense Income Tax Expense (Benefit) Gross gains Gains From Other Investments Gains From Other Investments Fair Value Fair Value Disclosures [Text Block] Fair value of collateral received at time of securities lending transactions Securities Loaned, Fair Value of Collateral Net cash flow hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Debt Instruments [Abstract] Debt Instruments [Abstract] Net losses on other investments Gain (Loss) on Sale of Other Investments Shareholders' other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Gross unrealized loss, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Entity [Domain] Entity [Domain] Covenant description Debt Instrument, Covenant Description Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-sale Securities Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-Sale Securities Legal Entity [Axis] Legal Entity [Axis] Gross unrealized loss, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Purchases of subsidiaries, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Two Point Seven Five Zero Percent Due Two Thousand Forty Two Two Point Seven Five Zero Percent Due Two Thousand Forty Two [Member] -- None. No documentation exists for this element. -- Liability for Claims and Claims Adjustment Expense [Abstract] Liability for Claims and Claims Adjustment Expense [Abstract] Due in one year or less, Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Credit Facility [Domain] Credit Facility [Domain] Repurchase and retirement of common stock, shares Shares repurchased Stock Repurchased and Retired During Period, Shares Approximate amount of damages sought for breaches Loss Contingency, Damages Sought, Value Long-term debt, less current portion Long-Term Debt, Excluding Current Maturities Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table] Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table] Reconciliation of net incurred medical claims to benefit expense [Table] Net Investment Gains (Losses) Gain (Loss) on Securities [Table Text Block] Denominator for diluted earnings per share Weighted Average Number of Shares Outstanding, Diluted BioPlus BioPlus [Member] BioPlus Debt Securities, Available-for-sale, Realized Gain (Loss) Debt Securities, Available-for-Sale, Realized Gain (Loss) Accounting Policies [Table] Accounting Policies [Table] Accounting Policies Indefinite-lived Intangible Assets Acquired Indefinite-Lived Intangible Assets Acquired Debt Securities, Available-for-sale, Realized Loss Debt Securities, Available-for-Sale, Realized Loss Repurchase and retirement of common stock, including excise tax Repurchase and retirement of common stock, including excise tax Repurchase and retirement of common stock, including excise tax Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Gain Contingency, Nature [Domain] Gain Contingency, Nature [Domain] Lease, Cost and Other Information [Abstract] Lease, Cost [Abstract] Net realized gains (losses) recognized on equity securities sold during the period Equity Securities, FV-NI, Realized Gain (Loss) Changes in securities lending payable Increase (Decrease) in Securities Lending Payable Total assets Assets Equity in net earnings of other invested assets Income (Loss) from Equity Method Investments Share Repurchase Program [Axis] Share Repurchase Program [Axis] Derivative liabilities Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement Cover [Abstract] Cover [Abstract] Position [Axis] Position [Axis] Number of states in which the Company is licensed to conduct insurance operations Number of States in which Entity Operates AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax AOCI, Cash Flow Hedge, Beginning Balance AOCI, Cash Flow Hedge, Ending Balance AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Premium receivables Premiums Receivable, Net Pension and other postretirement benefits Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Fair Value, Recurring [Member] Fair Value, Recurring [Member] Overnight and Continuous [Member] Maturity Overnight [Member] Cash dividends Total payment Payments of Dividends Other noncurrent liabilities Other Liabilities, Noncurrent Vested, Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Total future minimum payments Lessee, Operating Lease, Liability, to be Paid Forfeited or expired, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Cash Flow Hedging [Member] Cash Flow Hedging [Member] Loss Contingency Accrual, Payments Loss Contingency Accrual, Payments Segment Information Segment Reporting Disclosure [Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Equity Component [Domain] Equity Component [Domain] Denominator for basic earnings per share - weighted-average shares Weighted Average Number of Shares Outstanding, Basic Debt Instrument [Line Items] Debt Instrument [Line Items] Fixed maturities, allowance for credit Loss, noncurrent Debt Securities, Available-for-Sale, Allowance for Credit Loss, Noncurrent Entity Current Reporting Status Entity Current Reporting Status Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Operating gain (loss) Reportable segments operating gain Operating Income (Loss) Revenues Revenues [Abstract] Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract] Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract] Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Total operating revenue Total operating revenue Operating Revenue Revenue from insurance services and products sold. Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract] Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract] Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Noncontrolling Interest [Member] Noncontrolling Interest [Member] EX-101.PRE 11 elv-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 elv-20230630_g1.jpg ELEVANCE HEALTH LOGO begin 644 elv-20230630_g1.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information Document - shares
 6 Months Ended
Jun. 30, 2023
Jul. 13, 2023
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Current Fiscal Year End Date --12-31  
Entity Central Index Key 0001156039  
Entity File Number 001-16751  
Entity Registrant Name ELEVANCE HEALTH, INC.  
Entity Incorporation, State or Country Code IN  
Entity Tax Identification Number 35-2145715  
Entity Address, Address Line One 220 Virginia Avenue  
Entity Address, City or Town Indianapolis  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46204  
City Area Code 833  
Local Phone Number 401-1577  
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol ELV  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   235,647,808
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 9,991 $ 7,387
Fixed maturities, current 28,021 25,952
Equity securities 272 953
Premium receivables 7,431 7,083
Self-funded receivables 3,896 4,663
Other receivables 5,196 4,298
Other current assets 4,936 5,281
Total current assets 59,743 55,617
Long-term investments:    
Fixed maturities, long-term 775 752
Other invested assets 5,993 5,685
Property and equipment, net 4,547 4,316
Goodwill 25,274 24,383
Other intangible assets 10,703 10,315
Other noncurrent assets 2,133 1,687
Total assets 109,168 102,755
Current Liabilities:    
Medical claims payable 16,165 15,596
Other policyholder liabilities 5,954 5,933
Unearned income 4,458 1,112
Accounts payable and accrued expenses 5,033 5,607
Short-term borrowings 265 265
Current portion of long-term debt 0 1,500
Other current liabilities 9,696 9,683
Total current liabilities 41,571 39,696
Long-term debt, less current portion 24,859 22,349
Reserves for future policy benefits, noncurrent 797 803
Deferred tax liabilities, net 1,852 2,015
Other noncurrent liabilities 1,777 1,562
Total liabilities 70,856 66,425
Commitments and contingencies – Note 10
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Shareholders' equity    
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none $ 0 $ 0
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 235,861,650 and 237,958,067 2 2
Additional paid-in capital 8,761 9,084
Retained earnings 31,608 29,647
Accumulated other comprehensive loss (2,166) (2,490)
Total shareholders' equity 38,205 36,243
Noncontrolling interests 107 87
Total equity 38,312 36,330
Total liabilities and shareholders' equity $ 109,168 $ 102,755
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Fixed maturities, amortized cost, current $ 29,915 $ 28,226
Fixed maturities, allowance for credit loss, current 7 9
Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent 809 789
Fixed maturities, allowance for credit Loss, noncurrent $ 0 $ 0
Preferred stock, shares authorized 100,000,000 100,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 900,000,000 900,000,000
Common stock, shares issued 235,861,650 237,958,067
Common stock, shares outstanding 235,861,650 237,958,067
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements Of Income - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues        
Premiums $ 36,589 $ 33,076 $ 72,457 $ 65,861
Product revenue 4,859 3,568 8,881 6,869
Service fees 1,929 1,838 3,937 3,638
Total operating revenue 43,377 38,482 85,275 76,368
Net investment income 416 381 803 741
Net losses on financial instruments (121) (231) (234) (382)
Total revenues 43,672 38,632 85,844 76,727
Expenses        
Benefit expense 31,604 28,795 62,390 57,026
Cost of products sold 4,327 3,069 7,808 5,952
Operating expense 4,818 4,272 9,618 8,617
Interest expense 261 208 512 409
Amortization of other intangible assets 221 166 456 295
Total expenses 41,231 36,510 80,784 72,299
Income before income tax expense 2,441 2,122 5,060 4,428
Income tax expense 585 488 1,200 1,015
Net income 1,856 1,634 3,860 3,413
Net (income) loss attributable to noncontrolling interests (3) 3 (18) 13
Shareholders’ net income $ 1,853 $ 1,637 $ 3,842 $ 3,426
Shareholders’ net income per share        
Basic net income per share $ 7.83 $ 6.80 $ 16.21 $ 14.22
Diluted net income per share 7.79 6.73 16.10 14.05
Dividends per share $ 1.48 $ 1.28 $ 2.96 $ 2.56
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net income $ 1,856 $ 1,634 $ 3,860 $ 3,413
Other comprehensive (loss) income, net of tax:        
Change in net unrealized losses/gains on investments (119) (922) 308 (1,991)
Change in non-credit component of impairment losses on investments (1) (1) (3) (2)
Change in net unrealized gains/losses on cash flow hedges 4 3 15 6
Change in net periodic pension and postretirement costs 3 9 5 16
Change in future policy benefits (3) 8 (1) 17
Foreign currency translation adjustments 0 (5) 2 (8)
Other comprehensive (loss) income (116) (908) 326 (1,962)
Net (income) loss attributable to noncontrolling interests (3) 3 (18) 13
Other comprehensive loss (income) attributable to noncontrolling interests 0 3 (2) 8
Total shareholders’ comprehensive income $ 1,737 $ 732 $ 4,166 $ 1,472
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements Of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating activities    
Net income $ 3,860 $ 3,413
Adjustments to reconcile net income to net cash provided by operating activities:    
Net losses on financial instruments 234 382
Equity in net earnings of other invested assets 73 (258)
Depreciation and amortization 895 751
Deferred income taxes (393) (181)
Share-based compensation 139 122
Changes in operating assets and liabilities:    
Receivables, net (299) (662)
Other invested assets (42) 32
Other assets (529) (412)
Policy liabilities 583 1,548
Unearned income 3,346 (182)
Accounts payable and other liabilities 160 632
Income taxes 391 (159)
Other, net 1 (33)
Net cash provided by operating activities 8,419 4,993
Investing activities    
Purchases of investments (17,648) (13,253)
Proceeds from sale of investments 5,339 7,140
Maturities, calls and redemptions from investments 10,656 4,347
Changes in securities lending collateral 145 (620)
Purchases of subsidiaries, net of cash acquired (1,651) (609)
Purchases of property and equipment (651) (549)
Other, net (46) (58)
Net cash used in investing activities (3,856) (3,602)
Financing activities    
Net proceeds from commercial paper borrowings 90 250
Proceeds from long-term borrowings 2,574 1,300
Repayments of long-term borrowings (1,908) (943)
Proceeds from short-term borrowings 0 1,275
Repayments of Short-term Debt (90) (1,375)
Changes in securities lending payable (145) 620
Changes in bank overdrafts (500) 817
Repurchase and retirement of common stock (1,268) (1,169)
Cash dividends (701) (618)
Proceeds from issuance of common stock under employee stock plans 81 116
Taxes paid through withholding of common stock under employee stock plans (99) (88)
Other, net 5 10
Net cash (used in) provided by financing activities (1,961) 195
Effect of foreign exchange rates on cash and cash equivalents 2 (10)
Change in cash and cash equivalents 2,604 1,576
Cash and cash equivalents at beginning of period 7,387 4,880
Cash and cash equivalents at end of period $ 9,991 $ 6,456
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements Of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjusted Balance
Common Stock [Member]
Additional Paid-In Capital [Member]
Retained Earnings [Member]
Retained Earnings [Member]
Cumulative Effect, Period of Adoption, Adjustment
Retained Earnings [Member]
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Other Comprehensive (Loss) Income [Member]
Noncontrolling Interest [Member]
Balance (in shares), Beginning at Dec. 31, 2021       241.8            
Total shareholders' equity, Beginning Balance at Dec. 31, 2021       $ 2 $ 9,148 $ 27,142   $ 27,119 $ (197)  
Total shareholders' equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021             $ (23)      
Noncontrolling interests, Beginning Balance at Dec. 31, 2021                   $ 68
Total equity, Beginning Balance at Dec. 31, 2021 $ 36,163   $ 36,140              
Total equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021   $ (23)                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income           1,789        
Net Income (Loss) Attributable to Noncontrolling Interest                   (10)
Net income 1,779                  
Shareholders' other comprehensive income (loss)                 (1,049)  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest                   (5)
Other Comprehensive Income (Loss), Net of Tax (1,054)                  
Noncontrolling Interest [Abstract]                    
Noncontrolling Interest, Period Increase (Decrease) 3                 3
Repurchase and retirement of common stock, shares       (1.2)            
Repurchase and retirement of common stock (545)     $ 0 (45) (500)        
Dividends         0          
Dividends and dividend equivalents (312)         (312)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.5            
Issuance of common stock under employee stock plans, net of related tax benefits 39       39          
Convertible debenture repurchases, conversions and tax adjustments 9       9          
Balance (in shares), Ending at Mar. 31, 2022       241.1            
Total shareholders' equity, Ending Balance at Mar. 31, 2022       $ 2 9,151 28,096     (1,246)  
Noncontrolling interests, Ending Balance at Mar. 31, 2022                   56
Total equity, Ending Balance at Mar. 31, 2022 36,059                  
Balance (in shares), Beginning at Dec. 31, 2021       241.8            
Total shareholders' equity, Beginning Balance at Dec. 31, 2021       $ 2 9,148 27,142   27,119 (197)  
Total shareholders' equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021             $ (23)      
Noncontrolling interests, Beginning Balance at Dec. 31, 2021                   68
Total equity, Beginning Balance at Dec. 31, 2021 36,163   36,140              
Total equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021   $ (23)                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income 3,426                  
Net Income (Loss) Attributable to Noncontrolling Interest (13)                  
Net income 3,413                  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest (8)                  
Other Comprehensive Income (Loss), Net of Tax $ (1,962)                  
Noncontrolling Interest [Abstract]                    
Repurchase and retirement of common stock, shares (2.5)                  
Repurchase and retirement of common stock $ (1,169)                  
Balance (in shares), Ending at Jun. 30, 2022       240.0            
Total shareholders' equity, Ending Balance at Jun. 30, 2022       $ 2 9,134 28,847     (2,151)  
Noncontrolling interests, Ending Balance at Jun. 30, 2022                   55
Total equity, Ending Balance at Jun. 30, 2022 35,887                  
Balance (in shares), Beginning at Mar. 31, 2022       241.1            
Total shareholders' equity, Beginning Balance at Mar. 31, 2022       $ 2 9,151 28,096     (1,246)  
Noncontrolling interests, Beginning Balance at Mar. 31, 2022                   56
Total equity, Beginning Balance at Mar. 31, 2022 36,059                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income 1,637         1,637        
Net Income (Loss) Attributable to Noncontrolling Interest (3)                 (3)
Net income 1,634                  
Shareholders' other comprehensive income (loss)                 (905)  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest (3)                 (3)
Other Comprehensive Income (Loss), Net of Tax (908)                  
Noncontrolling Interest [Abstract]                    
Noncontrolling Interest, Period Increase (Decrease) 5                 5
Repurchase and retirement of common stock, shares       (1.3)            
Repurchase and retirement of common stock (624)     $ 0 (48) (576)        
Dividends and dividend equivalents (310)         (310)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.2            
Issuance of common stock under employee stock plans, net of related tax benefits 111       111          
Convertible debenture repurchases, conversions and tax adjustments (80)       (80)          
Balance (in shares), Ending at Jun. 30, 2022       240.0            
Total shareholders' equity, Ending Balance at Jun. 30, 2022       $ 2 9,134 28,847     (2,151)  
Noncontrolling interests, Ending Balance at Jun. 30, 2022                   55
Total equity, Ending Balance at Jun. 30, 2022 35,887                  
Balance (in shares), Beginning at Dec. 31, 2022       238.0            
Total shareholders' equity, Beginning Balance at Dec. 31, 2022 36,243     $ 2 9,084     29,647 (2,490)  
Noncontrolling interests, Beginning Balance at Dec. 31, 2022 87                 87
Total equity, Beginning Balance at Dec. 31, 2022 36,330   36,330              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income           1,989        
Net Income (Loss) Attributable to Noncontrolling Interest                   15
Net income 2,004                  
Shareholders' other comprehensive income (loss)                 440  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest                   2
Other Comprehensive Income (Loss), Net of Tax 442                  
Noncontrolling Interest [Abstract]                    
Repurchase and retirement of common stock, shares       (1.3)            
Repurchase and retirement of common stock         (51) (575)        
Repurchase and retirement of common stock, including excise tax (626)                  
Dividends and dividend equivalents (354)         (354)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.4            
Issuance of common stock under employee stock plans, net of related tax benefits 6       6 0        
Convertible debenture repurchases, conversions and tax adjustments (342)       (342)          
Balance (in shares), Ending at Mar. 31, 2023       237.1            
Total shareholders' equity, Ending Balance at Mar. 31, 2023       $ 2 8,697 30,707     (2,050)  
Noncontrolling interests, Ending Balance at Mar. 31, 2023                   104
Total equity, Ending Balance at Mar. 31, 2023 37,460                  
Balance (in shares), Beginning at Dec. 31, 2022       238.0            
Total shareholders' equity, Beginning Balance at Dec. 31, 2022 36,243     $ 2 9,084     $ 29,647 (2,490)  
Noncontrolling interests, Beginning Balance at Dec. 31, 2022 87                 87
Total equity, Beginning Balance at Dec. 31, 2022 36,330   $ 36,330              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income 3,842                  
Net Income (Loss) Attributable to Noncontrolling Interest 18                  
Net income 3,860                  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest 2                  
Other Comprehensive Income (Loss), Net of Tax $ 326                  
Noncontrolling Interest [Abstract]                    
Repurchase and retirement of common stock, shares (2.7)                  
Repurchase and retirement of common stock $ (1,268)                  
Balance (in shares), Ending at Jun. 30, 2023       235.9            
Total shareholders' equity, Ending Balance at Jun. 30, 2023 38,205     $ 2 8,761 31,608     (2,166)  
Noncontrolling interests, Ending Balance at Jun. 30, 2023 107                 107
Total equity, Ending Balance at Jun. 30, 2023 38,312                  
Balance (in shares), Beginning at Mar. 31, 2023       237.1            
Total shareholders' equity, Beginning Balance at Mar. 31, 2023       $ 2 8,697 30,707     (2,050)  
Noncontrolling interests, Beginning Balance at Mar. 31, 2023                   104
Total equity, Beginning Balance at Mar. 31, 2023 37,460                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income 1,853         1,853        
Net Income (Loss) Attributable to Noncontrolling Interest 3                 3
Net income 1,856                  
Shareholders' other comprehensive income (loss)                 (116)  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest 0                 0
Other Comprehensive Income (Loss), Net of Tax (116)                  
Noncontrolling Interest [Abstract]                    
Repurchase and retirement of common stock, shares       (1.4)            
Repurchase and retirement of common stock (652)       (52) (600)        
Dividends and dividend equivalents (352)         (352)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.2            
Issuance of common stock under employee stock plans, net of related tax benefits 116       116          
Balance (in shares), Ending at Jun. 30, 2023       235.9            
Total shareholders' equity, Ending Balance at Jun. 30, 2023 38,205     $ 2 $ 8,761 $ 31,608     $ (2,166)  
Noncontrolling interests, Ending Balance at Jun. 30, 2023 107                 $ 107
Total equity, Ending Balance at Jun. 30, 2023 $ 38,312                  
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Organization
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 48 million medical members through our affiliated health plans as of June 30, 2023. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (with the exception of 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also serve members in numerous states as Amerigroup, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, UniCare and/or Wellpoint. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services as CarelonRx and other healthcare-related services as Carelon Services, Aspire Health, Carelon Behavioral Health and CareMore.
As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans; and
•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable
segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Form 10-Q has been reclassified to conform to the new presentation. For additional discussion regarding our segments, including the changes made, see Note 14 “Segment Information.”
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Basis Of Presentation and Significant Accounting Policies
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) , unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and six months ended June 30, 2023 and 2022 have been recorded. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $391 and $258 at June 30, 2023 and December 31, 2022, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $184 and $152 at June 30, 2023 and December 31, 2022, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $86 and $68 at June 30, 2023 and December 31, 2022, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $816 and $744 at June 30, 2023 and December 31, 2022, respectively.
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at June 30, 2023. For the three and six months ended June 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our adoption as required by the new standard.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisitions
 6 Months Ended
Jun. 30, 2023
Business Combinations [Abstract]  
Business Acquisitions Business Acquisitions and Divestitures
Pending Divestiture
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected to close by the end of the first quarter of 2024 and is subject to standard closing conditions and customary approvals. The related net assets held for sale and results of operations for the employee benefits businesses to be divested as of and for the three and six months ending June 30, 2023 were not material.
Pending Acquisition
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health solutions to BCBSLA’s members. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.
Completed Acquisitions
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of June 30, 2023, the purchase price was allocated to the tangible and
intangible net assets acquired based on management’s initial estimates of their fair values, of which $820 has been allocated to finite-lived intangible assets and $877 to goodwill, including an increase to goodwill for measurement period adjustments of $149 during the quarter ended June 30, 2023. The majority of goodwill is not deductible for income tax purposes. As of June 30, 2023, the initial accounting for the acquisition had not been finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The initial accounting for this acquisition was finalized as of June 30, 2023. The purchase price was allocated to tangible and intangible net assets acquired based on management’s estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $139 to goodwill. Contractual purchase price adjustments during the quarter ended June 30, 2023 were $13 and resulted in an increase to goodwill. The majority of goodwill is deductible for income tax purposes. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Investments
 6 Months Ended
Jun. 30, 2023
Investments [Abstract]  
Investments Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.
A summary of current and long-term fixed maturity securities, available-for-sale, at June 30, 2023 and December 31, 2022 is as follows:
Cost or
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
June 30, 2023
Fixed maturity securities:
United States Government securities$1,957 $1 $(75)$— $1,883 
Government sponsored securities94 1 (4)— 91 
Foreign government securities337 2 (41)(1)297 
States, municipalities and political subdivisions, tax-exempt3,957 22 (207)— 3,772 
Corporate securities14,276 50 (997)(4)13,325 
Residential mortgage-backed securities3,617 11 (313)— 3,315 
Commercial mortgage-backed securities2,262 2 (180)(2)2,082 
Other asset-backed securities4,224 15 (208)— 4,031 
Total fixed maturity securities$30,724 $104 $(2,025)$(7)$28,796 
December 31, 2022
Fixed maturity securities:
United States Government securities$1,502 $2 $(103)$— $1,401 
Government sponsored securities82 1 (5)— 78 
Foreign government securities321 1 (46)(2)274 
States, municipalities and political subdivisions, tax-exempt4,389 19 (265)— 4,143 
Corporate securities13,721 31 (1,218)(5)12,529 
Residential mortgage-backed securities2,978 9 (324)— 2,663 
Commercial mortgage-backed securities2,055 1 (176)(2)1,878 
Other asset-backed securities3,967 12 (241)— 3,738 
Total fixed maturity securities$29,015 $76 $(2,378)$(9)$26,704 
Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities.
For fixed maturity securities in an unrealized loss position at June 30, 2023 and December 31, 2022, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
June 30, 2023
Fixed maturity securities:
United States Government securities58$1,019 $(29)48$278 $(46)
Government sponsored securities1863 (2)2918 (2)
Foreign government securities
9756 (2)224186 (39)
States, municipalities and political subdivisions, tax-exempt7021,278 (20)9251,598 (187)
Corporate securities2,0514,323 (129)3,2166,910 (868)
Residential mortgage-backed securities6421,251 (38)1,2861,714 (275)
Commercial mortgage-backed securities246701 (28)5531,316 (152)
Other asset-backed securities3481,258 (62)8272,265 (146)
Total fixed maturity securities4,162$9,949 $(310)7,108$14,285 $(1,715)
December 31, 2022
Fixed maturity securities:
United States Government securities61$701 $(40)38$442 $(63)
Government sponsored securities3973 (4)65 (1)
Foreign government securities
150100 (10)198142 (36)
States, municipalities and political subdivisions, tax-exempt1,3982,615 (147)396652 (118)
Corporate securities3,5517,826 (549)2,2043,521 (669)
Residential mortgage-backed securities
1,3411,435 (121)496982 (203)
Commercial mortgage-backed securities
4571,082 (76)324719 (100)
Other asset-backed securities7842,203 (124)3981,074 (117)
Total fixed maturity securities7,781$16,035 $(1,071)4,060$7,537 $(1,307)
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of June 30, 2023, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amounts of $7 and $9 at June 30, 2023 and December 31, 2022, respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest.
The amortized cost and fair value of fixed maturity securities at June 30, 2023, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$1,127 $1,118 
Due after one year through five years8,193 7,810 
Due after five years through ten years9,466 8,883 
Due after ten years6,059 5,588 
Mortgage-backed securities5,879 5,397 
Total fixed maturity securities$30,724 $28,796 
During the three and six months ended June 30, 2023, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $9,675 and $15,085, respectively. During the three and six months ended June 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $7,026 and $10,672, respectively.
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at June 30, 2023 and December 31, 2022 is as follows:
 June 30, 2023December 31, 2022
Equity securities:
Exchange traded funds$166 $822 
Common equity securities31 43 
Private equity securities75 88 
Total$272 $953 
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three month lag due to the timing of when we receive financial information from the companies.
Investment Gains and Losses
Net investment (losses) gains for the three and six months ended June 30, 2023 and 2022 are as follows:
Three Months Ended June 30Six Months Ended June 30
2023202220232022
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$11 $16 $21 $36 
Gross realized losses from sales(99)(176)(214)(254)
Impairment losses recognized in income(3)(1)(10)(21)
Net realized losses from sales of fixed maturity securities(91)(161)(203)(239)
Equity securities:
Unrealized gains (losses) recognized on equity securities still held at the end of the period2 (83)(2)(154)
Net realized gains (losses) recognized on equity securities sold during the period1 (5)4 (19)
Net gains (losses) on equity securities3 (88)2 (173)
Other investments:
Gross gains2 10 20 33 
Gross losses(16)(15)(9)(44)
Impairment losses recognized in income(26)(1)(29)(5)
Net losses on other investments(40)(6)(18)(16)
Net losses on investments$(128)$(255)$(219)$(428)
Accrued Investment Income
At June 30, 2023 and December 31, 2022, accrued investment income totaled $266 and $245, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,311 and $2,457 at June 30, 2023 and December 31, 2022, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of June 30, 2023 and December 31, 2022. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
At June 30, 2023 and December 31, 2022, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,237 and $2,221, respectively, of United States Government securities for $73 and $224, respectively, and of Residential Mortgage-Backed securities for $1 and $12, respectively.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Derivative Financial Instruments
 6 Months Ended
Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial InstrumentsWe primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $214 and $229 at June 30, 2023 and December 31, 2022, respectively.
During the three and six months ended months ended June 30, 2023, we recognized net gains of $7 and net losses of $15, respectively, on non-hedging derivatives. During the three and six months ended months ended June 30, 2022, we recognized net gains on non-hedging derivatives of $24 and $46, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,” of this Form 10-Q.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level InputInput Definition
Level IInputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level IIInputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level IIIUnobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.
Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty.
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 is as follows:
Level ILevel IILevel IIITotal
June 30, 2023
Assets:
Cash equivalents$6,100 $— $— $6,100 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,883 — 1,883 
Government sponsored securities— 91 — 91 
Foreign government securities— 297 — 297 
States, municipalities and political subdivisions, tax-exempt— 3,772 — 3,772 
Corporate securities— 13,222 103 13,325 
Residential mortgage-backed securities— 3,315 — 3,315 
Commercial mortgage-backed securities— 2,082 — 2,082 
Other asset-backed securities— 3,665 366 4,031 
Total fixed maturity securities, available-for-sale— 28,327 469 28,796 
Equity securities:
Exchange traded funds166 — — 166 
Common equity securities12 19 — 31 
Private equity securities— — 75 75 
Total equity securities178 19 75 272 
Other invested assets - common equity securities121 — — 121 
Securities lending collateral— 2,312 — 2,312 
Derivatives - other assets— 3 — 3 
Total assets$6,399 $30,661 $544 $37,604 
Liabilities:
Derivatives - other liabilities$— $(69)$— $(69)
Total liabilities$— $(69)$— $(69)
December 31, 2022
Assets:
Cash equivalents$3,567 $— $— $3,567 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,401 — 1,401 
Government sponsored securities— 78 — 78 
Foreign government securities— 274 — 274 
States, municipalities and political subdivisions, tax-exempt— 4,143 — 4,143 
Corporate securities— 12,392 137 12,529 
Residential mortgage-backed securities— 2,663 — 2,663 
Commercial mortgage-backed securities— 1,878 — 1,878 
Other asset-backed securities— 3,382 356 3,738 
Total fixed maturity securities, available-for-sale— 26,211 493 26,704 
Equity securities:
Exchange traded funds822 — — 822 
Common equity securities2 41 — 43 
Private equity securities— — 88 88 
Total equity securities824 41 88 953 
Other invested assets - common equity securities103 — — 103 
Securities lending collateral— 2,457 — 2,457 
Derivatives - other assets— 3 — 3 
Total assets$4,494 $28,712 $581 $33,787 
Liabilities:
Derivatives - other liabilities$— $(60)$— $(60)
Total liabilities$— $(60)$— $(60)
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended June 30, 2023 and 2022 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other Asset-
backed
Securities		Equity
Securities		Total
Three Months Ended June 30, 2023
Beginning balance at April 1, 2023$142 $— $390 $78 $610 
Total gains (losses):
Recognized in net income(2)— 1 2 1 
Recognized in accumulated other comprehensive loss1 — (9)— (8)
Purchases2 — 7 — 9 
Sales(10)— (5)(5)(20)
Settlements(4)— — — (4)
Transfers into Level III— — 6 — 6 
Transfers out of Level III(26)— (24)— (50)
Ending balance at June 30, 2023$103 $— $366 $75 $544 
Change in unrealized losses included in net income related to assets still held at June 30, 2023
$— $— $— $1 $1 
Three Months Ended June 30, 2022
Beginning balance at April 1, 2022$341 $4 $37 $99 $481 
Total gains (losses):
Recognized in net income(5)— — (2)(7)
Purchases11 — 190 11 212 
Sales(188)— — (14)(202)
Settlements(5)— — — (5)
Transfers into Level III14 — — — 14 
Transfers out of Level III(13)(4)(9)— (26)
Ending balance at June 30, 2022$155 $— $218 $94 $467 
Change in unrealized gains included in net income related to assets still held at June 30, 2022
$— $— $— $(3)$(3)
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the six months ended June 30, 2023 and 2022 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other Asset-
backed
Securities		Equity
Securities		Total
Six Months Ended June 30, 2023
Beginning balance at January 1, 2023$137 $— $356 $88 $581 
Total losses:
Recognized in net income(3)— 1 (5)(7)
Recognized in accumulated other comprehensive loss2 — (4)— (2)
Purchases4 — 18 1 23 
Sales(10)— (11)(9)(30)
Settlements(6)— — — (6)
Transfers into Level III— — 6 — 6 
Transfers out of Level III(21)— — — (21)
Ending balance at June 30, 2023$103 $— $366 $75 $544 
Change in unrealized gains included in net income related to assets still held at June 30, 2023
$— $— $— $(6)$(6)
Six Months Ended June 30, 2022
Beginning balance at January 1, 2022$336 $5 $19 $89 $449 
Total gains:
Recognized in net income(4)— — 1 (3)
Recognized in accumulated other comprehensive loss(2)— — — (2)
Purchases35 — 205 20 260 
Sales(175)— — (16)(191)
Settlements(39)— — — (39)
Transfers into Level III14 — — — 14 
Transfers out of Level III(10)(5)(6)— (21)
Ending balance at June 30, 2022$155 $— $218 $94 $467 
Change in unrealized gains included in net income related to assets still held at June 30, 2022
$— $— $— $1 $1 
There were no individually material transfers into or out of Level III during the three and six months ended June 30, 2023 or 2022.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of BioPlus in the first quarter of 2023 and Integra during the second quarter of 2022. The net assets acquired in our acquisitions of BioPlus and Integra and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of tangible assets acquired and liabilities assumed were recorded at their carrying values as of the acquisition date, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of BioPlus and Integra were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of BioPlus and Integra described above, there were no
material assets or liabilities measured at fair value on a nonrecurring basis during the three and six months ended June 30, 2023 or 2022.
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and six months ended June 30, 2023 or 2022.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets:
Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities. The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at June 30, 2023 and December 31, 2022 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
June 30, 2023
Assets:
Other invested assets$5,872 $— $— $5,872 $5,872 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Notes24,859 — 22,872 — 22,872 
December 31, 2022
Assets:
Other invested assets$5,582 $— $— $5,582 $5,582 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Notes23,786 — 21,861 — 21,861 
Convertible debentures63 — 463 — 463 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes
 6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
During the three months ended June 30, 2023 and 2022, we recognized income tax expense of $585 and $488 (restated), respectively, which represent effective income tax rates of 24.0% and 23.0% (restated), respectively. The increase in our effective income tax rate from the three months ended June 30, 2022 is primarily due to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits.
During the six months ended June 30, 2023 and 2022, we recognized income tax expense of $1,200 and $1,015 (restated), respectively, which represent effective income tax rates of 23.7% and 22.9% (restated), respectively. The increase in our effective income tax rate from the six months ended June 30, 2022 is primarily related to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits.
Income taxes receivable totaled $48 and $440 at June 30, 2023 and December 31, 2022, respectively. We recognize the income receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Medical Claims Payable
 6 Months Ended
Jun. 30, 2023
Liability for Claims and Claims Adjustment Expense [Abstract]  
Medical Claims payable Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2023 and 2022 is as follows:
20232022
Gross medical claims payable, beginning of period$15,348 $13,282 
Ceded medical claims payable, beginning of period(6)(21)
Net medical claims payable, beginning of period15,342 13,261 
Business combinations and purchase adjustments— 133 
Net incurred medical claims:
Current period61,290 55,737 
Prior periods redundancies(1,112)(972)
Total net incurred medical claims60,178 54,765 
Net payments attributable to:
Current period medical claims48,217 42,882 
Prior periods medical claims11,409 10,401 
Total net payments59,626 53,283 
Net medical claims payable, end of period15,894 14,876 
Ceded medical claims payable, end of period8 13 
Gross medical claims payable, end of period$15,902 $14,889 
At June 30, 2023, the total of net incurred but not reported liabilities plus expected development on reported claims was $597, $2,224 and $13,073 for the claim years 2021 and prior, 2022 and 2023, respectively.
The favorable development recognized in the six months ended June 30, 2023 and 2022 resulted primarily from trend factors in late 2022 and late 2021, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2022 developing faster than expected also contributed to the favorable development in the six months ended June 30, 2023.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2023 is as follows:
Three Months Ended Six Months Ended June 30, 2023
March 31, 2023June 30, 2023
Total net incurred medical claims$29,683 $30,495 $60,178 
Quality improvement and other claims expense1,103 1,109 2,212 
Benefit expense$30,786 $31,604 $62,390 
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2022 is as follows:
Three Months Ended Six Months Ended June 30, 2022
March 31, 2022June 30, 2022
(Restated)(Restated)(Restated)
Total net incurred medical claims$27,131 $27,634 $54,765 
Quality improvement and other claims expense1,100 1,161 2,261 
Benefit expense$28,231 $28,795 $57,026 
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of June 30, 2023 and December 31, 2022, is as follows:
June 30, 2023December 31, 2022
Net medical claims payable, end of period$15,894 $15,342 
Ceded medical claims payable, end of period8 6 
Insurance lines other than short duration263 248 
Gross medical claims payable, end of period$16,165 $15,596 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Debt
 6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Debt Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At June 30, 2023 and December 31, 2022, we had $24,834 and $23,761, respectively, outstanding under these notes.
On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the “2026 Notes”), $1,000 aggregate principal amount of 4.750% Notes due 2033 (the “2033 Notes”), and $1,100 aggregate principal amount of 5.125% Notes due 2053 (the “2053 Notes”) under our shelf registration statement. Interest on the 2026 Notes is payable semi-annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and 2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023. We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.
On January 17, 2023, we repaid, at maturity, the $1,000 outstanding balance of our 3.300% senior unsecured notes. On March 15, 2023, we repaid, at maturity, the $500 outstanding balance of our 0.450% senior unsecured notes.
We have an unsecured surplus note with an outstanding principal balance of $25 at both June 30, 2023 and December 31, 2022.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of June 30, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.6%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of June 30, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the six months ended June 30, 2023 or the year ended December 31, 2022.
Through certain subsidiaries, we had previously entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provided combined credit of up to $200. As of June 30, 2023, the Subsidiary Credit Facilities have been terminated.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. At June 30, 2023 and December 31, 2022, we had $90 and $0, respectively, outstanding under this program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.
On March 15, 2023, we redeemed all of our outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), pursuant to the indenture dated as of October 9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The Debentures were redeemed at a redemption price equal to 100% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption, for cash totaling $5. During the three months ended March 31, 2023, $59 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and conditions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three months ended March 31, 2023 of $404.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $175 and $265 of outstanding short-term borrowings from the FHLBs at June 30, 2023 and December 31, 2022, respectively.
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLBs borrowings.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments And Contingencies
 6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments And Contingencies Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint, or in other court filings, the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at June 30, 2023. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in 28 states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.
In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which amount was accrued in 2020.
Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit, which has scheduled oral argument on the appeals for September 2023. In the event that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that Ohio v. American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In November 2022, the Court issued an order requiring the parties to submit supplemental briefs on certain questions related to the providers’ renewed motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.) ("Alaska Air"); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.) ("Jet Blue"); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.) ("Bed Bath & Beyond"); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.). In February 2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in Alaska Air and Jet Blue. In March 2023, pursuant to a stipulation by the parties, the Court denied the
defendants’ motion to dismiss also based on a statute of limitations defense in Bed Bath & Beyond. We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.
Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.
In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit. In November 2021, the plaintiff appealed the summary judgment order. In March 2023, the appeal was argued before the California Second District Court of Appeal (the "Second District"). The Second District affirmed the Superior Court's summary judgment order in April 2023. The plaintiff filed a petition for review with the California Supreme Court in June 2023, and BCC filed its answer to the petition in the same month. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.

Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for pharmacy benefit management services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express
Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed, and the District Court denied in March 2023, allowing our operational breach claim to proceed. A trial date has been set for December 2023. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be complete by February 2025. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We have submitted corrected data to CMS related to these investigations. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the indemnity claims were resolved in the fourth quarters of 2021 and 2022, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our
business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The agreement superseded certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at June 30, 2023 is approximately $621. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.
We formed CarelonRx, formerly known as IngenioRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own, starting in the second quarter of 2019. The comprehensive pharmacy services portfolio includes, but is not limited to, formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services. CarelonRx delegates certain pharmacy services, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock
 6 Months Ended
Jun. 30, 2023
Banking Regulation, Total Capital [Abstract]  
Capital Stock Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the six months ended June 30, 2023 and 2022 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Six Months Ended June 30, 2023
January 24, 2023March 10, 2023March 24, 2023$1.48$351 
April 18, 2023June 9, 2023June 23, 2023$1.48$350 
Six Months Ended June 30, 2022
January 25, 2022March 10, 2022March 25, 2022$1.28$309 
April 19, 2022June 10, 2022June 24, 2022$1.28$309 
On July 18, 2023, our Audit Committee declared a third quarter 2023 dividend to shareholders of $1.48 per share, payable on September 22, 2023 to shareholders of record at the close of business on September 8, 2023.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
A summary of common stock repurchases for the six months ended June 30, 2023 and 2022 is as follows:
Six Months Ended June 30
 20232022
Shares repurchased2.7 2.5 
Average price per share$466.62 $471.72 
Aggregate cost$1,268 $1,169 
Authorization remaining at the end of the period$5,608 $3,022 
For additional information regarding the use of capital for debt security repurchases, see Note 9, “Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
Stock Incentive Plans
A summary of stock option activity for the six months ended June 30, 2023 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20232.8 $293.28 
Granted0.6 469.05 
Exercised(0.2)268.35 
Forfeited or expired— 391.44 
Outstanding at June 30, 20233.2 323.85 6.51$402 
Exercisable at June 30, 20232.1 265.51 5.31$376 
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the six months ended June 30, 2023 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20231.2 $357.21 
Granted0.6 469.60 
Vested(0.6)301.18 
Forfeited— 405.25 
Nonvested at June 30, 20231.2 422.67 
During the six months ended June 30, 2023, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three-year period from 2023 to 2025. These grants have been included in the activity shown above but will be subject to adjustment at the end of 2025 based on results in the three-year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the six months ended June 30, 2023 and 2022:
Six Months Ended June 30
20232022
Risk-free interest rate3.95 %1.97 %
Volatility factor29.00 %29.00 %
Quarterly dividend yield0.316 %0.282 %
Weighted-average expected life (years)4.405.10
The following weighted-average fair values per option or share were determined for the six months ended June 30, 2023 and 2022: 
Six Months Ended June 30
20232022
Options granted during the period$127.13 $116.80 
Restricted stock awards granted during the period469.60 452.78 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Accumulated Other Comprehensive Loss
 6 Months Ended
Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at June 30, 2023 and 2022 is as follows:
Three Months Ended
June 30		Six Months Ended
June 30
2023202220232022
(Restated)(Restated)
Net unrealized investment (losses) gains:
Beginning of period balance$(1,330)$(570)$(1,755)$494 
Other comprehensive (loss) gain before reclassifications, net of tax benefit (expense) of $61, $323, $(25) and $677, respectively
(191)(1,050)146 (2,196)
Amounts reclassified from accumulated other comprehensive loss, net of tax expense of $(23), $(34), $(51) and $(55), respectively
72 128 162 205 
Other comprehensive (loss) income(119)(922)308 (1,991)
Other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0 and $(3), respectively
— 3 (2)8 
End of period balance(1,449)(1,489)(1,449)(1,489)
Non-credit components of impairments on investments:
Beginning of period balance(5)(1)(3)— 
Other comprehensive loss, net of tax benefit of $0, $0, $1 and $1, respectively
(1)(1)(3)(2)
End of period balance(6)(2)(6)(2)
Net cash flow hedges:
Beginning of period balance(218)(236)(229)(239)
Other comprehensive income, net of tax (expense) of $(1), $(1), $7 and $(2), respectively
4 3 15 6 
End of period balance(214)(233)(214)(233)
Pension and other postretirement benefits:
Beginning of period balance(497)(422)(499)(429)
Other comprehensive income, net of tax expense of $(1), $(4), $(2) and $(6), respectively
3 9 5 16 
End of period balance(494)(413)(494)(413)
Future policy benefits:
Beginning of period balance15 (10)13 (19)
Other comprehensive (loss) income, net of tax expense of $1, $0, $1 and $0, respectively
(3)8 (1)17 
End of period balance12 (2)12 (2)
Foreign currency translation adjustments:
Beginning of period balance(15)(7)(17)(4)
Other comprehensive income (loss), net of tax benefit of $(5), $1, $(3) and $2, respectively
— (5)2 (8)
End of period balance(15)(12)(15)(12)
Total:
Total beginning of period accumulated other comprehensive loss(2,050)(1,246)(2,490)(197)
Total other comprehensive (loss) income, net of tax benefit (expense) of $32, $285, $(72), and $617, respectively
(116)(908)326 (1,962)
Total other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0and $(3) respectively
— 3 (2)8 
Total end of period accumulated other comprehensive loss$(2,166)$(2,151)$(2,166)$(2,151)
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Share
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings per Share
The denominator for basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
Denominator for basic earnings per share – weighted-average shares
236.6 240.7 237.0 241.0 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
1.2 2.7 1.7 2.9 
Denominator for diluted earnings per share
237.8 243.4 238.7 243.9 
During the three months ended June 30, 2023 and 2022, weighted-average shares related to certain stock options of 1.0 and 0.5 respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the six months ended June 30, 2023 and 2022, weighted-average shares related to certain stock options of 0.7 and 0.4, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options were anti-dilutive.
During the three and six months ended June 30, 2023, we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2023 through 2025. During the three and six months ended months ended June 30, 2022, we issued approximately 0.0 and 0.5 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2022 through 2024. The contingent restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if and when the contingency is met.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information
 6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Segment Information Segment Information
As discussed in Note 1 “Organization”, we are reorganizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business and the products in each of our operating segments, which has resulted in restructurings between some of our operating segments. As a result of these changes, we have changed our reportable segment presentation and its composition to reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources beginning on January 1, 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other. In 2022, we managed and presented our operations through the following four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx and Other. Previously reported information throughout this Form 10-Q has been reclassified to conform to the new presentation.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes services such as formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services.

Our Carelon Services segment is focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic
conditions. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as corporate expenses not allocated to our other reportable segments.
We define operating revenues to include premium income, product revenue and service fees. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense.
Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, in addition to certain back-office services provided by our international businesses, which are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.
Financial data by reportable segment for the three months ended June 30, 2023 and 2022 is as follows:
Carelon
Health
Benefits		CarelonRxCarelon
Services		TotalCorporate
& Other		EliminationsTotal
Three Months Ended June 30, 2023
Premiums$36,233 $— $429 $429 $— $(73)$36,589 
Product revenue— 4,859 — 4,859 — — 4,859 
Service fees1,767 — 201 201 (39)— 1,929 
Operating revenue - unaffiliated38,000 4,859 630 5,489 (39)(73)43,377 
Operating revenue - affiliated— 3,607 2,811 6,418 326 (6,744)— 
Operating revenue - total$38,000 $8,466 $3,441 $11,907 $287 $(6,817)$43,377 
Operating gain (loss)$2,148 $496 $136 $632 $(152)$— $2,628 
Three Months Ended June 30, 2022
Premiums$32,787 $— $327 $327 $— $(38)$33,076 
Product revenue— 3,568 — 3,568 — — 3,568 
Service fees1,609 — 220 220 9 — 1,838 
Operating revenue - unaffiliated34,396 3,568 547 4,115 9 (38)38,482 
Operating revenue - affiliated— 3,503 2,436 5,939 306 (6,245)— 
Operating revenue - total$34,396 $7,071 $2,983 $10,054 $315 $(6,283)$38,482 
Operating gain (loss) (restated)$1,781 $479 $113 $592 $(27)$— $2,346 
Financial data by reportable segment for the six months ended June 30, 2023 and 2022 is as follows:
Carelon
Health
Benefits		CarelonRxCarelon
Services		TotalCorporate
& Other		EliminationsTotal
Six Months Ended June 30, 2023
Premiums$71,767 $— $839 $839 $— $(149)$72,457 
Product revenue— 8,881 — 8,881 — — 8,881 
Service fees3,513 — 408 408 16 — 3,937 
Operating revenue - unaffiliated75,280 8,881 1,247 10,128 16 (149)85,275 
Operating revenue - affiliated— 7,609 5,506 13,115 522 (13,637)— 
Operating revenue - total$75,280 $16,490 $6,753 $23,243 $538 $(13,786)$85,275 
Operating gain (loss)$4,307 $1,008 $345 $1,353 (201)— 5,459 
Six Months Ended June 30, 2022
Premiums$65,250 $— $693 $693 $— $(82)$65,861 
Product revenue— 6,869 — 6,869 — — 6,869 
Service fees3,173 — 446 446 19 — 3,638 
Operating revenue - unaffiliated68,423 6,869 1,139 8,008 19 (82)76,368 
Operating revenue - affiliated— 6,885 4,792 11,677 569 (12,246)— 
Operating revenue - total$68,423 $13,754 $5,931 $19,685 $588 $(12,328)$76,368 
Operating gain (loss) (restated)$3,632 $877 $313 $1,190 $(49)$— $4,773 
For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated eliminations.
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
Reportable segments’ operating revenue43,377 $38,482 $85,275 $76,368 
Net investment income416 381 803 741 
Net losses on financial instruments(121)(231)(234)(382)
Total revenues$43,672 $38,632 $85,844 $76,727 
A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
(Restated)(Restated)
Income before income tax expense$2,441 $2,122 $5,060 $4,428 
Net investment income(416)(381)(803)(741)
Net losses on financial instruments121 231 234 382 
Interest expense261 208 512 409 
Amortization of other intangible assets221 166 456 295 
Reportable segments’ operating gain$2,628 $2,346 $5,459 $4,773 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Leases
 6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Leases Leases
We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases have remaining lease terms of 1 year to 11 years.
The information related to our leases is as follows:
Balance Sheet LocationJune 30, 2023December 31, 2022
Operating Leases
Right-of-use assetsOther noncurrent assets$605 $604 
Lease liabilities, currentOther current liabilities178 181 
Lease liabilities, noncurrentOther noncurrent liabilities717 751 
Three Months Ended 
 June 30		Six Months Ended 
 June 30
2023202220232022
Lease Expense
Operating lease expense$32 $33 $57 $65 
Short-term and variable lease expense16 11 29 24 
Sublease income(1)(1)(2)(2)
Total lease expense$47 $43 $84 $87 
Other information
 Operating cash paid for amounts included in the measurement of lease liabilities, operating leases$54 $53 $105 $105 
Right-of-use assets obtained in exchange for new lease liabilities, operating leases$18 $29 $40 $37 
As of June 30, 2023 and December 31, 2022, the weighted average remaining lease term of our operating leases was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 3.28% at June 30, 2023 and 2.98% at December 31, 2022.
Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:
2023 (excluding the six months ended June 30, 2023)$110 
2024195 
2025162 
2026128 
202793 
Thereafter329 
Total future minimum payments 1,017 
Less imputed interest122 
Total lease liabilities$895 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) , unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and six months ended June 30, 2023 and 2022 have been recorded. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
Foreign Currency Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $391 and $258 at June 30, 2023 and December 31, 2022, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investment, Policy
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivable
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $184 and $152 at June 30, 2023 and December 31, 2022, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $86 and $68 at June 30, 2023 and December 31, 2022, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $816 and $744 at June 30, 2023 and December 31, 2022, respectively.
Revenue Recognition Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at June 30, 2023. For the three and six months ended June 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
New Accounting Pronouncements Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our adoption as required by the new standard.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Tables)
 6 Months Ended
Jun. 30, 2023
Investments [Abstract]  
Current and Long-Term Investments, Available-For-Sale
A summary of current and long-term fixed maturity securities, available-for-sale, at June 30, 2023 and December 31, 2022 is as follows:
Cost or
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
June 30, 2023
Fixed maturity securities:
United States Government securities$1,957 $1 $(75)$— $1,883 
Government sponsored securities94 1 (4)— 91 
Foreign government securities337 2 (41)(1)297 
States, municipalities and political subdivisions, tax-exempt3,957 22 (207)— 3,772 
Corporate securities14,276 50 (997)(4)13,325 
Residential mortgage-backed securities3,617 11 (313)— 3,315 
Commercial mortgage-backed securities2,262 2 (180)(2)2,082 
Other asset-backed securities4,224 15 (208)— 4,031 
Total fixed maturity securities$30,724 $104 $(2,025)$(7)$28,796 
December 31, 2022
Fixed maturity securities:
United States Government securities$1,502 $2 $(103)$— $1,401 
Government sponsored securities82 1 (5)— 78 
Foreign government securities321 1 (46)(2)274 
States, municipalities and political subdivisions, tax-exempt4,389 19 (265)— 4,143 
Corporate securities13,721 31 (1,218)(5)12,529 
Residential mortgage-backed securities2,978 9 (324)— 2,663 
Commercial mortgage-backed securities2,055 1 (176)(2)1,878 
Other asset-backed securities3,967 12 (241)— 3,738 
Total fixed maturity securities$29,015 $76 $(2,378)$(9)$26,704 
Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position
For fixed maturity securities in an unrealized loss position at June 30, 2023 and December 31, 2022, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
June 30, 2023
Fixed maturity securities:
United States Government securities58$1,019 $(29)48$278 $(46)
Government sponsored securities1863 (2)2918 (2)
Foreign government securities
9756 (2)224186 (39)
States, municipalities and political subdivisions, tax-exempt7021,278 (20)9251,598 (187)
Corporate securities2,0514,323 (129)3,2166,910 (868)
Residential mortgage-backed securities6421,251 (38)1,2861,714 (275)
Commercial mortgage-backed securities246701 (28)5531,316 (152)
Other asset-backed securities3481,258 (62)8272,265 (146)
Total fixed maturity securities4,162$9,949 $(310)7,108$14,285 $(1,715)
December 31, 2022
Fixed maturity securities:
United States Government securities61$701 $(40)38$442 $(63)
Government sponsored securities3973 (4)65 (1)
Foreign government securities
150100 (10)198142 (36)
States, municipalities and political subdivisions, tax-exempt1,3982,615 (147)396652 (118)
Corporate securities3,5517,826 (549)2,2043,521 (669)
Residential mortgage-backed securities
1,3411,435 (121)496982 (203)
Commercial mortgage-backed securities
4571,082 (76)324719 (100)
Other asset-backed securities7842,203 (124)3981,074 (117)
Total fixed maturity securities7,781$16,035 $(1,071)4,060$7,537 $(1,307)
Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity
The amortized cost and fair value of fixed maturity securities at June 30, 2023, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$1,127 $1,118 
Due after one year through five years8,193 7,810 
Due after five years through ten years9,466 8,883 
Due after ten years6,059 5,588 
Mortgage-backed securities5,879 5,397 
Total fixed maturity securities$30,724 $28,796 
Investments In Equity Securities
A summary of marketable equity securities at June 30, 2023 and December 31, 2022 is as follows:
 June 30, 2023December 31, 2022
Equity securities:
Exchange traded funds$166 $822 
Common equity securities31 43 
Private equity securities75 88 
Total$272 $953 
Net Investment Gains (Losses)
Net investment (losses) gains for the three and six months ended June 30, 2023 and 2022 are as follows:
Three Months Ended June 30Six Months Ended June 30
2023202220232022
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$11 $16 $21 $36 
Gross realized losses from sales(99)(176)(214)(254)
Impairment losses recognized in income(3)(1)(10)(21)
Net realized losses from sales of fixed maturity securities(91)(161)(203)(239)
Equity securities:
Unrealized gains (losses) recognized on equity securities still held at the end of the period2 (83)(2)(154)
Net realized gains (losses) recognized on equity securities sold during the period1 (5)4 (19)
Net gains (losses) on equity securities3 (88)2 (173)
Other investments:
Gross gains2 10 20 33 
Gross losses(16)(15)(9)(44)
Impairment losses recognized in income(26)(1)(29)(5)
Net losses on other investments(40)(6)(18)(16)
Net losses on investments$(128)$(255)$(219)$(428)
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value (Tables)
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 is as follows:
Level ILevel IILevel IIITotal
June 30, 2023
Assets:
Cash equivalents$6,100 $— $— $6,100 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,883 — 1,883 
Government sponsored securities— 91 — 91 
Foreign government securities— 297 — 297 
States, municipalities and political subdivisions, tax-exempt— 3,772 — 3,772 
Corporate securities— 13,222 103 13,325 
Residential mortgage-backed securities— 3,315 — 3,315 
Commercial mortgage-backed securities— 2,082 — 2,082 
Other asset-backed securities— 3,665 366 4,031 
Total fixed maturity securities, available-for-sale— 28,327 469 28,796 
Equity securities:
Exchange traded funds166 — — 166 
Common equity securities12 19 — 31 
Private equity securities— — 75 75 
Total equity securities178 19 75 272 
Other invested assets - common equity securities121 — — 121 
Securities lending collateral— 2,312 — 2,312 
Derivatives - other assets— 3 — 3 
Total assets$6,399 $30,661 $544 $37,604 
Liabilities:
Derivatives - other liabilities$— $(69)$— $(69)
Total liabilities$— $(69)$— $(69)
December 31, 2022
Assets:
Cash equivalents$3,567 $— $— $3,567 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,401 — 1,401 
Government sponsored securities— 78 — 78 
Foreign government securities— 274 — 274 
States, municipalities and political subdivisions, tax-exempt— 4,143 — 4,143 
Corporate securities— 12,392 137 12,529 
Residential mortgage-backed securities— 2,663 — 2,663 
Commercial mortgage-backed securities— 1,878 — 1,878 
Other asset-backed securities— 3,382 356 3,738 
Total fixed maturity securities, available-for-sale— 26,211 493 26,704 
Equity securities:
Exchange traded funds822 — — 822 
Common equity securities2 41 — 43 
Private equity securities— — 88 88 
Total equity securities824 41 88 953 
Other invested assets - common equity securities103 — — 103 
Securities lending collateral— 2,457 — 2,457 
Derivatives - other assets— 3 — 3 
Total assets$4,494 $28,712 $581 $33,787 
Liabilities:
Derivatives - other liabilities$— $(60)$— $(60)
Total liabilities$— $(60)$— $(60)
Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended June 30, 2023 and 2022 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other Asset-
backed
Securities		Equity
Securities		Total
Three Months Ended June 30, 2023
Beginning balance at April 1, 2023$142 $— $390 $78 $610 
Total gains (losses):
Recognized in net income(2)— 1 2 1 
Recognized in accumulated other comprehensive loss1 — (9)— (8)
Purchases2 — 7 — 9 
Sales(10)— (5)(5)(20)
Settlements(4)— — — (4)
Transfers into Level III— — 6 — 6 
Transfers out of Level III(26)— (24)— (50)
Ending balance at June 30, 2023$103 $— $366 $75 $544 
Change in unrealized losses included in net income related to assets still held at June 30, 2023
$— $— $— $1 $1 
Three Months Ended June 30, 2022
Beginning balance at April 1, 2022$341 $4 $37 $99 $481 
Total gains (losses):
Recognized in net income(5)— — (2)(7)
Purchases11 — 190 11 212 
Sales(188)— — (14)(202)
Settlements(5)— — — (5)
Transfers into Level III14 — — — 14 
Transfers out of Level III(13)(4)(9)— (26)
Ending balance at June 30, 2022$155 $— $218 $94 $467 
Change in unrealized gains included in net income related to assets still held at June 30, 2022
$— $— $— $(3)$(3)
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the six months ended June 30, 2023 and 2022 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other Asset-
backed
Securities		Equity
Securities		Total
Six Months Ended June 30, 2023
Beginning balance at January 1, 2023$137 $— $356 $88 $581 
Total losses:
Recognized in net income(3)— 1 (5)(7)
Recognized in accumulated other comprehensive loss2 — (4)— (2)
Purchases4 — 18 1 23 
Sales(10)— (11)(9)(30)
Settlements(6)— — — (6)
Transfers into Level III— — 6 — 6 
Transfers out of Level III(21)— — — (21)
Ending balance at June 30, 2023$103 $— $366 $75 $544 
Change in unrealized gains included in net income related to assets still held at June 30, 2023
$— $— $— $(6)$(6)
Six Months Ended June 30, 2022
Beginning balance at January 1, 2022$336 $5 $19 $89 $449 
Total gains:
Recognized in net income(4)— — 1 (3)
Recognized in accumulated other comprehensive loss(2)— — — (2)
Purchases35 — 205 20 260 
Sales(175)— — (16)(191)
Settlements(39)— — — (39)
Transfers into Level III14 — — — 14 
Transfers out of Level III(10)(5)(6)— (21)
Ending balance at June 30, 2022$155 $— $218 $94 $467 
Change in unrealized gains included in net income related to assets still held at June 30, 2022
$— $— $— $1 $1 
Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at June 30, 2023 and December 31, 2022 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
June 30, 2023
Assets:
Other invested assets$5,872 $— $— $5,872 $5,872 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Notes24,859 — 22,872 — 22,872 
December 31, 2022
Assets:
Other invested assets$5,582 $— $— $5,582 $5,582 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Notes23,786 — 21,861 — 21,861 
Convertible debentures63 — 463 — 463 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Medical Claims Payable (Tables)
 6 Months Ended
Jun. 30, 2023
Liability for Claims and Claims Adjustment Expense [Abstract]  
Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2023 and 2022 is as follows:
20232022
Gross medical claims payable, beginning of period$15,348 $13,282 
Ceded medical claims payable, beginning of period(6)(21)
Net medical claims payable, beginning of period15,342 13,261 
Business combinations and purchase adjustments— 133 
Net incurred medical claims:
Current period61,290 55,737 
Prior periods redundancies(1,112)(972)
Total net incurred medical claims60,178 54,765 
Net payments attributable to:
Current period medical claims48,217 42,882 
Prior periods medical claims11,409 10,401 
Total net payments59,626 53,283 
Net medical claims payable, end of period15,894 14,876 
Ceded medical claims payable, end of period8 13 
Gross medical claims payable, end of period$15,902 $14,889 
Reconciliation of Net Incurred Medical Claims to Benefit Expense
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2023 is as follows:
Three Months Ended Six Months Ended June 30, 2023
March 31, 2023June 30, 2023
Total net incurred medical claims$29,683 $30,495 $60,178 
Quality improvement and other claims expense1,103 1,109 2,212 
Benefit expense$30,786 $31,604 $62,390 
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2022 is as follows:
Three Months Ended Six Months Ended June 30, 2022
March 31, 2022June 30, 2022
(Restated)(Restated)(Restated)
Total net incurred medical claims$27,131 $27,634 $54,765 
Quality improvement and other claims expense1,100 1,161 2,261 
Benefit expense$28,231 $28,795 $57,026 
Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of June 30, 2023 and December 31, 2022, is as follows:
June 30, 2023December 31, 2022
Net medical claims payable, end of period$15,894 $15,342 
Ceded medical claims payable, end of period8 6 
Insurance lines other than short duration263 248 
Gross medical claims payable, end of period$16,165 $15,596 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock (Tables)
 6 Months Ended
Jun. 30, 2023
Banking Regulation, Total Capital [Abstract]  
Summary of Cash Dividend Activity
A summary of our cash dividend activity for the six months ended June 30, 2023 and 2022 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Six Months Ended June 30, 2023
January 24, 2023March 10, 2023March 24, 2023$1.48$351 
April 18, 2023June 9, 2023June 23, 2023$1.48$350 
Six Months Ended June 30, 2022
January 25, 2022March 10, 2022March 25, 2022$1.28$309 
April 19, 2022June 10, 2022June 24, 2022$1.28$309 
Summary of Share Repurchases
A summary of common stock repurchases for the six months ended June 30, 2023 and 2022 is as follows:
Six Months Ended June 30
 20232022
Shares repurchased2.7 2.5 
Average price per share$466.62 $471.72 
Aggregate cost$1,268 $1,169 
Authorization remaining at the end of the period$5,608 $3,022 
Summary of Stock Option Activity
A summary of stock option activity for the six months ended June 30, 2023 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20232.8 $293.28 
Granted0.6 469.05 
Exercised(0.2)268.35 
Forfeited or expired— 391.44 
Outstanding at June 30, 20233.2 323.85 6.51$402 
Exercisable at June 30, 20232.1 265.51 5.31$376 
Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the six months ended June 30, 2023 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20231.2 $357.21 
Granted0.6 469.60 
Vested(0.6)301.18 
Forfeited— 405.25 
Nonvested at June 30, 20231.2 422.67 
Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods
The following weighted-average assumptions were used to estimate the fair values of options granted during the six months ended June 30, 2023 and 2022:
Six Months Ended June 30
20232022
Risk-free interest rate3.95 %1.97 %
Volatility factor29.00 %29.00 %
Quarterly dividend yield0.316 %0.282 %
Weighted-average expected life (years)4.405.10
Schedule of Weighted-Average Fair Values Determined for the Periods
The following weighted-average fair values per option or share were determined for the six months ended June 30, 2023 and 2022: 
Six Months Ended June 30
20232022
Options granted during the period$127.13 $116.80 
Restricted stock awards granted during the period469.60 452.78 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Accumulated Other Comprehensive Loss (Tables)
 6 Months Ended
Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Reconciliation Of Components Of Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at June 30, 2023 and 2022 is as follows:
Three Months Ended
June 30		Six Months Ended
June 30
2023202220232022
(Restated)(Restated)
Net unrealized investment (losses) gains:
Beginning of period balance$(1,330)$(570)$(1,755)$494 
Other comprehensive (loss) gain before reclassifications, net of tax benefit (expense) of $61, $323, $(25) and $677, respectively
(191)(1,050)146 (2,196)
Amounts reclassified from accumulated other comprehensive loss, net of tax expense of $(23), $(34), $(51) and $(55), respectively
72 128 162 205 
Other comprehensive (loss) income(119)(922)308 (1,991)
Other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0 and $(3), respectively
— 3 (2)8 
End of period balance(1,449)(1,489)(1,449)(1,489)
Non-credit components of impairments on investments:
Beginning of period balance(5)(1)(3)— 
Other comprehensive loss, net of tax benefit of $0, $0, $1 and $1, respectively
(1)(1)(3)(2)
End of period balance(6)(2)(6)(2)
Net cash flow hedges:
Beginning of period balance(218)(236)(229)(239)
Other comprehensive income, net of tax (expense) of $(1), $(1), $7 and $(2), respectively
4 3 15 6 
End of period balance(214)(233)(214)(233)
Pension and other postretirement benefits:
Beginning of period balance(497)(422)(499)(429)
Other comprehensive income, net of tax expense of $(1), $(4), $(2) and $(6), respectively
3 9 5 16 
End of period balance(494)(413)(494)(413)
Future policy benefits:
Beginning of period balance15 (10)13 (19)
Other comprehensive (loss) income, net of tax expense of $1, $0, $1 and $0, respectively
(3)8 (1)17 
End of period balance12 (2)12 (2)
Foreign currency translation adjustments:
Beginning of period balance(15)(7)(17)(4)
Other comprehensive income (loss), net of tax benefit of $(5), $1, $(3) and $2, respectively
— (5)2 (8)
End of period balance(15)(12)(15)(12)
Total:
Total beginning of period accumulated other comprehensive loss(2,050)(1,246)(2,490)(197)
Total other comprehensive (loss) income, net of tax benefit (expense) of $32, $285, $(72), and $617, respectively
(116)(908)326 (1,962)
Total other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0and $(3) respectively
— 3 (2)8 
Total end of period accumulated other comprehensive loss$(2,166)$(2,151)$(2,166)$(2,151)
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Denominator for Basic and Diluted Earnings Per Share
The denominator for basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
Denominator for basic earnings per share – weighted-average shares
236.6 240.7 237.0 241.0 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
1.2 2.7 1.7 2.9 
Denominator for diluted earnings per share
237.8 243.4 238.7 243.9 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Financial Data By Reportable Segment
Financial data by reportable segment for the three months ended June 30, 2023 and 2022 is as follows:
Carelon
Health
Benefits		CarelonRxCarelon
Services		TotalCorporate
& Other		EliminationsTotal
Three Months Ended June 30, 2023
Premiums$36,233 $— $429 $429 $— $(73)$36,589 
Product revenue— 4,859 — 4,859 — — 4,859 
Service fees1,767 — 201 201 (39)— 1,929 
Operating revenue - unaffiliated38,000 4,859 630 5,489 (39)(73)43,377 
Operating revenue - affiliated— 3,607 2,811 6,418 326 (6,744)— 
Operating revenue - total$38,000 $8,466 $3,441 $11,907 $287 $(6,817)$43,377 
Operating gain (loss)$2,148 $496 $136 $632 $(152)$— $2,628 
Three Months Ended June 30, 2022
Premiums$32,787 $— $327 $327 $— $(38)$33,076 
Product revenue— 3,568 — 3,568 — — 3,568 
Service fees1,609 — 220 220 9 — 1,838 
Operating revenue - unaffiliated34,396 3,568 547 4,115 9 (38)38,482 
Operating revenue - affiliated— 3,503 2,436 5,939 306 (6,245)— 
Operating revenue - total$34,396 $7,071 $2,983 $10,054 $315 $(6,283)$38,482 
Operating gain (loss) (restated)$1,781 $479 $113 $592 $(27)$— $2,346 
Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
Reportable segments’ operating revenue43,377 $38,482 $85,275 $76,368 
Net investment income416 381 803 741 
Net losses on financial instruments(121)(231)(234)(382)
Total revenues$43,672 $38,632 $85,844 $76,727 
Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income
A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:
 Three Months Ended 
 June 30		Six Months Ended 
 June 30
 2023202220232022
(Restated)(Restated)
Income before income tax expense$2,441 $2,122 $5,060 $4,428 
Net investment income(416)(381)(803)(741)
Net losses on financial instruments121 231 234 382 
Interest expense261 208 512 409 
Amortization of other intangible assets221 166 456 295 
Reportable segments’ operating gain$2,628 $2,346 $5,459 $4,773 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Tables)
 6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Lessee, Operating Lease, Disclosure [Table Text Block]
The information related to our leases is as follows:
Balance Sheet LocationJune 30, 2023December 31, 2022
Operating Leases
Right-of-use assetsOther noncurrent assets$605 $604 
Lease liabilities, currentOther current liabilities178 181 
Lease liabilities, noncurrentOther noncurrent liabilities717 751 
Three Months Ended 
 June 30		Six Months Ended 
 June 30
2023202220232022
Lease Expense
Operating lease expense$32 $33 $57 $65 
Short-term and variable lease expense16 11 29 24 
Sublease income(1)(1)(2)(2)
Total lease expense$47 $43 $84 $87 
Other information
 Operating cash paid for amounts included in the measurement of lease liabilities, operating leases$54 $53 $105 $105 
Right-of-use assets obtained in exchange for new lease liabilities, operating leases$18 $29 $40 $37 
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:
2023 (excluding the six months ended June 30, 2023)$110 
2024195 
2025162 
2026128 
202793 
Thereafter329 
Total future minimum payments 1,017 
Less imputed interest122 
Total lease liabilities$895 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Organization (Details)
medical_member in Millions
Jun. 30, 2023
medical_member
county
states
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of Medical Members | medical_member 48
Number of counties in the Kansas City area the Company does not serve | county 30
Number of states in which the Company is licensed to conduct insurance operations | states 50
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Line Items]    
Customer funds and cash and cash equivalents on deposit for regulatory requirements $ 391 $ 258
Securities lending transactions, initial collateral percentage value 102.00%  
Premium receivable, allowance for doubtful accounts $ 184 152
Self-funded receivables, allowance for doubtful accounts 86 68
Allowance for doubtful accounts, other receivables $ 816 $ 744
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Goodwill $ 25,274 $ 25,274 $ 24,383
Integra Managed Care [Member]      
Business Acquisition [Line Items]      
Finite-lived Intangible Assets Acquired   89  
Indefinite-lived Intangible Assets Acquired   250  
Goodwill, Acquired During Period   139  
Goodwill, Purchase Accounting Adjustments 13    
BioPlus      
Business Acquisition [Line Items]      
Finite-lived Intangible Assets Acquired 820    
Goodwill, Acquired During Period   $ 877  
Goodwill, Purchase Accounting Adjustments $ 149    
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost $ 30,724 $ 29,015
Gross Unrealized Gains 104 76
Gross Unrealized Losses (2,025) (2,378)
Debt Securities, Available-for-Sale, Allowance for Credit Loss (7) (9)
Available-for-sale Securities 28,796 26,704
United States Government Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 1,957 1,502
Gross Unrealized Gains 1 2
Gross Unrealized Losses (75) (103)
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0 0
Available-for-sale Securities 1,883 1,401
Government Sponsored Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 94 82
Gross Unrealized Gains 1 1
Gross Unrealized Losses (4) (5)
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0 0
Available-for-sale Securities 91 78
Foreign Government Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 337 321
Gross Unrealized Gains 2 1
Gross Unrealized Losses (41) (46)
Debt Securities, Available-for-Sale, Allowance for Credit Loss (1) (2)
Available-for-sale Securities 297 274
States, Municipalities And Political Subdivisions [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 3,957 4,389
Gross Unrealized Gains 22 19
Gross Unrealized Losses (207) (265)
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0 0
Available-for-sale Securities 3,772 4,143
Corporate Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 14,276 13,721
Gross Unrealized Gains 50 31
Gross Unrealized Losses (997) (1,218)
Debt Securities, Available-for-Sale, Allowance for Credit Loss (4) (5)
Available-for-sale Securities 13,325 12,529
Residential Mortgage-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 3,617 2,978
Gross Unrealized Gains 11 9
Gross Unrealized Losses (313) (324)
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0 0
Available-for-sale Securities 3,315 2,663
Commercial Mortgage-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 2,262 2,055
Gross Unrealized Gains 2 1
Gross Unrealized Losses (180) (176)
Debt Securities, Available-for-Sale, Allowance for Credit Loss (2) (2)
Available-for-sale Securities 2,082 1,878
Other Asset-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 4,224 3,967
Gross Unrealized Gains 15 12
Gross Unrealized Losses (208) (241)
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0 0
Available-for-sale Securities $ 4,031 $ 3,738
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) - Fixed Maturities [Member]
securities in Millions, $ in Millions
Jun. 30, 2023
USD ($)
securities
Dec. 31, 2022
USD ($)
securities
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 4,162 7,781
Estimated fair value, less than 12 months $ 9,949 $ 16,035
Gross unrealized loss, less than 12 months $ (310) $ (1,071)
Number of securities, 12 months or greater | securities 7,108 4,060
Estimated fair value, 12 months or greater $ 14,285 $ 7,537
Gross unrealized loss, 12 months or greater $ (1,715) $ (1,307)
United States Government Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 58 61
Estimated fair value, less than 12 months $ 1,019 $ 701
Gross unrealized loss, less than 12 months $ (29) $ (40)
Number of securities, 12 months or greater | securities 48 38
Estimated fair value, 12 months or greater $ 278 $ 442
Gross unrealized loss, 12 months or greater $ (46) $ (63)
Government Sponsored Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 18 39
Estimated fair value, less than 12 months $ 63 $ 73
Gross unrealized loss, less than 12 months $ (2) $ (4)
Number of securities, 12 months or greater | securities 29 6
Estimated fair value, 12 months or greater $ 18 $ 5
Gross unrealized loss, 12 months or greater $ (2) $ (1)
Foreign Government Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 97 150
Estimated fair value, less than 12 months $ 56 $ 100
Gross unrealized loss, less than 12 months $ (2) $ (10)
Number of securities, 12 months or greater | securities 224 198
Estimated fair value, 12 months or greater $ 186 $ 142
Gross unrealized loss, 12 months or greater $ (39) $ (36)
States, Municipalities And Political Subdivisions [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 702 1,398
Estimated fair value, less than 12 months $ 1,278 $ 2,615
Gross unrealized loss, less than 12 months $ (20) $ (147)
Number of securities, 12 months or greater | securities 925 396
Estimated fair value, 12 months or greater $ 1,598 $ 652
Gross unrealized loss, 12 months or greater $ (187) $ (118)
Corporate Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 2,051 3,551
Estimated fair value, less than 12 months $ 4,323 $ 7,826
Gross unrealized loss, less than 12 months $ (129) $ (549)
Number of securities, 12 months or greater | securities 3,216 2,204
Estimated fair value, 12 months or greater $ 6,910 $ 3,521
Gross unrealized loss, 12 months or greater $ (868) $ (669)
Residential Mortgage-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 642 1,341
Estimated fair value, less than 12 months $ 1,251 $ 1,435
Gross unrealized loss, less than 12 months $ (38) $ (121)
Number of securities, 12 months or greater | securities 1,286 496
Estimated fair value, 12 months or greater $ 1,714 $ 982
Gross unrealized loss, 12 months or greater $ (275) $ (203)
Commercial Mortgage-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 246 457
Estimated fair value, less than 12 months $ 701 $ 1,082
Gross unrealized loss, less than 12 months $ (28) $ (76)
Number of securities, 12 months or greater | securities 553 324
Estimated fair value, 12 months or greater $ 1,316 $ 719
Gross unrealized loss, 12 months or greater $ (152) $ (100)
Other Asset-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 348 784
Estimated fair value, less than 12 months $ 1,258 $ 2,203
Gross unrealized loss, less than 12 months $ (62) $ (124)
Number of securities, 12 months or greater | securities 827 398
Estimated fair value, 12 months or greater $ 2,265 $ 1,074
Gross unrealized loss, 12 months or greater $ (146) $ (117)
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Due in one year or less, Amortized Cost $ 1,127  
Due after one year through five years, Amortized Cost 8,193  
Due after five years through ten years, Amortized Cost 9,466  
Due after ten years, Amortized Cost 6,059  
Mortgage-backed securities, Amortized Cost 5,879  
Available-for-sale securities, Amortized Cost 30,724 $ 29,015
Due in one year or less, Estimated Fair Value 1,118  
Due after one year through five years, Estimated Fair Value 7,810  
Due after five years through ten years, Estimated Fair Value 8,883  
Due after ten years, Estimated Fair Value 5,588  
Mortgage-backed securities, Estimated Fair Value 5,397  
Available-for-sale securities, Estimated Fair Value $ 28,796 $ 26,704
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Current Equity Securities) (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Equity Securities [Line Items]    
Equity securities $ 272 $ 953
Exchange Traded Funds [Member]    
Equity Securities [Line Items]    
Equity securities 166 822
Common Equity Securities [Member]    
Equity Securities [Line Items]    
Equity securities 31 43
Private Equity Funds [Member]    
Equity Securities [Line Items]    
Equity securities $ 75 $ 88
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Net Investment Gains/Losses) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Investment [Line Items]        
Net losses on investments $ (128) $ (255) $ (219) $ (428)
Fixed Maturities [Member]        
Investment [Line Items]        
Debt Securities, Available-for-sale, Realized Gain 11 16 21 36
Debt Securities, Available-for-sale, Realized Loss (99) (176) (214) (254)
Impairment losses recognized in income (3) (1) (10) (21)
Debt Securities, Available-for-sale, Realized Gain (Loss) (91) (161) (203) (239)
Equity Securities [Member]        
Investment [Line Items]        
Unrealized gains (losses) recognized on equity securities still held at the end of the period 2 (83) (2) (154)
Net realized gains (losses) recognized on equity securities sold during the period 1 (5) 4 (19)
Net gains (losses) on equity securities 3 (88) 2 (173)
Other Investments [Member]        
Investment [Line Items]        
Gross gains 2 10 20 33
Gross losses (16) (15) (9) (44)
Impairment losses recognized in income (26) (1) (29) (5)
Net losses on other investments $ (40) $ (6) $ (18) $ (16)
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Schedule of Investments [Line Items]          
Accrued investment income receivable $ 266   $ 266   $ 245
Fair value of collateral received at time of securities lending transactions $ 2,311   $ 2,311   $ 2,457
Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned 102.00%   102.00%   102.00%
Debt Securities, Available-for-Sale, Allowance for Credit Loss $ (7)   $ (7)   $ (9)
United States Government Securities [Member]          
Schedule of Investments [Line Items]          
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0   0   0
Residential Mortgage-Backed Securities [Member]          
Schedule of Investments [Line Items]          
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0   0   0
Fixed Maturities [Member]          
Schedule of Investments [Line Items]          
Proceeds from Sale of Available-for-sale Securities 9,675 $ 7,026 15,085 $ 10,672  
Overnight and Continuous [Member] | Cash [Member]          
Schedule of Investments [Line Items]          
Collateral received for securities loaned, at carrying value 2,237   2,237   2,221
Overnight and Continuous [Member] | United States Government Securities [Member]          
Schedule of Investments [Line Items]          
Collateral received for securities loaned, at carrying value 73   73   224
Overnight and Continuous [Member] | Residential Mortgage-Backed Securities [Member]          
Schedule of Investments [Line Items]          
Collateral received for securities loaned, at carrying value $ 1   $ 1   $ 12
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Derivative Financial Instruments (Financial Statement Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Derivative, Gain (Loss) Recognized $ 7 $ 24 $ (15) $ 46  
Cash Flow Hedging [Member]          
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax $ (214)   $ (214)   $ (229)
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 6,100 $ 3,567
Available-for-sale Securities 28,796 26,704
Other invested assets 5,993 5,685
Securities lending collateral 2,312 2,457
Total assets 37,604 33,787
Total liabilities (69) (60)
United States Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 1,883 1,401
Government Sponsored Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 91 78
Foreign Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 297 274
States, Municipalities And Political Subdivisions [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 3,772 4,143
Corporate Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 13,325 12,529
Residential Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 3,315 2,663
Commercial Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 2,082 1,878
Other Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 4,031 3,738
Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 272 953
Equity Securities [Member] | Exchange Traded Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 166 822
Equity Securities [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 31 43
Equity Securities [Member] | Private Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 75 88
Other Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 5,872 5,582
Other Investments [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 121 103
Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 3 3
Derivative liabilities (69) (60)
Level I [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 6,100 3,567
Available-for-sale Securities 0 0
Securities lending collateral 0 0
Total assets 6,399 4,494
Total liabilities 0 0
Level I [Member] | United States Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Government Sponsored Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Foreign Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | States, Municipalities And Political Subdivisions [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Corporate Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Residential Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Commercial Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Other Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 178 824
Level I [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 166 822
Level I [Member] | Equity Securities [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 12 2
Level I [Member] | Equity Securities [Member] | Private Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level I [Member] | Other Investments [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 121 103
Level I [Member] | Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 0 0
Derivative liabilities 0 0
Level II [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Available-for-sale Securities 28,327 26,211
Securities lending collateral 2,312 2,457
Total assets 30,661 28,712
Total liabilities (69) (60)
Level II [Member] | United States Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 1,883 1,401
Level II [Member] | Government Sponsored Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 91 78
Level II [Member] | Foreign Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 297 274
Level II [Member] | States, Municipalities And Political Subdivisions [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 3,772 4,143
Level II [Member] | Corporate Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 13,222 12,392
Level II [Member] | Residential Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 3,315 2,663
Level II [Member] | Commercial Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 2,082 1,878
Level II [Member] | Other Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 3,665 3,382
Level II [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 19 41
Level II [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level II [Member] | Equity Securities [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 19 41
Level II [Member] | Equity Securities [Member] | Private Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level II [Member] | Other Investments [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 0 0
Level II [Member] | Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 3 3
Derivative liabilities (69) (60)
Level III [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Available-for-sale Securities 469 493
Securities lending collateral 0 0
Total assets 544 581
Total liabilities 0 0
Level III [Member] | United States Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Government Sponsored Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Foreign Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | States, Municipalities And Political Subdivisions [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Corporate Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 103 137
Level III [Member] | Residential Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Commercial Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Other Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 366 356
Level III [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 75 88
Level III [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level III [Member] | Equity Securities [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level III [Member] | Equity Securities [Member] | Private Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 75 88
Level III [Member] | Other Investments [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 0 0
Level III [Member] | Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 0 0
Derivative liabilities $ 0 $ 0
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance $ 610 $ 481 $ 581 $ 449
Total gains (losses) recognized in net income 1 (7) (7) (3)
Total gains (losses) recognized in accumulated other comprehensive loss (8)   (2) (2)
Purchases 9 212 23 260
Sales (20) (202) (30) (191)
Settlements (4) (5) (6) (39)
Transfers into Level III 6 14 6 14
Transfers out of Level III (50) (26) (21) (21)
Ending balance 544 467 544 467
Change in unrealized gains (losses) included in net income related to assets still held 1 (3) (6) 1
Corporate Securities [Member]        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance 142 341 137 336
Total gains (losses) recognized in net income (2) (5) (3) (4)
Total gains (losses) recognized in accumulated other comprehensive loss 1   2 (2)
Purchases 2 11 4 35
Sales (10) (188) (10) (175)
Settlements (4) (5) (6) (39)
Transfers into Level III 0 14 0 14
Transfers out of Level III (26) (13) (21) (10)
Ending balance 103 155 103 155
Change in unrealized gains (losses) included in net income related to assets still held 0 0 0 0
Residential Mortgage-Backed Securities [Member]        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance 0 4 0 5
Total gains (losses) recognized in net income 0 0 0 0
Total gains (losses) recognized in accumulated other comprehensive loss 0   0 0
Purchases 0 0 0 0
Sales 0 0 0 0
Settlements 0 0 0 0
Transfers into Level III 0 0 0 0
Transfers out of Level III 0 (4) 0 (5)
Ending balance 0 0 0 0
Change in unrealized gains (losses) included in net income related to assets still held 0 0 0 0
Other Asset-backed Securities [Member]        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance 390 37 356 19
Total gains (losses) recognized in net income 1 0 1 0
Total gains (losses) recognized in accumulated other comprehensive loss (9)   (4) 0
Purchases 7 190 18 205
Sales (5) 0 (11) 0
Settlements 0 0 0 0
Transfers into Level III 6 0 6 0
Transfers out of Level III (24) (9) 0 (6)
Ending balance 366 218 366 218
Change in unrealized gains (losses) included in net income related to assets still held 0 0 0 0
Equity Securities [Member]        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance 78 99 88 89
Total gains (losses) recognized in net income 2 (2) (5) 1
Total gains (losses) recognized in accumulated other comprehensive loss 0   0 0
Purchases 0 11 1 20
Sales (5) (14) (9) (16)
Settlements 0 0 0 0
Transfers into Level III 0 0 0 0
Transfers out of Level III 0 0 0 0
Ending balance 75 94 75 94
Change in unrealized gains (losses) included in net income related to assets still held $ 1 $ (3) $ (6) $ 1
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets $ 5,993 $ 5,685
Short-term borrowings 265 265
Notes 22,872 21,861
Convertible debentures   463
Fair Value, Recurring [Member] | Level III [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term borrowings 0 0
Notes 0 0
Convertible debentures   0
Fair Value, Recurring [Member] | Level II [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term borrowings 265 265
Notes 22,872 21,861
Convertible debentures   463
Fair Value, Recurring [Member] | Level I [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term borrowings 0 0
Notes 0 0
Convertible debentures   0
Fair Value, Nonrecurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 5,872 5,582
Short-term borrowings 265 265
Notes 24,859 23,786
Convertible debentures   63
Other Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 5,872 5,582
Other Investments [Member] | Fair Value, Recurring [Member] | Level III [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 5,872 5,582
Other Investments [Member] | Fair Value, Recurring [Member] | Level II [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 0 0
Other Investments [Member] | Fair Value, Recurring [Member] | Level I [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets $ 0 $ 0
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Income Tax Disclosure [Abstract]          
Income tax expense $ 585 $ 488 $ 1,200 $ 1,015  
Effective tax rate 24.00% 23.00% 23.70% 22.90%  
Income taxes receivable $ 48   $ 48   $ 440
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Medical Claims Payable [Line Items]            
Gross medical claims payable, beginning of period   $ 15,348   $ 13,282 $ 15,348 $ 13,282
Ceded medical claims payable, beginning of period   (6)   (21) (6) (21)
Net medical claims payable, beginning of period   15,342   13,261 15,342 13,261
Business combinations and purchase adjustments         0 133
Current period net incurred medical claims         61,290 55,737
Prior periods redundancies         (1,112) (972)
Total net incurred medical claims $ 30,495 $ 29,683 $ 27,634 $ 27,131 60,178 54,765
Net payments attributable to current period medical claims         48,217 42,882
Net payments attributable to prior periods medical claims         11,409 10,401
Total net payments         59,626 53,283
Net medical claims payable, end of period 15,894   14,876   15,894 14,876
Ceded medical claims payable, end of period 8   13   8 13
Gross medical claims payable, end of period $ 15,902   $ 14,889   $ 15,902 $ 14,889
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Reconciliation of net incurred medical claims to benefit expense [Line Items]            
Total net incurred medical claims $ 30,495 $ 29,683 $ 27,634 $ 27,131 $ 60,178 $ 54,765
Quality improvement and other claims expense 1,109 1,103 1,161 1,100 2,212 2,261
Benefit expense $ 31,604 $ 30,786 $ 28,795 $ 28,231 $ 62,390 $ 57,026
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]                
Net medical claims payable, end of period $ 15,894       $ 15,894   $ 15,342  
Ceded medical claims payable end of period 8   $ 13   8 $ 13 6 $ 21
Insurance lines other than short duration 263       263   248  
Gross medical claims payable, end of period 16,165       16,165   $ 15,596  
Total net incurred medical claims 30,495 $ 29,683 27,634 $ 27,131 60,178 54,765    
Quality improvement and other claims expense 1,109 1,103 1,161 1,100 2,212 2,261    
Benefit expense $ 31,604 $ 30,786 $ 28,795 $ 28,231 $ 62,390 $ 57,026    
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Medical Claims Payable (Narrative) (Details)
$ in Millions
Jun. 30, 2023
USD ($)
Short-Duration Insurance Contract, Accident Year 2021 [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net $ 597
Short-Duration Insurance Contract, Accident Year 2022 [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 2,224
Short-Duration Insurance Contract, Accident Year 2023 [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net $ 13,073
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Debt (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 15, 2023
Jun. 30, 2023
Jun. 30, 2023
Jun. 30, 2022
Feb. 08, 2023
Jan. 17, 2023
Dec. 31, 2022
Debt Instrument [Line Items]              
Repayments of Long-term Debt     $ 1,908 $ 943      
Short-term borrowings   $ 265 $ 265       $ 265
Revolving Credit Facility [Member]              
Debt Instrument [Line Items]              
Covenant description     Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.        
Covenant compliance     As of June 30, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.6%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of June 30, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility.        
Maximum borrowing capacity   4,000 $ 4,000        
Subsidiary Credit Facilities [Member]              
Debt Instrument [Line Items]              
Maximum borrowing capacity   200 200        
Federal Home Loan Bank Advances [Member]              
Debt Instrument [Line Items]              
Federal Home Loan Bank, advances, short-term   175 175       265
Surplus Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   25 25       25
Senior Unsecured Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   24,834 24,834       23,761
Senior Unsecured Notes [Member] | Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six              
Debt Instrument [Line Items]              
Debt instrument interest rate         4.90%    
Debt Instrument, Face Amount         $ 500    
Senior Unsecured Notes [Member] | Four Point Seven Five Zero Percent Due Two Thousand Thirty Three              
Debt Instrument [Line Items]              
Debt instrument interest rate         4.75%    
Debt Instrument, Face Amount         $ 1,000    
Senior Unsecured Notes [Member] | Five Point One Two Five Percent Due Two Thousand Fifty Three              
Debt Instrument [Line Items]              
Debt instrument interest rate         5.125%    
Debt Instrument, Face Amount         $ 1,100    
Senior Unsecured Notes [Member] | Three Point Three Zero Zero Percent Due Two Thousand Twenty Three              
Debt Instrument [Line Items]              
Debt instruments, repurchased face amount           $ 1,000  
Debt instrument interest rate           3.30%  
Senior Unsecured Notes [Member] | Zero Point Four Five Zero Percent Due Two Thousand Twenty Three              
Debt Instrument [Line Items]              
Debt instruments, repurchased face amount $ 500            
Debt instrument interest rate 0.45%            
Commercial Paper              
Debt Instrument [Line Items]              
Commercial paper authorized   4,000 4,000        
Commercial paper   90 $ 90       $ 0
Senior Convertible Debenture [Member] | Two Point Seven Five Zero Percent Due Two Thousand Forty Two              
Debt Instrument [Line Items]              
Debt Conversion Debt Principal Amount   59          
Repayments of Long-term Debt $ 5 $ 404          
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed 100.00%            
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments And Contingencies (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2023
USD ($)
Commitments And Contingencies [Line Items]  
Gross premium tax rate, state of California 2.35%
Long-term purchase commitment, amount $ 621
Minimum [Member]  
Commitments And Contingencies [Line Items]  
Aggregate settlement amount 0
Maximum [Member]  
Commitments And Contingencies [Line Items]  
Aggregate settlement amount 250
Anthem, Inc. v. Express Scripts, Inc. [Member]  
Commitments And Contingencies [Line Items]  
Proceeds originally received at time of divestiture 4,675
Anthem, Inc. v. Express Scripts, Inc. [Member] | Damages for Pharmacy Pricing [Member]  
Commitments And Contingencies [Line Items]  
Approximate amount of damages sought for breaches 14,800
Anthem, Inc. v. Express Scripts, Inc. [Member] | Damages for Operational Breaches [Member]  
Commitments And Contingencies [Line Items]  
Approximate amount of damages sought for breaches 158
BCBS Antitrust Litigation [Member]  
Commitments And Contingencies [Line Items]  
Aggregate settlement amount 596
Loss Contingency Accrual, Payments $ 506
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock (Summary of Cash Dividend Activity) (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Banking Regulation, Total Capital [Abstract]            
Declaration date Apr. 18, 2023 Jan. 24, 2023 Apr. 19, 2022 Jan. 25, 2022    
Record date Jun. 09, 2023 Mar. 10, 2023 Jun. 10, 2022 Mar. 10, 2022    
Payment date Jun. 23, 2023 Mar. 24, 2023 Jun. 24, 2022 Mar. 25, 2022    
Cash dividends per share $ 1.48 $ 1.48 $ 1.28 $ 1.28    
Total payment $ 350 $ 351 $ 309 $ 309 $ 701 $ 618
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock (Summary of Share Repurchases) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Equity, Class of Treasury Stock [Line Items]          
Shares repurchased       2.7 2.5
Average price per share       $ 466.62 $ 471.72
Aggregate cost $ 652 $ 624 $ 545 $ 1,268 $ 1,169
Authorization remaining at the end of the period $ 5,608 $ 3,022   $ 5,608 $ 3,022
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock (Summary of Stock Option Activity) (Details)
$ / shares in Units, shares in Millions, $ in Millions
 6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Number of Shares [Roll Forward]  
Outstanding at beginning of period, Number of Shares | shares 2.8
Granted, Number of Shares | shares 0.6
Exercised, Number of Shares | shares (0.2)
Forfeited or expired, Number of Shares | shares 0.0
Outstanding at end of period, Number of Shares | shares 3.2
Exercisable at end of period, Number of Shares | shares 2.1
Weighted-Average Option Price Per Share [Roll Forward]  
Outstanding at beginning of period, Weighted-Average Option Price per Share | $ / shares $ 293.28
Granted, Weighted-Average Option Price per Share | $ / shares 469.05
Exercised, Weighted-Average Option Price per Share | $ / shares 268.35
Forfeited or expired, Weighted-Average Option Price per Share | $ / shares 391.44
Outstanding at end of period, Weighted-Average Option Price per Share | $ / shares 323.85
Exercisable at end of period, Weighted-Average Option Price per Share | $ / shares $ 265.51
Outstanding at end of period, Weighted-Average Remaining Contractual Life 6 years 6 months 3 days
Exercisable at end of period, Weighted-Average Remaining Contractual Life 5 years 3 months 21 days
Outstanding at end of period, Aggregate Intrinsic Value | $ $ 402
Exercisable at end of period, Aggregate Intrinsic Value | $ $ 376
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) - $ / shares
shares in Millions
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Restricted Stock Shares and Units [Roll Forward]    
Nonvested at Beginning Balance, Restricted Stock Shares and Units 1.2  
Granted, Restricted Stock Shares and Units 0.6  
Vested, Restricted Stock Shares And Units (0.6)  
Forfeited, Restricted Stock Shares And Units 0.0  
Nonvested at Ending Balance, Restricted Stock Shares and Units 1.2  
Weighted-Average Grant Date Fair Value Per Share [Roll Forward]    
Nonvested at Beginning Balance, Weighted-Average Grant Date Fair Value per Share $ 357.21  
Granted, Weighted-Average Grant Date Fair Value per Share 469.60 $ 452.78
Vested, Weighted-Average Grant Date Fair Value per Share 301.18  
Forfeited, Weighted-Average Grant Date Fair Value per Share 405.25  
Nonvested at Ending Balance, Weighted-Average Grant Date Fair Value per Share $ 422.67  
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details)
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Banking Regulation, Total Capital [Abstract]    
Risk-free interest rate 3.95% 1.97%
Volatility factor 29.00% 29.00%
Quarterly dividend yield 0.316% 0.282%
Weighted-average expected life (years) 4 years 4 months 24 days 5 years 1 month 6 days
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) - $ / shares
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Banking Regulation, Total Capital [Abstract]    
Options granted during the period $ 127.13 $ 116.80
Restricted stock awards granted during the period $ 469.60 $ 452.78
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.23.2
Capital Stock (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jul. 18, 2023
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jan. 26, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]              
Dividends Payable, Date to be Paid   Jun. 23, 2023 Mar. 24, 2023 Jun. 24, 2022 Mar. 25, 2022    
Dividends Payable, Date of Record   Jun. 09, 2023 Mar. 10, 2023 Jun. 10, 2022 Mar. 10, 2022    
Increase In Stock Repurchase Program Authorization             $ 5,000
Subsequent Event [Member]              
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]              
Dividends Payable, Amount Per Share $ 1.48            
Dividends Payable, Date to be Paid Sep. 22, 2023            
Dividends Payable, Date of Record Sep. 08, 2023            
2023 to 2025 | Restricted Stock Units (RSUs) [Member]              
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           0.2  
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.23.2
Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Accumulated Other Comprehensive Loss, Beginning Balance $ (2,050) $ (2,490) $ (1,246) $ (197) $ (2,490) $ (197)
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax (119)   (922)   308 (1,991)
Other comprehensive loss (income) attributable to noncontrolling interests 0   3   (2) 8
Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest 0   (1)   0 (3)
Cash flow hedges, holding gain (loss), net of tax 4   3   15 6
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 3   9   5 16
Change in future policy benefits, net of tax (3)   8   (1) 17
Foreign currency translation adjustment, net of tax 0   (5)   2 (8)
Other Comprehensive Income (Loss), Net of Tax (116) 442 (908) (1,054) 326 (1,962)
Accumulated Other Comprehensive Loss, Ending Balance (2,166) (2,050) (2,151) (1,246) (2,166) (2,151)
Other Comprehensive Income (Loss), Tax (Expense) Benefit, Portion Attributable to Parent 32   285   (72) 617
Net unrealized investment (losses) gains            
AOCI, Debt Securities, Beginning Balance (1,330) (1,755) (570) 494 (1,755) 494
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax (191)   (1,050)   146 (2,196)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 72   128   162 205
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax (119)   (922)   308 (1,991)
Other comprehensive loss (income) attributable to noncontrolling interests 0   3   (2) 8
AOCI, Debt Securities, Ending Balance (1,449) (1,330) (1,489) (570) (1,449) (1,489)
Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit 61   323   (25) 677
Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense (23)   (34)   (51) (55)
Non-credit components of impairments on investments [Member]            
AOCI, Other than Temporary Impairment, Not Credit Loss, Beginning Balance (5) (3) (1) 0 (3) 0
Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-sale Securities (1)   (1)   (3) (2)
AOCI, Other than Temporary Impairment, Not Credit Loss, Ending Balance (6) (5) (2) (1) (6) (2)
Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss) 0   0   1 1
Net cash flow hedges            
AOCI, Cash Flow Hedge, Beginning Balance (218) (229) (236) (239) (229) (239)
Cash flow hedges, holding gain (loss), net of tax 4   3   15 6
AOCI, Cash Flow Hedge, Ending Balance (214) (218) (233) (236) (214) (233)
Cash flow hedges, holding gain (loss), tax (expense) benefit (1)   (1)   7 (2)
Pension and other postretirement benefits            
AOCI, Defined Benefit Plan, Beginning Balance (497) (499) (422) (429) (499) (429)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 3   9   5 16
AOCI, Defined Benefit Plan, Ending Balance (494) (497) (413) (422) (494) (413)
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense (1)   (4)   (2) (6)
Future Policy Benefits            
AOCI, Liability for Future Policy Benefit, After Tax, Beginning Balance 15 13 (10) (19) 13 (19)
Change in future policy benefits, net of tax (3)   8   (1) 17
AOCI, Liability for Future Policy Benefit, After Tax, Ending Balance 12 15 (2) (10) 12 (2)
Change in future policy benefits, tax expense 1   0   1 0
Foreign currency translation adjustments            
AOCI, Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance (15) (17) (7) (4) (17) (4)
Foreign currency translation adjustment, net of tax 0   (5)   2 (8)
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance (15) $ (15) (12) $ (7) (15) (12)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Expense) Benefit $ (5)   $ 1   $ (3) $ 2
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) - shares
shares in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share [Abstract]        
Denominator for basic earnings per share - weighted-average shares 236.6 240.7 237.0 241.0
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures 1.2 2.7 1.7 2.9
Denominator for diluted earnings per share 237.8 243.4 238.7 243.9
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Share (Narrative) (Details) - shares
shares in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share [Abstract]        
Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive 1.0 0.5 0.7 0.4
Restricted stock units issued under stock incentive plan     0.6  
2022 to 2024 [Member]        
Restricted stock units issued under stock incentive plan   0.0   0.5
Restricted stock units excluded from the denominator for diluted earnings per share   0.0   0.2
2023 to 2025        
Restricted stock units issued under stock incentive plan 0.0   0.6  
Restricted stock units excluded from the denominator for diluted earnings per share 0.0   0.2  
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information (Financial Data By Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting Information [Line Items]        
Premiums $ 36,589 $ 33,076 $ 72,457 $ 65,861
Product revenue 4,859 3,568 8,881 6,869
Service fees 1,929 1,838 3,937 3,638
Total operating revenue 43,377 38,482 85,275 76,368
Operating gain (loss) 2,628 2,346 5,459 4,773
Health Benefits Segment        
Segment Reporting Information [Line Items]        
Premiums 36,233 32,787 71,767 65,250
Product revenue 0 0 0 0
Service fees 1,767 1,609 3,513 3,173
Total operating revenue 38,000 34,396 75,280 68,423
Operating gain (loss) 2,148 1,781 4,307 3,632
Carelon Services Segment        
Segment Reporting Information [Line Items]        
Premiums 429 327 839 693
Product revenue 0 0 0 0
Service fees 201 220 408 446
Total operating revenue 3,441 2,983 6,753 5,931
Operating gain (loss) 136 113 345 313
Carelon Total        
Segment Reporting Information [Line Items]        
Premiums 429 327 839 693
Product revenue 4,859 3,568 8,881 6,869
Service fees 201 220 408 446
Total operating revenue 11,907 10,054 23,243 19,685
Operating gain (loss) 632 592 1,353 1,190
Corporate & Other Segment        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Product revenue 0 0 0 0
Service fees (39) 9 16 19
Total operating revenue 287 315 538 588
Operating gain (loss) (152) (27) (201) (49)
Segment Eliminations [Member]        
Segment Reporting Information [Line Items]        
Premiums (73) (38) (149) (82)
Total operating revenue (6,817) (6,283) (13,786) (12,328)
Operating gain (loss) 0 0 0 0
CarelonRx Segment [Member]        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Product revenue 4,859 3,568 8,881 6,869
Service fees 0 0 0 0
Total operating revenue 8,466 7,071 16,490 13,754
Operating gain (loss) 496 479 1,008 877
Unaffiliated        
Segment Reporting Information [Line Items]        
Total operating revenue 43,377 38,482 85,275 76,368
Unaffiliated | Health Benefits Segment        
Segment Reporting Information [Line Items]        
Total operating revenue 38,000 34,396 75,280 68,423
Unaffiliated | Carelon Services Segment        
Segment Reporting Information [Line Items]        
Total operating revenue 630 547 1,247 1,139
Unaffiliated | Carelon Total        
Segment Reporting Information [Line Items]        
Total operating revenue 5,489 4,115 10,128 8,008
Unaffiliated | Corporate & Other Segment        
Segment Reporting Information [Line Items]        
Total operating revenue (39) 9 16 19
Unaffiliated | Segment Eliminations [Member]        
Segment Reporting Information [Line Items]        
Total operating revenue (73) (38) (149) (82)
Unaffiliated | CarelonRx Segment [Member]        
Segment Reporting Information [Line Items]        
Total operating revenue 4,859 3,568 8,881 6,869
Affiliated [Member] | Carelon Services Segment        
Segment Reporting Information [Line Items]        
Total operating revenue 2,811 2,436 5,506 4,792
Affiliated [Member] | Carelon Total        
Segment Reporting Information [Line Items]        
Total operating revenue 6,418 5,939 13,115 11,677
Affiliated [Member] | Corporate & Other Segment        
Segment Reporting Information [Line Items]        
Total operating revenue 326 306 522 569
Affiliated [Member] | Segment Eliminations [Member]        
Segment Reporting Information [Line Items]        
Total operating revenue (6,744) (6,245) (13,637) (12,246)
Affiliated [Member] | CarelonRx Segment [Member]        
Segment Reporting Information [Line Items]        
Total operating revenue $ 3,607 $ 3,503 $ 7,609 $ 6,885
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting [Abstract]        
Total operating revenue $ 43,377 $ 38,482 $ 85,275 $ 76,368
Net investment income 416 381 803 741
Net losses on financial instruments (121) (231) (234) (382)
Total revenues $ 43,672 $ 38,632 $ 85,844 $ 76,727
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting [Abstract]        
Income before income tax expense $ 2,441 $ 2,122 $ 5,060 $ 4,428
Net investment income (416) (381) (803) (741)
Net losses (gains) on financial instruments 121 231 234 382
Interest expense 261 208 512 409
Amortization of other intangible assets 221 166 456 295
Reportable segments operating gain $ 2,628 $ 2,346 $ 5,459 $ 4,773
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information Segment Information (Narrative) (Details)
 6 Months Ended
Jun. 30, 2023
segment
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]  
Number of Reportable Segments 4
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Lease and Other Information) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Assets and Liabilities, Lessee          
Operating Lease, Right-of-Use Asset $ 605   $ 605   $ 604
Operating Lease, Liability, Current 178   178   181
Operating Lease, Liability, Noncurrent $ 717   $ 717   $ 751
Balance sheet location of operating lease right-of-use assets Other noncurrent assets   Other noncurrent assets   Other noncurrent assets
Balance sheet location of current operating lease liabilities Other current liabilities   Other current liabilities   Other current liabilities
Balance sheet location of noncurrent operating lease liabilities Other noncurrent liabilities   Other noncurrent liabilities   Other noncurrent liabilities
Lease, Cost and Other Information [Abstract]          
Operating Lease, Cost $ 32 $ 33 $ 57 $ 65  
Short-term Lease, Cost 16 11 29 24  
Sublease Income (1) (1) (2) (2)  
Lease, Cost 47 43 84 87  
Operating Lease, Payments 54 53 105 105  
Right-of-use assets obtained in exchange for new operating lease liabilities $ 18 $ 29 $ 40 $ 37  
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)
$ in Millions
Jun. 30, 2023
USD ($)
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]  
Operating lease payments, 2023; excluding the six months ended June 30, 2023 $ 110
Operating lease payments, 2024 195
Operating lease payments, 2025 162
Operating lease payments, 2026 128
Operating lease payments, 2027 93
Operating lease payments, Thereafter 329
Total future minimum payments 1,017
Imputed Interest, Leases 122
Operating Lease Liabilities $ 895
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Narrative) (Details)
Jun. 30, 2023
Dec. 31, 2022
Lessee, Lease and Other Information [Line Items]    
Operating Lease, Weighted Average Remaining Lease Term 7 years 7 years
Weighted Average Discount Rate, Percent 3.28% 2.98%
Minimum [Member]    
Lessee, Lease and Other Information [Line Items]    
Lessee, Operating Lease, Term of Contract 1 year  
Maximum [Member]    
Lessee, Lease and Other Information [Line Items]    
Lessee, Operating Lease, Term of Contract 11 years  
XML 81 elv-20230630_htm.xml IDEA: XBRL DOCUMENT 0001156039 2023-01-01 2023-06-30 0001156039 2023-07-13 0001156039 2023-06-30 0001156039 2022-12-31 0001156039 2023-04-01 2023-06-30 0001156039 2022-04-01 2022-06-30 0001156039 2022-01-01 2022-06-30 0001156039 2021-12-31 0001156039 2022-06-30 0001156039 us-gaap:CommonStockMember 2022-12-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2022-12-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001156039 us-gaap:NoncontrollingInterestMember 2022-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2022-12-31 0001156039 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 2023-01-01 2023-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001156039 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001156039 us-gaap:CommonStockMember 2023-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001156039 us-gaap:RetainedEarningsMember 2023-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2023-03-31 0001156039 2023-03-31 0001156039 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001156039 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001156039 us-gaap:CommonStockMember 2023-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001156039 us-gaap:RetainedEarningsMember 2023-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2023-06-30 0001156039 us-gaap:CommonStockMember 2021-12-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001156039 us-gaap:RetainedEarningsMember 2021-12-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001156039 us-gaap:NoncontrollingInterestMember 2021-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member us-gaap:RetainedEarningsMember 2021-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member 2021-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2021-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2021-12-31 0001156039 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001156039 2022-01-01 2022-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001156039 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001156039 us-gaap:CommonStockMember 2022-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001156039 us-gaap:RetainedEarningsMember 2022-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2022-03-31 0001156039 2022-03-31 0001156039 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001156039 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001156039 us-gaap:CommonStockMember 2022-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001156039 us-gaap:RetainedEarningsMember 2022-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2022-06-30 0001156039 elv:BioPlusMember 2023-04-01 2023-06-30 0001156039 elv:BioPlusMember 2023-01-01 2023-06-30 0001156039 elv:IntegraManagedCareMember 2023-01-01 2023-06-30 0001156039 elv:IntegraManagedCareMember 2023-04-01 2023-06-30 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:ForeignGovernmentDebtMember 2023-06-30 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-06-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:OtherAggregatedInvestmentsMember 2023-06-30 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:ForeignGovernmentDebtMember 2022-12-31 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:OtherAggregatedInvestmentsMember 2022-12-31 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:ForeignGovernmentDebtMember us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:CorporateDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:FixedMaturitiesMember 2023-06-30 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:ForeignGovernmentDebtMember us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:FixedMaturitiesMember 2022-12-31 0001156039 us-gaap:FixedMaturitiesMember 2023-04-01 2023-06-30 0001156039 us-gaap:FixedMaturitiesMember 2023-01-01 2023-06-30 0001156039 us-gaap:FixedMaturitiesMember 2022-04-01 2022-06-30 0001156039 us-gaap:FixedMaturitiesMember 2022-01-01 2022-06-30 0001156039 us-gaap:ExchangeTradedFundsMember 2023-06-30 0001156039 us-gaap:ExchangeTradedFundsMember 2022-12-31 0001156039 elv:CommonEquitySecuritiesMember 2023-06-30 0001156039 elv:CommonEquitySecuritiesMember 2022-12-31 0001156039 us-gaap:PrivateEquityFundsMember 2023-06-30 0001156039 us-gaap:PrivateEquityFundsMember 2022-12-31 0001156039 us-gaap:EquitySecuritiesMember 2023-04-01 2023-06-30 0001156039 us-gaap:EquitySecuritiesMember 2022-04-01 2022-06-30 0001156039 us-gaap:EquitySecuritiesMember 2023-01-01 2023-06-30 0001156039 us-gaap:EquitySecuritiesMember 2022-01-01 2022-06-30 0001156039 us-gaap:OtherInvestmentsMember 2023-04-01 2023-06-30 0001156039 us-gaap:OtherInvestmentsMember 2022-04-01 2022-06-30 0001156039 us-gaap:OtherInvestmentsMember 2023-01-01 2023-06-30 0001156039 us-gaap:OtherInvestmentsMember 2022-01-01 2022-06-30 0001156039 us-gaap:MaturityOvernightMember us-gaap:CashMember 2023-06-30 0001156039 us-gaap:MaturityOvernightMember us-gaap:CashMember 2022-12-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:MaturityOvernightMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:MaturityOvernightMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:CashFlowHedgingMember 2023-06-30 0001156039 us-gaap:CashFlowHedgingMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:OtherDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2023-06-30 0001156039 elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2023-06-30 0001156039 us-gaap:DerivativeMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:OtherDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2022-12-31 0001156039 elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2022-12-31 0001156039 us-gaap:DerivativeMember 2022-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-03-31 0001156039 us-gaap:OtherDebtSecuritiesMember 2023-03-31 0001156039 us-gaap:EquitySecuritiesMember 2023-03-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2023-04-01 2023-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-04-01 2023-06-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2023-04-01 2023-06-30 0001156039 us-gaap:EquitySecuritiesMember 2023-04-01 2023-06-30 0001156039 us-gaap:EquitySecuritiesMember 2023-06-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-03-31 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-03-31 0001156039 us-gaap:EquitySecuritiesMember 2022-03-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-04-01 2022-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-04-01 2022-06-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-04-01 2022-06-30 0001156039 us-gaap:EquitySecuritiesMember 2022-04-01 2022-06-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-06-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-06-30 0001156039 us-gaap:EquitySecuritiesMember 2022-06-30 0001156039 us-gaap:EquitySecuritiesMember 2022-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2023-01-01 2023-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-01-01 2023-06-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2023-01-01 2023-06-30 0001156039 us-gaap:EquitySecuritiesMember 2023-01-01 2023-06-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-01-01 2022-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-01-01 2022-06-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-01-01 2022-06-30 0001156039 us-gaap:EquitySecuritiesMember 2022-01-01 2022-06-30 0001156039 us-gaap:FairValueMeasurementsNonrecurringMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2023-06-30 0001156039 us-gaap:OtherInvestmentsMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001156039 us-gaap:FairValueMeasurementsNonrecurringMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2022-12-31 0001156039 us-gaap:OtherInvestmentsMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2021Member 2023-06-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2022Member 2023-06-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2023Member 2023-06-30 0001156039 elv:SeniorUnsecuredNotesMember 2023-06-30 0001156039 elv:SeniorUnsecuredNotesMember 2022-12-31 0001156039 elv:FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember elv:SeniorUnsecuredNotesMember 2023-02-08 0001156039 elv:FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember elv:SeniorUnsecuredNotesMember 2023-02-08 0001156039 elv:FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember elv:SeniorUnsecuredNotesMember 2023-02-08 0001156039 elv:ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember elv:SeniorUnsecuredNotesMember 2023-01-17 0001156039 elv:ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember elv:SeniorUnsecuredNotesMember 2023-03-15 0001156039 elv:SurplusNotesMember 2022-12-31 0001156039 elv:SurplusNotesMember 2023-06-30 0001156039 us-gaap:RevolvingCreditFacilityMember 2023-06-30 0001156039 us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-06-30 0001156039 us-gaap:LineOfCreditMember 2023-06-30 0001156039 us-gaap:CommercialPaperMember 2023-06-30 0001156039 us-gaap:CommercialPaperMember 2022-12-31 0001156039 elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember us-gaap:ConvertibleDebtMember 2023-03-15 2023-03-15 0001156039 elv:TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember us-gaap:ConvertibleDebtMember 2023-04-01 2023-06-30 0001156039 us-gaap:FederalHomeLoanBankAdvancesMember 2023-06-30 0001156039 us-gaap:FederalHomeLoanBankAdvancesMember 2022-12-31 0001156039 srt:MinimumMember 2023-06-30 0001156039 srt:MaximumMember 2023-06-30 0001156039 elv:BCBSAntitrustLitigationMember 2023-01-01 2023-06-30 0001156039 elv:BCBSAntitrustLitigationMember 2023-06-30 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member elv:PharmacypricingMember 2023-01-01 2023-06-30 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member elv:OperationalMember 2023-01-01 2023-06-30 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member 2023-01-01 2023-06-30 0001156039 us-gaap:SubsequentEventMember 2023-07-18 0001156039 us-gaap:SubsequentEventMember 2023-07-18 2023-07-18 0001156039 2021-01-26 0001156039 us-gaap:RestrictedStockUnitsRSUMember elv:A2023To2025Member 2023-01-01 2023-06-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 2023-06-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-04-01 2022-06-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-06-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-06-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2023-03-31 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-03-31 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-12-31 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2021-12-31 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2023-04-01 2023-06-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-04-01 2022-06-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2023-01-01 2023-06-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-01-01 2022-06-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2023-06-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-06-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-03-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-12-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-04-01 2023-06-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-04-01 2022-06-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-01-01 2023-06-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-01-01 2022-06-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-06-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-06-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 2023-06-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-04-01 2022-06-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-06-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-06-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001156039 elv:FuturePolicyBenefitsMember 2023-03-31 0001156039 elv:FuturePolicyBenefitsMember 2022-03-31 0001156039 elv:FuturePolicyBenefitsMember 2022-12-31 0001156039 elv:FuturePolicyBenefitsMember 2021-12-31 0001156039 elv:FuturePolicyBenefitsMember 2023-04-01 2023-06-30 0001156039 elv:FuturePolicyBenefitsMember 2022-04-01 2022-06-30 0001156039 elv:FuturePolicyBenefitsMember 2023-01-01 2023-06-30 0001156039 elv:FuturePolicyBenefitsMember 2022-01-01 2022-06-30 0001156039 elv:FuturePolicyBenefitsMember 2023-06-30 0001156039 elv:FuturePolicyBenefitsMember 2022-06-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 2023-06-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-04-01 2022-06-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-06-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-06-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001156039 elv:A2023To2025Member 2023-04-01 2023-06-30 0001156039 elv:A2023To2025Member 2023-01-01 2023-06-30 0001156039 elv:A2022To2024Member 2022-04-01 2022-06-30 0001156039 elv:A2022To2024Member 2022-01-01 2022-06-30 0001156039 elv:HealthBenefitsSegmentMember 2023-04-01 2023-06-30 0001156039 elv:CarelonRxSegmentMember 2023-04-01 2023-06-30 0001156039 elv:CarelonServicesSegmentMember 2023-04-01 2023-06-30 0001156039 elv:CarelonTotalMember 2023-04-01 2023-06-30 0001156039 elv:CorporateOtherSegmentMember 2023-04-01 2023-06-30 0001156039 elv:SegmentEliminationsMember 2023-04-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:HealthBenefitsSegmentMember 2023-04-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonRxSegmentMember 2023-04-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonServicesSegmentMember 2023-04-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonTotalMember 2023-04-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:CorporateOtherSegmentMember 2023-04-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:SegmentEliminationsMember 2023-04-01 2023-06-30 0001156039 elv:UnaffiliatedMember 2023-04-01 2023-06-30 0001156039 elv:AffiliatedMember elv:CarelonRxSegmentMember 2023-04-01 2023-06-30 0001156039 elv:AffiliatedMember elv:CarelonServicesSegmentMember 2023-04-01 2023-06-30 0001156039 elv:AffiliatedMember elv:CarelonTotalMember 2023-04-01 2023-06-30 0001156039 elv:AffiliatedMember elv:CorporateOtherSegmentMember 2023-04-01 2023-06-30 0001156039 elv:AffiliatedMember elv:SegmentEliminationsMember 2023-04-01 2023-06-30 0001156039 elv:HealthBenefitsSegmentMember 2022-04-01 2022-06-30 0001156039 elv:CarelonRxSegmentMember 2022-04-01 2022-06-30 0001156039 elv:CarelonServicesSegmentMember 2022-04-01 2022-06-30 0001156039 elv:CarelonTotalMember 2022-04-01 2022-06-30 0001156039 elv:CorporateOtherSegmentMember 2022-04-01 2022-06-30 0001156039 elv:SegmentEliminationsMember 2022-04-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:HealthBenefitsSegmentMember 2022-04-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonRxSegmentMember 2022-04-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonServicesSegmentMember 2022-04-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonTotalMember 2022-04-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:CorporateOtherSegmentMember 2022-04-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:SegmentEliminationsMember 2022-04-01 2022-06-30 0001156039 elv:UnaffiliatedMember 2022-04-01 2022-06-30 0001156039 elv:AffiliatedMember elv:CarelonRxSegmentMember 2022-04-01 2022-06-30 0001156039 elv:AffiliatedMember elv:CarelonServicesSegmentMember 2022-04-01 2022-06-30 0001156039 elv:AffiliatedMember elv:CarelonTotalMember 2022-04-01 2022-06-30 0001156039 elv:AffiliatedMember elv:CorporateOtherSegmentMember 2022-04-01 2022-06-30 0001156039 elv:AffiliatedMember elv:SegmentEliminationsMember 2022-04-01 2022-06-30 0001156039 elv:HealthBenefitsSegmentMember 2023-01-01 2023-06-30 0001156039 elv:CarelonRxSegmentMember 2023-01-01 2023-06-30 0001156039 elv:CarelonServicesSegmentMember 2023-01-01 2023-06-30 0001156039 elv:CarelonTotalMember 2023-01-01 2023-06-30 0001156039 elv:CorporateOtherSegmentMember 2023-01-01 2023-06-30 0001156039 elv:SegmentEliminationsMember 2023-01-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:HealthBenefitsSegmentMember 2023-01-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonRxSegmentMember 2023-01-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonServicesSegmentMember 2023-01-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonTotalMember 2023-01-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:CorporateOtherSegmentMember 2023-01-01 2023-06-30 0001156039 elv:UnaffiliatedMember elv:SegmentEliminationsMember 2023-01-01 2023-06-30 0001156039 elv:UnaffiliatedMember 2023-01-01 2023-06-30 0001156039 elv:AffiliatedMember elv:CarelonRxSegmentMember 2023-01-01 2023-06-30 0001156039 elv:AffiliatedMember elv:CarelonServicesSegmentMember 2023-01-01 2023-06-30 0001156039 elv:AffiliatedMember elv:CarelonTotalMember 2023-01-01 2023-06-30 0001156039 elv:AffiliatedMember elv:CorporateOtherSegmentMember 2023-01-01 2023-06-30 0001156039 elv:AffiliatedMember elv:SegmentEliminationsMember 2023-01-01 2023-06-30 0001156039 elv:HealthBenefitsSegmentMember 2022-01-01 2022-06-30 0001156039 elv:CarelonRxSegmentMember 2022-01-01 2022-06-30 0001156039 elv:CarelonServicesSegmentMember 2022-01-01 2022-06-30 0001156039 elv:CarelonTotalMember 2022-01-01 2022-06-30 0001156039 elv:CorporateOtherSegmentMember 2022-01-01 2022-06-30 0001156039 elv:SegmentEliminationsMember 2022-01-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:HealthBenefitsSegmentMember 2022-01-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonRxSegmentMember 2022-01-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonServicesSegmentMember 2022-01-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:CarelonTotalMember 2022-01-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:CorporateOtherSegmentMember 2022-01-01 2022-06-30 0001156039 elv:UnaffiliatedMember elv:SegmentEliminationsMember 2022-01-01 2022-06-30 0001156039 elv:UnaffiliatedMember 2022-01-01 2022-06-30 0001156039 elv:AffiliatedMember elv:CarelonRxSegmentMember 2022-01-01 2022-06-30 0001156039 elv:AffiliatedMember elv:CarelonServicesSegmentMember 2022-01-01 2022-06-30 0001156039 elv:AffiliatedMember elv:CarelonTotalMember 2022-01-01 2022-06-30 0001156039 elv:AffiliatedMember elv:CorporateOtherSegmentMember 2022-01-01 2022-06-30 0001156039 elv:AffiliatedMember elv:SegmentEliminationsMember 2022-01-01 2022-06-30 shares iso4217:USD iso4217:USD shares elv:medical_member elv:county elv:states pure elv:securities elv:segment false 2023 Q2 0001156039 --12-31 http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent 10-Q true 2023-06-30 false 001-16751 ELEVANCE HEALTH, INC. IN 35-2145715 220 Virginia Avenue Indianapolis IN 46204 833 401-1577 Common Stock, $0.01 par value ELV NYSE Yes Yes Large Accelerated Filer false false false 235647808 9991000000 7387000000 29915000000 28226000000 7000000 9000000 28021000000 25952000000 272000000 953000000 7431000000 7083000000 3896000000 4663000000 5196000000 4298000000 4936000000 5281000000 59743000000 55617000000 809000000 789000000 0 0 775000000 752000000 5993000000 5685000000 4547000000 4316000000 25274000000 24383000000 10703000000 10315000000 2133000000 1687000000 109168000000 102755000000 16165000000 15596000000 5954000000 5933000000 4458000000 1112000000 5033000000 5607000000 265000000 265000000 0 1500000000 9696000000 9683000000 41571000000 39696000000 24859000000 22349000000 797000000 803000000 1852000000 2015000000 1777000000 1562000000 70856000000 66425000000 100000000 100000000 0 0 0 0 0 0 0.01 0.01 900000000 900000000 235861650 235861650 237958067 237958067 2000000 2000000 8761000000 9084000000 31608000000 29647000000 -2166000000 -2490000000 38205000000 36243000000 107000000 87000000 38312000000 36330000000 109168000000 102755000000 36589000000 33076000000 72457000000 65861000000 4859000000 3568000000 8881000000 6869000000 1929000000 1838000000 3937000000 3638000000 43377000000 38482000000 85275000000 76368000000 416000000 381000000 803000000 741000000 -121000000 -231000000 -234000000 -382000000 43672000000 38632000000 85844000000 76727000000 31604000000 28795000000 62390000000 57026000000 4327000000 3069000000 7808000000 5952000000 4818000000 4272000000 9618000000 8617000000 261000000 208000000 512000000 409000000 221000000 166000000 456000000 295000000 41231000000 36510000000 80784000000 72299000000 2441000000 2122000000 5060000000 4428000000 585000000 488000000 1200000000 1015000000 1856000000 1634000000 3860000000 3413000000 3000000 -3000000 18000000 -13000000 1853000000 1637000000 3842000000 3426000000 7.83 6.80 16.21 14.22 7.79 6.73 16.10 14.05 1.48 1.28 2.96 2.56 1856000000 1634000000 3860000000 3413000000 -119000000 -922000000 308000000 -1991000000 -1000000 -1000000 -3000000 -2000000 4000000 3000000 15000000 6000000 -3000000 -9000000 -5000000 -16000000 -3000000 8000000 -1000000 17000000 0 -5000000 2000000 -8000000 -116000000 -908000000 326000000 -1962000000 3000000 -3000000 18000000 -13000000 0 -3000000 2000000 -8000000 1737000000 732000000 4166000000 1472000000 3860000000 3413000000 -234000000 -382000000 -73000000 258000000 895000000 751000000 -393000000 -181000000 139000000 122000000 299000000 662000000 42000000 -32000000 529000000 412000000 583000000 1548000000 3346000000 -182000000 160000000 632000000 391000000 -159000000 -1000000 33000000 8419000000 4993000000 17648000000 13253000000 5339000000 7140000000 10656000000 4347000000 -145000000 620000000 1651000000 609000000 651000000 549000000 46000000 58000000 -3856000000 -3602000000 90000000 250000000 2574000000 1300000000 1908000000 943000000 0 1275000000 90000000 1375000000 -145000000 620000000 -500000000 817000000 1268000000 1169000000 701000000 618000000 81000000 116000000 99000000 88000000 5000000 10000000 -1961000000 195000000 2000000 -10000000 2604000000 1576000000 7387000000 4880000000 9991000000 6456000000 238000000.0 2000000 9084000000 29647000000 -2490000000 87000000 36330000000 1989000000 15000000 2004000000 440000000 2000000 442000000 1300000 51000000 575000000 626000000 354000000 354000000 400000 6000000 0 6000000 -342000000 -342000000 237100000 2000000 8697000000 30707000000 -2050000000 104000000 37460000000 1853000000 3000000 1856000000 -116000000 0 -116000000 1400000 52000000 600000000 652000000 352000000 352000000 200000 116000000 116000000 235900000 2000000 8761000000 31608000000 -2166000000 107000000 38312000000 241800000 2000000 9148000000 27142000000 -197000000 68000000 36163000000 -23000000 -23000000 241800000 2000000 9148000000 27119000000 -197000000 68000000 36140000000 1789000000 -10000000 1779000000 -1049000000 -5000000 -1054000000 3000000 3000000 1200000 0 45000000 500000000 545000000 0 312000000 312000000 500000 39000000 39000000 9000000 9000000 241100000 2000000 9151000000 28096000000 -1246000000 56000000 36059000000 1637000000 -3000000 1634000000 -905000000 -3000000 -908000000 5000000 5000000 1300000 0 48000000 576000000 624000000 310000000 310000000 200000 111000000 111000000 -80000000 -80000000 240000000.0 2000000 9134000000 28847000000 -2151000000 55000000 35887000000 Organization<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 48 million medical members through our affiliated health plans as of June 30, 2023. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products &amp; Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (with the exception of 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also serve members in numerous states as Amerigroup, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, UniCare and/or Wellpoint. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services as CarelonRx and other healthcare-related services as Carelon Services, Aspire Health, Carelon Behavioral Health and CareMore. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial &amp; Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate &amp; Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable </span></div>segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Form 10-Q has been reclassified to conform to the new presentation. For additional discussion regarding our segments, including the changes made, see Note 14 “Segment Information.” 48000000 30 50 Basis of Presentation and Significant Accounting Policies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) , unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and six months ended June 30, 2023 and 2022 have been recorded. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $391 and $258 at June 30, 2023 and December 31, 2022, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $184 and $152 at June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $86 and $68 at June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $816 and $744 at June 30, 2023 and December 31, 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at June 30, 2023. For the three and six months ended June 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Services—Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our adoption as required by the new standard.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) , unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and six months ended June 30, 2023 and 2022 have been recorded. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.</span> Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $391 and $258 at June 30, 2023 and December 31, 2022, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.</span> 391000000 258000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.</span></div> 1.02 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $184 and $152 at June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $86 and $68 at June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $816 and $744 at June 30, 2023 and December 31, 2022, respectively.</span></div> 184000000 152000000 86000000 68000000 816000000 744000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at June 30, 2023. For the three and six months ended June 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at June 30, 2023. For the three and six months ended June 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Services—Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our adoption as required by the new standard.</span> Business Acquisitions and Divestitures<div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending Divestiture</span></div><div style="margin-bottom:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected to close by the end of the first quarter of 2024 and is subject to standard closing conditions and customary approvals. The related net assets held for sale and results of operations for the employee benefits businesses to be divested as of and for the three and six months ending June 30, 2023 were not material. </span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending Acquisition</span></div><div style="margin-bottom:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service &amp; Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health solutions to BCBSLA’s members. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals.</span></div><div style="margin-bottom:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Completed Acquisitions </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of June 30, 2023, the purchase price was allocated to the tangible and </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible net assets acquired based on management’s initial estimates of their fair values, of which $820 has been allocated to finite-lived intangible assets and $877 to goodwill, including an increase to goodwill for measurement period adjustments of $149 during the quarter ended June 30, 2023. The majority of goodwill is not deductible for income tax purposes. As of June 30, 2023, the initial accounting for the acquisition had not been finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The initial accounting for this acquisition was finalized as of June 30, 2023. The purchase price was allocated to tangible and intangible net assets acquired based on management’s estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $139 to goodwill. Contractual purchase price adjustments during the quarter ended June 30, 2023 were $13 and resulted in an increase to goodwill. The majority of goodwill is deductible for income tax purposes. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.</span></div> 820000000 877000000 149000000 89000000 250000000 139000000 13000000 Investments <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Maturity Securities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at June 30, 2023 and December 31, 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost or <br/>Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance <br/>For Credit <br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,025)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,015 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities.</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at June 30, 2023 and December 31, 2022, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,715)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,035 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Unrealized losses on our securities shown in the table above have not been recognized into income because, as of June 30, 2023, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for credit losses have been recorded in the amounts of $7 and $9 at June 30, 2023 and December 31, 2022, respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at June 30, 2023, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,724 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2023, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $9,675 and $15,085, respectively. During the three and six months ended June 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $7,026 and $10,672, respectively.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of marketable equity securities at June 30, 2023 and December 31, 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:68.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Invested Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three month lag due to the timing of when we receive financial information from the companies.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Gains and Losses</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) gains for the three and six months ended June 30, 2023 and 2022 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized losses from sales of fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized on equity securities still held at the end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses) recognized on equity securities sold during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Investment Income</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and December 31, 2022, accrued investment income totaled $266 and $245, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Lending Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,311 and $2,457 at June 30, 2023 and December 31, 2022, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of June 30, 2023 and December 31, 2022. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and December 31, 2022, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,237 and $2,221, respectively, of United States Government securities for $73 and $224, respectively, and of Residential Mortgage-Backed securities for $1 and $12, respectively.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at June 30, 2023 and December 31, 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost or <br/>Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance <br/>For Credit <br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,025)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,015 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1957000000 1000000 75000000 0 1883000000 94000000 1000000 4000000 0 91000000 337000000 2000000 41000000 1000000 297000000 3957000000 22000000 207000000 0 3772000000 14276000000 50000000 997000000 4000000 13325000000 3617000000 11000000 313000000 0 3315000000 2262000000 2000000 180000000 2000000 2082000000 4224000000 15000000 208000000 0 4031000000 30724000000 104000000 2025000000 7000000 28796000000 1502000000 2000000 103000000 0 1401000000 82000000 1000000 5000000 0 78000000 321000000 1000000 46000000 2000000 274000000 4389000000 19000000 265000000 0 4143000000 13721000000 31000000 1218000000 5000000 12529000000 2978000000 9000000 324000000 0 2663000000 2055000000 1000000 176000000 2000000 1878000000 3967000000 12000000 241000000 0 3738000000 29015000000 76000000 2378000000 9000000 26704000000 <div style="margin-bottom:3pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at June 30, 2023 and December 31, 2022, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,715)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,035 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 58000000 1019000000 29000000 48000000 278000000 46000000 18000000 63000000 2000000 29000000 18000000 2000000 97000000 56000000 2000000 224000000 186000000 39000000 702000000 1278000000 20000000 925000000 1598000000 187000000 2051000000 4323000000 129000000 3216000000 6910000000 868000000 642000000 1251000000 38000000 1286000000 1714000000 275000000 246000000 701000000 28000000 553000000 1316000000 152000000 348000000 1258000000 62000000 827000000 2265000000 146000000 4162000000 9949000000 310000000 7108000000 14285000000 1715000000 61000000 701000000 40000000 38000000 442000000 63000000 39000000 73000000 4000000 6000000 5000000 1000000 150000000 100000000 10000000 198000000 142000000 36000000 1398000000 2615000000 147000000 396000000 652000000 118000000 3551000000 7826000000 549000000 2204000000 3521000000 669000000 1341000000 1435000000 121000000 496000000 982000000 203000000 457000000 1082000000 76000000 324000000 719000000 100000000 784000000 2203000000 124000000 398000000 1074000000 117000000 7781000000 16035000000 1071000000 4060000000 7537000000 1307000000 7000000 9000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at June 30, 2023, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,724 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1127000000 1118000000 8193000000 7810000000 9466000000 8883000000 6059000000 5588000000 5879000000 5397000000 30724000000 28796000000 9675000000 15085000000 7026000000 10672000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of marketable equity securities at June 30, 2023 and December 31, 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:68.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 166000000 822000000 31000000 43000000 75000000 88000000 272000000 953000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) gains for the three and six months ended June 30, 2023 and 2022 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized losses from sales of fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized on equity securities still held at the end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses) recognized on equity securities sold during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 11000000 16000000 21000000 36000000 -99000000 -176000000 -214000000 -254000000 3000000 1000000 10000000 21000000 -91000000 -161000000 -203000000 -239000000 2000000 -83000000 -2000000 -154000000 1000000 -5000000 4000000 -19000000 3000000 -88000000 2000000 -173000000 2000000 10000000 20000000 33000000 16000000 15000000 9000000 44000000 26000000 1000000 29000000 5000000 -40000000 -6000000 -18000000 -16000000 -128000000 -255000000 -219000000 -428000000 266000000 245000000 2311000000 2457000000 1.02 1.02 2237000000 2221000000 73000000 224000000 1000000 12000000 Derivative Financial InstrumentsWe primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $214 and $229 at June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three and six months ended months ended June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we recognized net gains of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> $7 and net losses of $15,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> respectively, on non-hedging derivatives. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three and six months ended months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we recognized net gains on non-hedging derivatives of $24 and $46, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,” of this Form 10-Q.</span></div> -214000000 -229000000 7000000 -15000000 24000000 46000000 Fair Value<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:8.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.736%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Level Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Input Definition</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed maturity securities, available-for-sale:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities lending collateral:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,327 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,661 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,604 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,494 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,712 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,787 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-bottom:3pt;margin-top:15pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Asset- <br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at April 1, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-5.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses included in net income related to assets still held at June 30, 2023</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at April 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-5.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at June 30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Asset- <br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total losses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at June 30, 2023</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at June 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no individually material transfers into or out of Level III during the three and six months ended June 30, 2023 or 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of BioPlus in the first quarter of 2023 and Integra during the second quarter of 2022. The net assets acquired in our acquisitions of BioPlus and Integra and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of tangible assets acquired and liabilities assumed were recorded at their carrying values as of the acquisition date, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of BioPlus and Integra were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of BioPlus and Integra described above, there were no </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material assets or liabilities measured at fair value on a nonrecurring basis during the three and six months ended June 30, 2023 or 2022.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and six months ended June 30, 2023 or 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other invested assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term borrowings:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities. The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt—senior unsecured notes and surplus notes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt—convertible debentures:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at June 30, 2023 and December 31, 2022 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,327 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,661 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,604 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,494 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,712 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,787 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 6100000000 0 0 6100000000 0 1883000000 0 1883000000 0 91000000 0 91000000 0 297000000 0 297000000 0 3772000000 0 3772000000 0 13222000000 103000000 13325000000 0 3315000000 0 3315000000 0 2082000000 0 2082000000 0 3665000000 366000000 4031000000 0 28327000000 469000000 28796000000 166000000 0 0 166000000 12000000 19000000 0 31000000 0 0 75000000 75000000 178000000 19000000 75000000 272000000 121000000 0 0 121000000 0 2312000000 0 2312000000 0 3000000 0 3000000 6399000000 30661000000 544000000 37604000000 0 69000000 0 69000000 0 69000000 0 69000000 3567000000 0 0 3567000000 0 1401000000 0 1401000000 0 78000000 0 78000000 0 274000000 0 274000000 0 4143000000 0 4143000000 0 12392000000 137000000 12529000000 0 2663000000 0 2663000000 0 1878000000 0 1878000000 0 3382000000 356000000 3738000000 0 26211000000 493000000 26704000000 822000000 0 0 822000000 2000000 41000000 0 43000000 0 0 88000000 88000000 824000000 41000000 88000000 953000000 103000000 0 0 103000000 0 2457000000 0 2457000000 0 3000000 0 3000000 4494000000 28712000000 581000000 33787000000 0 60000000 0 60000000 0 60000000 0 60000000 <div style="margin-bottom:3pt;margin-top:15pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Asset- <br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at April 1, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-5.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses included in net income related to assets still held at June 30, 2023</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at April 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-5.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at June 30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Asset- <br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total losses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at June 30, 2023</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at June 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 142000000 0 390000000 78000000 610000000 -2000000 0 1000000 2000000 1000000 1000000 0 -9000000 0 -8000000 2000000 0 7000000 0 9000000 10000000 0 5000000 5000000 20000000 4000000 0 0 0 4000000 0 0 6000000 0 6000000 26000000 0 24000000 0 50000000 103000000 0 366000000 75000000 544000000 0 0 0 1000000 1000000 341000000 4000000 37000000 99000000 481000000 -5000000 0 0 -2000000 -7000000 11000000 0 190000000 11000000 212000000 188000000 0 0 14000000 202000000 5000000 0 0 0 5000000 14000000 0 0 0 14000000 13000000 4000000 9000000 0 26000000 155000000 0 218000000 94000000 467000000 0 0 0 -3000000 -3000000 137000000 0 356000000 88000000 581000000 -3000000 0 1000000 -5000000 -7000000 2000000 0 -4000000 0 -2000000 4000000 0 18000000 1000000 23000000 10000000 0 11000000 9000000 30000000 6000000 0 0 0 6000000 0 0 6000000 0 6000000 21000000 0 0 0 21000000 103000000 0 366000000 75000000 544000000 0 0 0 -6000000 -6000000 336000000 5000000 19000000 89000000 449000000 -4000000 0 0 1000000 -3000000 -2000000 0 0 0 -2000000 35000000 0 205000000 20000000 260000000 175000000 0 0 16000000 191000000 39000000 0 0 0 39000000 14000000 0 0 0 14000000 10000000 5000000 6000000 0 21000000 155000000 0 218000000 94000000 467000000 0 0 0 1000000 1000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at June 30, 2023 and December 31, 2022 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5872000000 0 0 5872000000 5872000000 265000000 0 265000000 0 265000000 24859000000 0 22872000000 0 22872000000 5582000000 0 0 5582000000 5582000000 265000000 0 265000000 0 265000000 23786000000 0 21861000000 0 21861000000 63000000 0 463000000 0 463000000 Income Taxes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recognized income tax expense of $585 an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $488 (restated), respectively, which represent effective income tax rates of 24.0% and 23.0% (restated), respectively. The increase in our effective incom</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e tax rate from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is primarily due to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recognized income tax expense of $1,200 an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $1,015 (restated), respectively, which represent effective income tax rates of 23.7% and 22.9% (restated), respectively. The increase in our effective incom</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e tax rate from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is primarily related to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes receivable totaled $48 and $440 at June 30, 2023 and December 31, 2022, respectively. We recognize the income receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.</span></div> 585000000 488000000 0.240 0.230 1200000000 1015000000 0.237 0.229 48000000 440000000 Medical Claims Payable<div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,765 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,626 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,902 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023, the total of net incurred but not reported liabilities plus expected development on reported claims was $597, $2,224 and $13,073 for the claim years 2021 and prior, 2022 and 2023, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in the six months ended June 30, 2023 and 2022 resulted primarily from trend factors in late 2022 and late 2021, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2022 developing faster than expected also contributed to the favorable development in the six months ended June 30, 2023.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,390 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,795 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,026 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of June 30, 2023 and December 31, 2022, is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,165 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,596 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,765 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,626 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,902 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 15348000000 13282000000 6000000 21000000 15342000000 13261000000 0 133000000 61290000000 55737000000 1112000000 972000000 60178000000 54765000000 48217000000 42882000000 11409000000 10401000000 59626000000 53283000000 15894000000 14876000000 8000000 13000000 15902000000 14889000000 597000000 2224000000 13073000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,604 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,390 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2022 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,795 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,026 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29683000000 30495000000 60178000000 1103000000 1109000000 2212000000 30786000000 31604000000 62390000000 27131000000 27634000000 54765000000 1100000000 1161000000 2261000000 28231000000 28795000000 57026000000 <div style="margin-bottom:3pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of June 30, 2023 and December 31, 2022, is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,165 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,596 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 15894000000 15342000000 8000000 6000000 263000000 248000000 16165000000 15596000000 Debt<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally issue senior unsecured notes for long-term borrowing purposes. At June 30, 2023 and December 31, 2022, we had $24,834 and $23,761, respectively, outstanding under these notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the “2026 Notes”), $1,000 aggregate principal amount of 4.750% Notes due 2033 (the “2033 Notes”), and $1,100 aggregate principal amount of 5.125% Notes due 2053 (the “2053 Notes”) under our shelf registration statement. Interest on the 2026 Notes is payable semi-annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and 2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023. We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On January 17, 2023, we repaid, at maturity, the $1,000 outstanding balance of our 3.300% senior unsecured notes. On March 15, 2023, we repaid, at maturity, the $500 outstanding balance of our 0.450% senior unsecured notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an unsecured surplus note with an outstanding principal balance of $25 at both June 30, 2023 and December 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of June 30, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.6%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of June 30, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the six months ended June 30, 2023 or the year ended December 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Through certain subsidiaries, we had previously entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provided combined credit of up to $200. As of June 30, 2023, the Subsidiary Credit Facilities have been terminated.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. At June 30, 2023 and December 31, 2022, we had $90 and $0, respectively, outstanding under this program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2023, we redeemed all of our outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), pursuant to the indenture dated as of October 9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The Debentures were redeemed at a redemption price equal to 100% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption, for cash totaling $5. During the three months ended March 31, 2023, $59 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and conditions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three months ended March 31, 2023 of $404.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $175 and $265 of outstanding short-term borrowings from the FHLBs at June 30, 2023 and December 31, 2022, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLBs borrowings.</span></div> 24834000000 23761000000 500000000 0.04900 1000000000 0.04750 1100000000 0.05125 1000000000 0.03300 500000000 0.00450 25000000 25000000 4000000000 Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of June 30, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.6%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of June 30, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility. 200000000 4000000000 90000000 0 1 5000000 59000000 404000000 175000000 265000000 Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Proceedings </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint, or in other court filings, the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss. </span></div><div style="margin-bottom:9pt;padding-right:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at June 30, 2023. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Cross Blue Shield Antitrust Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in 28 states were consolidated into a single, multi-district proceeding captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Blue Cross Blue Shield Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which amount was accrued in 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit, which has scheduled oral argument on the appeals for September 2023. In the event that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio v. American Express Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In November 2022, the Court issued an order requiring the parties to submit supplemental briefs on certain questions related to the providers’ renewed motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alaska Air Group, Inc., et al. v. Anthem, Inc., et al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No. 2:21-cv-01209-AMM (N.D. Ala.) (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Alaska Air"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JetBlue Airways Corp., et al. v. Anthem, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00558-GMB (N.D. Ala.) (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Jet Blue"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00265-RDP (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bed Bath &amp; Beyond Inc. v. Anthem, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-01256-SGC (N.D. Ala.) (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Bed Bath &amp; Beyond"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">);</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Hoover, et al. v. Blue Cross Blue Shield Association, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00261-RDP (N.D. Ala.); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VHS Liquidating Trust v. Blue Cross of California, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. RG21106600 (Cal. Super.). In February 2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alaska Air</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jet Blue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2023, pursuant to a stipulation by the parties, the Court denied the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defendants’ motion to dismiss also based on a statute of limitations defense in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bed Bath &amp; Beyond</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Blue Cross of California Taxation Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael D. Myers v. State Board of Equalization, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit. In November 2021, the plaintiff appealed the summary judgment order. In March 2023, the appeal was argued before the California Second District Court of Appeal (the "Second District"). The Second District affirmed the Superior Court's summary judgment order in April 2023. The plaintiff filed a petition for review with the California Supreme Court in June 2023, and BCC filed its answer to the petition in the same month. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Express Scripts, Inc. Pharmacy Benefit Management Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for pharmacy benefit management services, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anthem, Inc. v. Express Scripts, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed, and the District Court denied in March 2023, allowing our operational breach claim to proceed. A trial date has been set for December 2023. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Risk Adjustment Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Anthem, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be complete by February 2025. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Investigations of CareMore and HealthSun</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We have submitted corrected data to CMS related to these investigations. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the indemnity claims were resolved in the fourth quarters of 2021 and 2022, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The agreement superseded certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at June 30, 2023 is approximately $621. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formed CarelonRx, formerly known as IngenioRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own, starting in the second quarter of 2019. The comprehensive pharmacy services portfolio includes, but is not limited to, formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services. CarelonRx delegates certain pharmacy services, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.</span></div> 0 250000000 506000000 596000000 0.0235 14800000000 158000000 4675000000 621000000 Capital Stock<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Capital – Dividends and Stock Repurchase Program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash dividend activity for the six months ended June 30, 2023 and 2022 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:34.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Record Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Payment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 24, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 18, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 9, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 23, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, our Audit Committee declared a third quarter 2023 dividend to shareholders of $1.48 per share, payable on September 22, 2023 to shareholders of record at the close of business on September 8, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings. </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at the end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding the use of capital for debt security repurchases, see Note 9, “Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the six months ended June 30, 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:44.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Option Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the six months ended June 30, 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2023, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three-year period from 2023 to 2025. These grants have been included in the activity shown above but will be subject to adjustment at the end of 2025 based on results in the three-year period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K. </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the six months ended June 30, 2023 and 2022:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10</span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values per option or share were determined for the six months ended June 30, 2023 and 2022:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash dividend activity for the six months ended June 30, 2023 and 2022 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:34.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Record Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Payment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 24, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 18, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 9, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 23, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2023-01-24 2023-03-10 2023-03-24 1.48 351000000 2023-04-18 2023-06-09 2023-06-23 1.48 350000000 2022-01-25 2022-03-10 2022-03-25 1.28 309000000 2022-04-19 2022-06-10 2022-06-24 1.28 309000000 1.48 2023-09-22 2023-09-08 5000000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at the end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2700000 2500000 466.62 471.72 1268000000 1169000000 5608000000 3022000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the six months ended June 30, 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:44.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Option Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2800000 293.28 600000 469.05 200000 268.35 0 391.44 3200000 323.85 P6Y6M3D 402000000 2100000 265.51 P5Y3M21D 376000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the six months ended June 30, 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1200000 357.21 600000 469.60 600000 301.18 0 405.25 1200000 422.67 200000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the six months ended June 30, 2023 and 2022:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10</span></td></tr></table></div> 0.0395 0.0197 0.2900 0.2900 0.00316 0.00282 P4Y4M24D P5Y1M6D <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values per option or share were determined for the six months ended June 30, 2023 and 2022:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 127.13 116.80 469.60 452.78 Accumulated Other Comprehensive Loss<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive loss at June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/>June 30</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized investment (losses) gains:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain before reclassifications, net of tax benefit (expense) of $61, $323, $(25) and $677, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss, net of tax expense of $(23), $(34), $(51) and $(55), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(922)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,991)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0 and $(3), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax benefit of $0, $0, $1 and $1, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (expense) of $(1), $(1), $7 and $(2), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(1), $(4), $(2) and $(6), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(494)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(494)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Future policy benefits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax expense of $1, $0, $1 and $0, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax benefit of $(5), $1, $(3) and $2, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total beginning of period accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax benefit (expense) of $32, $285, $(72), and $617, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0and $(3) respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total end of period accumulated other comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive loss at June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/>June 30</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized investment (losses) gains:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain before reclassifications, net of tax benefit (expense) of $61, $323, $(25) and $677, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss, net of tax expense of $(23), $(34), $(51) and $(55), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(922)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,991)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0 and $(3), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax benefit of $0, $0, $1 and $1, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (expense) of $(1), $(1), $7 and $(2), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(1), $(4), $(2) and $(6), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(494)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(494)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Future policy benefits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax expense of $1, $0, $1 and $0, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax benefit of $(5), $1, $(3) and $2, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total beginning of period accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax benefit (expense) of $32, $285, $(72), and $617, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0and $(3) respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total end of period accumulated other comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -1330000000 -570000000 -1755000000 494000000 61000000 323000000 -25000000 677000000 -191000000 -1050000000 146000000 -2196000000 23000000 34000000 51000000 55000000 72000000 128000000 162000000 205000000 -119000000 -922000000 308000000 -1991000000 0 -1000000 0 -3000000 0 -3000000 2000000 -8000000 -1449000000 -1489000000 -1449000000 -1489000000 -5000000 -1000000 -3000000 0 0 0 1000000 1000000 -1000000 -1000000 -3000000 -2000000 -6000000 -2000000 -6000000 -2000000 -218000000 -236000000 -229000000 -239000000 -1000000 -1000000 7000000 -2000000 4000000 3000000 15000000 6000000 -214000000 -233000000 -214000000 -233000000 497000000 422000000 499000000 429000000 -1000000 -4000000 -2000000 -6000000 -3000000 -9000000 -5000000 -16000000 494000000 413000000 494000000 413000000 15000000 -10000000 13000000 -19000000 1000000 0 1000000 0 -3000000 8000000 -1000000 17000000 12000000 -2000000 12000000 -2000000 -15000000 -7000000 -17000000 -4000000 -5000000 1000000 -3000000 2000000 0 -5000000 2000000 -8000000 -15000000 -12000000 -15000000 -12000000 -2050000000 -1246000000 -2490000000 -197000000 32000000 285000000 -72000000 617000000 -116000000 -908000000 326000000 -1962000000 0 -1000000 0 -3000000 0 -3000000 2000000 -8000000 -2166000000 -2151000000 -2166000000 -2151000000 Earnings per Share<div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/> June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings per share – weighted-average shares</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted earnings per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023 and 2022, weighted-average shares related to certain stock options of 1.0 and 0.5 respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the six months ended June 30, 2023 and 2022, weighted-average shares related to certain stock options of 0.7 and 0.4, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options were anti-dilutive.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2023, we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2023 through 2025. During the three and six months ended months ended June 30, 2022, we issued approximately 0.0 and 0.5 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2022 through 2024. The contingent restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if and when the contingency is met.</span></div> <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/> June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings per share – weighted-average shares</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted earnings per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 236600000 240700000 237000000.0 241000000.0 1200000 2700000 1700000 2900000 237800000 243400000 238700000 243900000 1000000.0 500000 700000 400000 0.0 600000 0.0 200000 0.0 500000 0.0 200000 Segment Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 “Organization”, we are reorganizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business and the products in each of our operating segments, which has resulted in restructurings between some of our operating segments. As a result of these changes, we have changed our reportable segment presentation and its composition to reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources beginning on January 1, 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial &amp; Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate &amp; Other. In 2022, we managed and presented our operations through the following four reportable segments: Commercial &amp; Specialty Business, Government Business, CarelonRx and Other. Previously reported information throughout this Form 10-Q has been reclassified to conform to the new presentation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance benefits.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes services such as formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Carelon Services segment is focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Corporate &amp; Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as corporate expenses not allocated to our other reportable segments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define operating revenues to include premium income, product revenue and service fees. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, in addition to certain back-office services provided by our international businesses, which are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the three months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health <br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon <br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate <br/>&amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,811 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,466 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,441 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,817)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,283)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss) (restated)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health <br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon <br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate <br/>&amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,881 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,637)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,008 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss) (restated)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated eliminations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/> June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,672 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,632 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,844 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,727 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:46.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.512%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.512%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/> June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Restated)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,459 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the three months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health <br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon <br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate <br/>&amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,811 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,466 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,441 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,907 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,817)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,283)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss) (restated)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 36233000000 0 429000000 429000000 0 -73000000 36589000000 0 4859000000 0 4859000000 0 4859000000 1767000000 0 201000000 201000000 -39000000 1929000000 38000000000 4859000000 630000000 5489000000 -39000000 -73000000 43377000000 3607000000 2811000000 6418000000 326000000 -6744000000 38000000000 8466000000 3441000000 11907000000 287000000 -6817000000 43377000000 2148000000 496000000 136000000 632000000 -152000000 0 2628000000 32787000000 0 327000000 327000000 0 -38000000 33076000000 0 3568000000 0 3568000000 0 3568000000 1609000000 0 220000000 220000000 9000000 1838000000 34396000000 3568000000 547000000 4115000000 9000000 -38000000 38482000000 3503000000 2436000000 5939000000 306000000 -6245000000 34396000000 7071000000 2983000000 10054000000 315000000 -6283000000 38482000000 1781000000 479000000 113000000 592000000 -27000000 0 2346000000 71767000000 0 839000000 839000000 0 -149000000 72457000000 0 8881000000 0 8881000000 0 8881000000 3513000000 0 408000000 408000000 16000000 3937000000 75280000000 8881000000 1247000000 10128000000 16000000 -149000000 85275000000 7609000000 5506000000 13115000000 522000000 -13637000000 75280000000 16490000000 6753000000 23243000000 538000000 -13786000000 85275000000 4307000000 1008000000 345000000 1353000000 -201000000 0 5459000000 65250000000 0 693000000 693000000 0 -82000000 65861000000 0 6869000000 0 6869000000 0 6869000000 3173000000 0 446000000 446000000 19000000 3638000000 68423000000 6869000000 1139000000 8008000000 19000000 -82000000 76368000000 6885000000 4792000000 11677000000 569000000 -12246000000 68423000000 13754000000 5931000000 19685000000 588000000 -12328000000 76368000000 3632000000 877000000 313000000 1190000000 -49000000 0 4773000000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/> June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,672 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,632 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,844 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,727 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 43377000000 38482000000 85275000000 76368000000 416000000 381000000 803000000 741000000 -121000000 -231000000 -234000000 -382000000 43672000000 38632000000 85844000000 76727000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:46.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.512%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.512%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/> June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Restated)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,459 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2441000000 2122000000 5060000000 4428000000 416000000 381000000 803000000 741000000 -121000000 -231000000 -234000000 -382000000 261000000 208000000 512000000 409000000 221000000 166000000 456000000 295000000 2628000000 2346000000 5459000000 4773000000 Leases<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases have remaining lease terms of 1 year to 11 years.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information related to our leases is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:44.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1765"><span style="-sec-ix-hidden:f-1766">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1769"><span style="-sec-ix-hidden:f-1770">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1773"><span style="-sec-ix-hidden:f-1774">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.726%"><tr><td style="width:1.0%"></td><td style="width:55.361%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/> June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Operating cash paid for amounts included in the measurement of lease liabilities, operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities, operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, the weighted average remaining lease term of our operating leases was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 3.28% at June 30, 2023 and 2.98% at December 31, 2022.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the six months ended June 30, 2023)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P1Y P11Y <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information related to our leases is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:44.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1765"><span style="-sec-ix-hidden:f-1766">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1769"><span style="-sec-ix-hidden:f-1770">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1773"><span style="-sec-ix-hidden:f-1774">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.726%"><tr><td style="width:1.0%"></td><td style="width:55.361%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended <br/> June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Operating cash paid for amounts included in the measurement of lease liabilities, operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities, operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 605000000 604000000 178000000 181000000 717000000 751000000 32000000 33000000 57000000 65000000 16000000 11000000 29000000 24000000 1000000 1000000 2000000 2000000 47000000 43000000 84000000 87000000 54000000 53000000 105000000 105000000 18000000 29000000 40000000 37000000 P7Y P7Y 0.0328 0.0298 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the six months ended June 30, 2023)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 110000000 195000000 162000000 128000000 93000000 329000000 1017000000 122000000 895000000 EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 454 389 1 false 75 0 false 9 false false R1.htm 0000001 - Document - Document And Entity Information Document Sheet http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument Document And Entity Information Document Cover 1 false false R2.htm 0000002 - Statement - Consolidated Balance Sheets Sheet http://www.elevancehealth.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements Of Income Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome Consolidated Statements Of Income Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements Of Cash Flows Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements Of Changes in Equity Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity Consolidated Statements Of Changes in Equity Statements 7 false false R8.htm 0000008 - Disclosure - Organization Sheet http://www.elevancehealth.com/role/Organization Organization Notes 8 false false R9.htm 0000009 - Disclosure - Basis Of Presentation and Significant Accounting Policies Sheet http://www.elevancehealth.com/role/BasisOfPresentationandSignificantAccountingPolicies Basis Of Presentation and Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Business Acquisitions Sheet http://www.elevancehealth.com/role/BusinessAcquisitions Business Acquisitions Notes 10 false false R11.htm 0000011 - Disclosure - Investments Sheet http://www.elevancehealth.com/role/Investments Investments Notes 11 false false R12.htm 0000012 - Disclosure - Derivative Financial Instruments Sheet http://www.elevancehealth.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value Sheet http://www.elevancehealth.com/role/FairValue Fair Value Notes 13 false false R14.htm 0000014 - Disclosure - Income Taxes Sheet http://www.elevancehealth.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 0000015 - Disclosure - Medical Claims Payable Sheet http://www.elevancehealth.com/role/MedicalClaimsPayable Medical Claims Payable Notes 15 false false R16.htm 0000016 - Disclosure - Debt Sheet http://www.elevancehealth.com/role/Debt Debt Notes 16 false false R17.htm 0000017 - Disclosure - Commitments And Contingencies Sheet http://www.elevancehealth.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 17 false false R18.htm 0000018 - Disclosure - Capital Stock Sheet http://www.elevancehealth.com/role/CapitalStock Capital Stock Notes 18 false false R19.htm 0000019 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 19 false false R20.htm 0000020 - Disclosure - Earnings Per Share Sheet http://www.elevancehealth.com/role/EarningsPerShare Earnings Per Share Notes 20 false false R21.htm 0000021 - Disclosure - Segment Information Sheet http://www.elevancehealth.com/role/SegmentInformation Segment Information Notes 21 false false R22.htm 0000022 - Disclosure - Leases Sheet http://www.elevancehealth.com/role/Leases Leases Notes 22 false false R23.htm 9954701 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.elevancehealth.com/role/BasisOfPresentationandSignificantAccountingPolicies 23 false false R24.htm 9954702 - Disclosure - Investments (Tables) Sheet http://www.elevancehealth.com/role/InvestmentsTables Investments (Tables) Tables http://www.elevancehealth.com/role/Investments 24 false false R25.htm 9954703 - Disclosure - Fair Value (Tables) Sheet http://www.elevancehealth.com/role/FairValueTables Fair Value (Tables) Tables http://www.elevancehealth.com/role/FairValue 25 false false R26.htm 9954704 - Disclosure - Medical Claims Payable (Tables) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableTables Medical Claims Payable (Tables) Tables http://www.elevancehealth.com/role/MedicalClaimsPayable 26 false false R27.htm 9954705 - Disclosure - Capital Stock (Tables) Sheet http://www.elevancehealth.com/role/CapitalStockTables Capital Stock (Tables) Tables http://www.elevancehealth.com/role/CapitalStock 27 false false R28.htm 9954706 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss 28 false false R29.htm 9954707 - Disclosure - Earnings Per Share (Tables) Sheet http://www.elevancehealth.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.elevancehealth.com/role/EarningsPerShare 29 false false R30.htm 9954708 - Disclosure - Segment Information (Tables) Sheet http://www.elevancehealth.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.elevancehealth.com/role/SegmentInformation 30 false false R31.htm 9954709 - Disclosure - Leases (Tables) Sheet http://www.elevancehealth.com/role/LeasesTables Leases (Tables) Tables http://www.elevancehealth.com/role/Leases 31 false false R32.htm 9954710 - Disclosure - Organization (Details) Sheet http://www.elevancehealth.com/role/OrganizationDetails Organization (Details) Details http://www.elevancehealth.com/role/Organization 32 false false R33.htm 9954711 - Disclosure - Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) Sheet http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) Details 33 false false R34.htm 9954712 - Disclosure - Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) Sheet http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) Details 34 false false R35.htm 9954713 - Disclosure - Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 35 false false R36.htm 9954714 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 36 false false R37.htm 9954715 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 37 false false R38.htm 9954716 - Disclosure - Investments (Current Equity Securities) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails Investments (Current Equity Securities) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 38 false false R39.htm 9954717 - Disclosure - Investments (Net Investment Gains/Losses) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails Investments (Net Investment Gains/Losses) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 39 false false R40.htm 9954718 - Disclosure - Investments (Narrative) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsNarrativeDetails Investments (Narrative) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 40 false false R41.htm 9954719 - Disclosure - Derivative Financial Instruments (Financial Statement Narrative) (Details) Sheet http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails Derivative Financial Instruments (Financial Statement Narrative) (Details) Details http://www.elevancehealth.com/role/DerivativeFinancialInstruments 41 false false R42.htm 9954720 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) Sheet http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) Details http://www.elevancehealth.com/role/FairValueTables 42 false false R43.htm 9954721 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) Sheet http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) Details http://www.elevancehealth.com/role/FairValueTables 43 false false R44.htm 9954722 - Disclosure - Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) Sheet http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) Details http://www.elevancehealth.com/role/FairValueTables 44 false false R45.htm 9954724 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.elevancehealth.com/role/IncomeTaxes 45 false false R46.htm 9954725 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details) Details http://www.elevancehealth.com/role/MedicalClaimsPayableTables 46 false false R47.htm 9954726 - Disclosure - Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) Details http://www.elevancehealth.com/role/MedicalClaimsPayableTables 47 false false R48.htm 9954727 - Disclosure - Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) Details 48 false false R49.htm 9954728 - Disclosure - Medical Claims Payable (Narrative) (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails Medical Claims Payable (Narrative) (Details) Details http://www.elevancehealth.com/role/MedicalClaimsPayableTables 49 false false R50.htm 9954729 - Disclosure - Debt (Narrative) (Details) Sheet http://www.elevancehealth.com/role/DebtNarrativeDetails Debt (Narrative) (Details) Details http://www.elevancehealth.com/role/Debt 50 false false R51.htm 9954730 - Disclosure - Commitments And Contingencies (Details) Sheet http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails Commitments And Contingencies (Details) Details http://www.elevancehealth.com/role/CommitmentsAndContingencies 51 false false R52.htm 9954731 - Disclosure - Capital Stock (Summary of Cash Dividend Activity) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails Capital Stock (Summary of Cash Dividend Activity) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 52 false false R53.htm 9954732 - Disclosure - Capital Stock (Summary of Share Repurchases) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails Capital Stock (Summary of Share Repurchases) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 53 false false R54.htm 9954733 - Disclosure - Capital Stock (Summary of Stock Option Activity) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails Capital Stock (Summary of Stock Option Activity) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 54 false false R55.htm 9954734 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 55 false false R56.htm 9954735 - Disclosure - Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 56 false false R57.htm 9954736 - Disclosure - Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockScheduleOfWeightedAverageFairValuesDeterminedForThePeriodsDetails Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 57 false false R58.htm 9954737 - Disclosure - Capital Stock (Narrative) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockNarrativeDetails Capital Stock (Narrative) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 58 false false R59.htm 9954738 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) Details http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables 59 false false R60.htm 9954739 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) Sheet http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) Details http://www.elevancehealth.com/role/EarningsPerShareTables 60 false false R61.htm 9954740 - Disclosure - Earnings Per Share (Narrative) (Details) Sheet http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails Earnings Per Share (Narrative) (Details) Details http://www.elevancehealth.com/role/EarningsPerShareTables 61 false false R62.htm 9954741 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails Segment Information (Financial Data By Reportable Segment) (Details) Details http://www.elevancehealth.com/role/SegmentInformationTables 62 false false R63.htm 9954742 - Disclosure - Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) Details http://www.elevancehealth.com/role/SegmentInformationTables 63 false false R64.htm 9954743 - Disclosure - Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) Details http://www.elevancehealth.com/role/SegmentInformationTables 64 false false R65.htm 9954744 - Disclosure - Segment Information Segment Information (Narrative) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationSegmentInformationNarrativeDetails Segment Information Segment Information (Narrative) (Details) Details 65 false false R66.htm 9954745 - Disclosure - Leases (Lease and Other Information) (Details) Sheet http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails Leases (Lease and Other Information) (Details) Details http://www.elevancehealth.com/role/LeasesTables 66 false false R67.htm 9954746 - Disclosure - Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details) Sheet http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details) Details http://www.elevancehealth.com/role/LeasesTables 67 false false R68.htm 9954747 - Disclosure - Leases (Narrative) (Details) Sheet http://www.elevancehealth.com/role/LeasesNarrativeDetails Leases (Narrative) (Details) Details http://www.elevancehealth.com/role/LeasesTables 68 false false All Reports Book All Reports elv-20230630.htm elv-20230630.xsd elv-20230630_cal.xml elv-20230630_def.xml elv-20230630_lab.xml elv-20230630_pre.xml exhibit107directorcompensa.htm exhibit311-20230630q22023.htm exhibit312-20230630q22023.htm exhibit321-20230630q22023.htm exhibit322-20230630q22023.htm elv-20230630_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "elv-20230630.htm": { "axisCustom": 1, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1562, "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 454, "dts": { "calculationLink": { "local": [ "elv-20230630_cal.xml" ] }, "definitionLink": { "local": [ "elv-20230630_def.xml" ] }, "inline": { "local": [ "elv-20230630.htm" ] }, "labelLink": { "local": [ "elv-20230630_lab.xml" ] }, "presentationLink": { "local": [ "elv-20230630_pre.xml" ] }, "schema": { "local": [ "elv-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 624, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 6, "http://xbrl.sec.gov/dei/2023": 5, "total": 11 }, "keyCustom": 30, "keyStandard": 359, "memberCustom": 27, "memberStandard": 47, "nsprefix": "elv", "nsuri": "http://www.elevancehealth.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Document And Entity Information Document", "menuCat": "Cover", "order": "1", "role": "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument", "shortName": "Document And Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Business Acquisitions", "menuCat": "Notes", "order": "10", "role": "http://www.elevancehealth.com/role/BusinessAcquisitions", "shortName": "Business Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Investments", "menuCat": "Notes", "order": "11", "role": "http://www.elevancehealth.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Derivative Financial Instruments", "menuCat": "Notes", "order": "12", "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Fair Value", "menuCat": "Notes", "order": "13", "role": "http://www.elevancehealth.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "14", "role": "http://www.elevancehealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Medical Claims Payable", "menuCat": "Notes", "order": "15", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayable", "shortName": "Medical Claims Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Debt", "menuCat": "Notes", "order": "16", "role": "http://www.elevancehealth.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Commitments And Contingencies", "menuCat": "Notes", "order": "17", "role": "http://www.elevancehealth.com/role/CommitmentsAndContingencies", "shortName": "Commitments And Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Capital Stock", "menuCat": "Notes", "order": "18", "role": "http://www.elevancehealth.com/role/CapitalStock", "shortName": "Capital Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Accumulated Other Comprehensive Loss", "menuCat": "Notes", "order": "19", "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "20", "role": "http://www.elevancehealth.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Segment Information", "menuCat": "Notes", "order": "21", "role": "http://www.elevancehealth.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Leases", "menuCat": "Notes", "order": "22", "role": "http://www.elevancehealth.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - Investments (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.elevancehealth.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Fair Value (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.elevancehealth.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Medical Claims Payable (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableTables", "shortName": "Medical Claims Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Capital Stock (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.elevancehealth.com/role/CapitalStockTables", "shortName": "Capital Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.elevancehealth.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - Segment Information (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.elevancehealth.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.elevancehealth.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:NumberOfMedicalMembersServed", "reportCount": 1, "unique": true, "unitRef": "medical_member", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Organization (Details)", "menuCat": "Details", "order": "32", "role": "http://www.elevancehealth.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:NumberOfMedicalMembersServed", "reportCount": 1, "unique": true, "unitRef": "medical_member", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndInvestmentsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details)", "menuCat": "Details", "order": "33", "role": "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "shortName": "Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndInvestmentsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details)", "menuCat": "Details", "order": "34", "role": "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails", "shortName": "Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-71", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details)", "menuCat": "Details", "order": "35", "role": "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "shortName": "Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-97", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "securities", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)", "menuCat": "Details", "order": "36", "role": "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "shortName": "Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-97", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "securities", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)", "menuCat": "Details", "order": "37", "role": "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "shortName": "Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Investments (Current Equity Securities) (Details)", "menuCat": "Details", "order": "38", "role": "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "shortName": "Investments (Current Equity Securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:InvestmentsinequitysecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-111", "decimals": "-6", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:InvestmentGainsLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Investments (Net Investment Gains/Losses) (Details)", "menuCat": "Details", "order": "39", "role": "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails", "shortName": "Investments (Net Investment Gains/Losses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:InvestmentGainsLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Statements Of Income", "menuCat": "Statements", "order": "4", "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements Of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccruedInvestmentIncomeReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Investments (Narrative) (Details)", "menuCat": "Details", "order": "40", "role": "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "shortName": "Investments (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-4", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccruedInvestmentIncomeReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Derivative Financial Instruments (Financial Statement Narrative) (Details)", "menuCat": "Details", "order": "41", "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails", "shortName": "Derivative Financial Instruments (Financial Statement Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)", "menuCat": "Details", "order": "42", "role": "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "shortName": "Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-27", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)", "menuCat": "Details", "order": "43", "role": "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "shortName": "Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-27", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherLongTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)", "menuCat": "Details", "order": "44", "role": "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "shortName": "Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954724 - Disclosure - Income Taxes (Narrative) (Details)", "menuCat": "Details", "order": "45", "role": "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954725 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details)", "menuCat": "Details", "order": "46", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails", "shortName": "Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954726 - Disclosure - Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details)", "menuCat": "Details", "order": "47", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "shortName": "Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954727 - Disclosure - Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details)", "menuCat": "Details", "order": "48", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "shortName": "Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-4", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-287", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954728 - Disclosure - Medical Claims Payable (Narrative) (Details)", "menuCat": "Details", "order": "49", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails", "shortName": "Medical Claims Payable (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-287", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Comprehensive Income", "menuCat": "Statements", "order": "5", "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "lang": "en-US", "name": "elv:Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954729 - Disclosure - Debt (Narrative) (Details)", "menuCat": "Details", "order": "50", "role": "http://www.elevancehealth.com/role/DebtNarrativeDetails", "shortName": "Debt (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-300", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentCovenantDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "4", "first": true, "lang": "en-US", "name": "elv:GrossPremiumTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954730 - Disclosure - Commitments And Contingencies (Details)", "menuCat": "Details", "order": "51", "role": "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments And Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "4", "first": true, "lang": "en-US", "name": "elv:GrossPremiumTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954731 - Disclosure - Capital Stock (Summary of Cash Dividend Activity) (Details)", "menuCat": "Details", "order": "52", "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails", "shortName": "Capital Stock (Summary of Cash Dividend Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954732 - Disclosure - Capital Stock (Summary of Share Repurchases) (Details)", "menuCat": "Details", "order": "53", "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "shortName": "Capital Stock (Summary of Share Repurchases) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "2", "lang": "en-US", "name": "elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-4", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954733 - Disclosure - Capital Stock (Summary of Stock Option Activity) (Details)", "menuCat": "Details", "order": "54", "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails", "shortName": "Capital Stock (Summary of Stock Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-4", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-4", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954734 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)", "menuCat": "Details", "order": "55", "role": "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails", "shortName": "Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-4", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954735 - Disclosure - Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details)", "menuCat": "Details", "order": "56", "role": "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails", "shortName": "Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954736 - Disclosure - Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details)", "menuCat": "Details", "order": "57", "role": "http://www.elevancehealth.com/role/CapitalStockScheduleOfWeightedAverageFairValuesDeterminedForThePeriodsDetails", "shortName": "Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendPayableDateToBePaidDayMonthAndYear", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954737 - Disclosure - Capital Stock (Narrative) (Details)", "menuCat": "Details", "order": "58", "role": "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "shortName": "Capital Stock (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-317", "decimals": "-6", "lang": "en-US", "name": "elv:IncreaseInStockRepurchaseProgramAuthorization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-27", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954738 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)", "menuCat": "Details", "order": "59", "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "shortName": "Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements Of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements Of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954739 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)", "menuCat": "Details", "order": "60", "role": "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails", "shortName": "Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954740 - Disclosure - Earnings Per Share (Narrative) (Details)", "menuCat": "Details", "order": "61", "role": "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails", "shortName": "Earnings Per Share (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954741 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details)", "menuCat": "Details", "order": "62", "role": "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "shortName": "Segment Information (Financial Data By Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-383", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:OperatingRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954742 - Disclosure - Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details)", "menuCat": "Details", "order": "63", "role": "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails", "shortName": "Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954743 - Disclosure - Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details)", "menuCat": "Details", "order": "64", "role": "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails", "shortName": "Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954744 - Disclosure - Segment Information Segment Information (Narrative) (Details)", "menuCat": "Details", "order": "65", "role": "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationNarrativeDetails", "shortName": "Segment Information Segment Information (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954745 - Disclosure - Leases (Lease and Other Information) (Details)", "menuCat": "Details", "order": "66", "role": "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails", "shortName": "Leases (Lease and Other Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-4", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954746 - Disclosure - Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)", "menuCat": "Details", "order": "67", "role": "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails", "shortName": "Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954747 - Disclosure - Leases (Narrative) (Details)", "menuCat": "Details", "order": "68", "role": "http://www.elevancehealth.com/role/LeasesNarrativeDetails", "shortName": "Leases (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-38", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements Of Changes in Equity", "menuCat": "Statements", "order": "7", "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "shortName": "Consolidated Statements Of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-47", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Organization", "menuCat": "Notes", "order": "8", "role": "http://www.elevancehealth.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Basis Of Presentation and Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.elevancehealth.com/role/BasisOfPresentationandSignificantAccountingPolicies", "shortName": "Basis Of Presentation and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 75, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r970" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r968" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r968" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r968" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r972" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r968" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r968" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r968" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r968" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r967" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r969" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "elv_A2022To2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 to 2024", "label": "2022 to 2024 [Member]", "verboseLabel": "2022 to 2024 [Member]" } } }, "localname": "A2022To2024Member", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_A2023To2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2023 to 2025", "label": "2023 to 2025 [Member]", "terseLabel": "2023 to 2025" } } }, "localname": "A2023To2025Member", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "terseLabel": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "stringItemType" }, "elv_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies", "label": "Accounting Policies [Table]", "terseLabel": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "stringItemType" }, "elv_AffiliatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Affiliated [Member]", "label": "Affiliated [Member]", "terseLabel": "Affiliated [Member]" } } }, "localname": "AffiliatedMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_AnthemInc.v.ExpressScriptsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anthem, Inc. v. Express Scripts, Inc. [Member]", "label": "Anthem, Inc. v. Express Scripts, Inc. [Member]", "terseLabel": "Anthem, Inc. v. Express Scripts, Inc. [Member]" } } }, "localname": "AnthemInc.v.ExpressScriptsInc.Member", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "elv_BCBSAntitrustLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BCBS Antitrust Litigation", "label": "BCBS Antitrust Litigation [Member]", "terseLabel": "BCBS Antitrust Litigation [Member]" } } }, "localname": "BCBSAntitrustLitigationMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "elv_BioPlusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioPlus", "label": "BioPlus [Member]", "terseLabel": "BioPlus" } } }, "localname": "BioPlusMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "domainItemType" }, "elv_CarelonRxSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CarelonRx Segment [Member]", "label": "CarelonRx Segment [Member]", "terseLabel": "CarelonRx Segment [Member]" } } }, "localname": "CarelonRxSegmentMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_CarelonServicesSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carelon Services Segment", "label": "Carelon Services Segment [Member]", "terseLabel": "Carelon Services Segment" } } }, "localname": "CarelonServicesSegmentMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_CarelonTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carelon Total", "label": "Carelon Total [Member]", "terseLabel": "Carelon Total" } } }, "localname": "CarelonTotalMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet [Table Text Block]", "terseLabel": "Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet" } } }, "localname": "CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "elv_Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in non-credit component of impairment losses on investments, net of tax effect.", "label": "Change in non-credit component of impairment losses on investments net of tax", "terseLabel": "Change in non-credit component of impairment losses on investments" } } }, "localname": "Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "elv_CommercialPaperMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commercial Paper, Maximum Borrowing Capacity", "label": "Commercial Paper Maximum Borrowing Capacity", "terseLabel": "Commercial paper authorized" } } }, "localname": "CommercialPaperMaximumBorrowingCapacity", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elv_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "elv_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies [Table].", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "elv_CommonEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Equity Securities [Member]", "label": "Common Equity Securities [Member]", "terseLabel": "Common Equity Securities [Member]" } } }, "localname": "CommonEquitySecuritiesMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "elv_CorporateOtherSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate & Other Segment", "label": "Corporate & Other Segment [Member]", "terseLabel": "Corporate & Other Segment" } } }, "localname": "CorporateOtherSegmentMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_DebtConversionDebtPrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate principal amount of the original debt instrument that was surrendered for conversion.", "label": "Debt Conversion Debt Principal Amount", "terseLabel": "Debt Conversion Debt Principal Amount" } } }, "localname": "DebtConversionDebtPrincipalAmount", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elv_EquitySecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investments in equity securities.", "label": "Equity Securities", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecurities", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "elv_FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point One Two Five Percent Due Two Thousand Fifty Three", "label": "Five Point One Two Five Percent Due Two Thousand Fifty Three [Member]", "terseLabel": "Five Point One Two Five Percent Due Two Thousand Fifty Three" } } }, "localname": "FivePointOneTwoFivePercentDueTwoThousandFiftyThreeMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six", "label": "Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six [Member]", "terseLabel": "Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six" } } }, "localname": "FourPointNineZeroZeroPercentDueTwoThousandTwentySixMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point Seven Five Zero Percent Due Two Thousand Thirty Three", "label": "Four Point Seven Five Zero Percent Due Two Thousand Thirty Three [Member]", "terseLabel": "Four Point Seven Five Zero Percent Due Two Thousand Thirty Three" } } }, "localname": "FourPointSevenFiveZeroPercentDueTwoThousandThirtyThreeMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_FuturePolicyBenefitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Future Policy Benefits", "label": "Future Policy Benefits [Member]", "terseLabel": "Future Policy Benefits" } } }, "localname": "FuturePolicyBenefitsMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "elv_GainsFromOtherInvestments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains From Other Investments", "label": "Gains From Other Investments", "terseLabel": "Gross gains" } } }, "localname": "GainsFromOtherInvestments", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "elv_GrossLossesFromOtherInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross Losses From Other Investments", "label": "Gross Losses From Other Investments", "negatedTerseLabel": "Gross losses" } } }, "localname": "GrossLossesFromOtherInvestments", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "elv_GrossPremiumTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross premium tax rate", "label": "Gross Premium Tax Rate", "terseLabel": "Gross premium tax rate, state of California" } } }, "localname": "GrossPremiumTaxRate", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "elv_HealthBenefitsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Benefits Segment", "label": "Health Benefits Segment [Member]", "terseLabel": "Health Benefits Segment" } } }, "localname": "HealthBenefitsSegmentMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_Impairmentlossesreversalsoninvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Impairment (losses) reversals on investments", "negatedTerseLabel": "Impairment losses recognized in income" } } }, "localname": "Impairmentlossesreversalsoninvestments", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "elv_IncreaseInStockRepurchaseProgramAuthorization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program.", "label": "Increase In Stock Repurchase Program Authorization", "terseLabel": "Increase In Stock Repurchase Program Authorization" } } }, "localname": "IncreaseInStockRepurchaseProgramAuthorization", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elv_IntegraManagedCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Integra Managed Care", "label": "Integra Managed Care [Member]", "terseLabel": "Integra Managed Care [Member]" } } }, "localname": "IntegraManagedCareMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "domainItemType" }, "elv_InvestmentGainsLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Gains (Losses)", "label": "Investment Gains (Losses)", "verboseLabel": "Net losses on investments" } } }, "localname": "InvestmentGainsLosses", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "elv_InvestmentsinequitysecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments in equity securities [Table Text Block]", "label": "Investments in equity securities [Table Text Block]", "terseLabel": "Investments In Equity Securities" } } }, "localname": "InvestmentsinequitysecuritiesTableTextBlock", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "elv_MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract]", "label": "Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract]", "terseLabel": "Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract]" } } }, "localname": "MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseAbstract", "nsuri": "http://www.elevancehealth.com/20230630", "xbrltype": "stringItemType" }, "elv_NetLossesGainsOnFinancialInstruments": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net (losses) gains on financial instruments", "label": "Net (losses) gains on financial instruments", "negatedLabel": "Net losses on financial instruments", "negatedTerseLabel": "Net losses (gains) on financial instruments", "terseLabel": "Net losses on financial instruments" } } }, "localname": "NetLossesGainsOnFinancialInstruments", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-credit components of impairments on investments", "label": "Non-credit components of impairments on investments [Member]", "terseLabel": "Non-credit components of impairments on investments [Member]" } } }, "localname": "NonCreditComponentsOfImpairmentsOnInvestmentsMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "elv_NumberOfCountiesInStateOfKansasCompanyDoesNotServe": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Counties In The State Of Kansas Company Does Not Serve", "label": "Number Of Counties In State Of Kansas Company Does Not Serve", "terseLabel": "Number of counties in the Kansas City area the Company does not serve" } } }, "localname": "NumberOfCountiesInStateOfKansasCompanyDoesNotServe", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "elv_NumberOfMedicalMembersServed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of medical members served", "label": "Number Of Medical Members Served", "verboseLabel": "Number of Medical Members" } } }, "localname": "NumberOfMedicalMembersServed", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "xbrltype": "decimalItemType" }, "elv_OperatingRevenue": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from insurance services and products sold.", "label": "Operating Revenue", "terseLabel": "Total operating revenue", "totalLabel": "Total operating revenue" } } }, "localname": "OperatingRevenue", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "elv_OperationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operational [Member]", "label": "Operational [Member]", "terseLabel": "Damages for Operational Breaches [Member]" } } }, "localname": "OperationalMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense", "terseLabel": "Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense" } } }, "localname": "OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "elv_PerformanceMeasurementPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance measurement period [Domain]", "label": "Performance measurement period [Domain]", "terseLabel": "Performance measurement period [Domain]" } } }, "localname": "PerformanceMeasurementPeriodDomain", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_PerformancemeasurementperiodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance measurement period [Axis]", "label": "Performance measurement period [Axis]", "terseLabel": "Performance measurement period [Axis]" } } }, "localname": "PerformancemeasurementperiodAxis", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "elv_PharmacypricingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy pricing [Member]", "label": "Pharmacy pricing [Member]", "terseLabel": "Damages for Pharmacy Pricing [Member]" } } }, "localname": "PharmacypricingMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Potentially Dilutive Restricted Stock Units Contingent On Operating Results", "label": "Potentially Dilutive Restricted Stock Units Contingent On Operating Results", "terseLabel": "Restricted stock units excluded from the denominator for diluted earnings per share" } } }, "localname": "PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "elv_Proceedsfromsaleofequityandfixedmaturitysecurities": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of equity and fixed maturity securities.", "label": "Proceeds from sale of equity and fixed maturity securities", "terseLabel": "Proceeds from sale of investments" } } }, "localname": "Proceedsfromsaleofequityandfixedmaturitysecurities", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "elv_ProductRevenue": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "elv_OperatingRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold.", "label": "Product Revenue", "terseLabel": "Product revenue" } } }, "localname": "ProductRevenue", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]", "label": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]", "terseLabel": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]" } } }, "localname": "ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract", "nsuri": "http://www.elevancehealth.com/20230630", "xbrltype": "stringItemType" }, "elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of net incurred medical claims to benefit expense [Table]", "label": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table]", "terseLabel": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table]" } } }, "localname": "ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "stringItemType" }, "elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense.", "label": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table Text Block]", "terseLabel": "Reconciliation of Net Incurred Medical Claims to Benefit Expense" } } }, "localname": "ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "xbrltype": "textBlockItemType" }, "elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Reconciliation of net incurred medical claims to benefit expense [Table]", "label": "reconciliation of net incurred medical claims to benefit expense [Line Items]", "terseLabel": "Reconciliation of net incurred medical claims to benefit expense [Line Items]" } } }, "localname": "ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "stringItemType" }, "elv_RepurchaseAndRetirementOfCommonStockIncludingExciseTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Repurchase and retirement of common stock, including excise tax", "label": "Repurchase and retirement of common stock, including excise tax", "negatedTerseLabel": "Repurchase and retirement of common stock, including excise tax" } } }, "localname": "RepurchaseAndRetirementOfCommonStockIncludingExciseTax", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "elv_SecuritiesLendingTransactionsInitialCollateralPercentageValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial minimum percentage of cash and/or securities collateral accepted as compared to the value of securities on loan in a securities lending transaction.", "label": "Securities Lending Transactions Initial Collateral Percentage Value", "terseLabel": "Securities lending transactions, initial collateral percentage value" } } }, "localname": "SecuritiesLendingTransactionsInitialCollateralPercentageValue", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "percentItemType" }, "elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions.", "label": "Securities Lending Transactions Ratio of Fair Value of Collateral Held To Securities On Loan", "terseLabel": "Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned" } } }, "localname": "SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "elv_SegmentEliminationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Segment Eliminations [Member]", "label": "Segment Eliminations [Member]", "terseLabel": "Segment Eliminations [Member]" } } }, "localname": "SegmentEliminationsMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_SelfFundedReceivablesNet": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts.", "label": "Self-Funded Receivables, Net", "terseLabel": "Self-funded receivables" } } }, "localname": "SelfFundedReceivablesNet", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "elv_SelffundedReceivablesAllowanceForDoubtfulAccounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value.", "label": "Self-funded Receivables, Allowance For Doubtful Accounts", "terseLabel": "Self-funded receivables, allowance for doubtful accounts" } } }, "localname": "SelffundedReceivablesAllowanceForDoubtfulAccounts", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "elv_SeniorUnsecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Notes [Member]", "label": "Senior Unsecured Notes [Member]", "terseLabel": "Senior Unsecured Notes [Member]" } } }, "localname": "SeniorUnsecuredNotesMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration.", "label": "Short Duration Contract Liability For Claims Adjustment Expense", "periodEndLabel": "Gross medical claims payable, end of period", "periodStartLabel": "Gross medical claims payable, beginning of period" } } }, "localname": "ShortDurationContractLiabilityForClaimsAdjustmentExpense", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims.", "label": "Short duration contract liability for unpaid claims and adjustment expense, Net", "periodEndLabel": "Net medical claims payable, end of period", "periodStartLabel": "Net medical claims payable, beginning of period" } } }, "localname": "ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Repurchased and Retired During Period Average Price", "label": "Stock Repurchased and Retired During Period Average Price", "terseLabel": "Average price per share" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodAveragePrice", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "perShareItemType" }, "elv_SurplusNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surplus Notes [Member]", "label": "Surplus Notes [Member]", "terseLabel": "Surplus Notes [Member]" } } }, "localname": "SurplusNotesMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax (expense) benefit of non-credit component of impairment loss on available-for-sale securities recognized in other comprehensive income", "label": "Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss)", "terseLabel": "Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss)" } } }, "localname": "Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "elv_ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Three Zero Zero Percent Due Two Thousand Twenty Three", "label": "Three Point Three Zero Zero Percent Due Two Thousand Twenty Three [Member]", "terseLabel": "Three Point Three Zero Zero Percent Due Two Thousand Twenty Three" } } }, "localname": "ThreePointThreeZeroZeroPercentDueTwoThousandTwentyThreeMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Two Point Seven Five Zero Percent Due Two Thousand Forty Two [Member]", "terseLabel": "Two Point Seven Five Zero Percent Due Two Thousand Forty Two" } } }, "localname": "TwoPointSevenFiveZeroPercentDueTwoThousandFortyTwoMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_UnaffiliatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unaffiliated [Member]", "label": "Unaffiliated [Member]", "terseLabel": "Unaffiliated" } } }, "localname": "UnaffiliatedMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zero Point Four Five Zero Percent Due Two Thousand Twenty Three", "label": "Zero Point Four Five Zero Percent Due Two Thousand Twenty Three [Member]", "terseLabel": "Zero Point Four Five Zero Percent Due Two Thousand Twenty Three" } } }, "localname": "ZeroPointFourFiveZeroPercentDueTwoThousandTwentyThreeMember", "nsuri": "http://www.elevancehealth.com/20230630", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r977", "r986", "r1009", "r1037", "r1038", "r1062", "r1063", "r1064", "r1065", "r1066", "r1068", "r1069", "r1070", "r1078" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r196", "r260", "r267", "r273", "r366", "r372", "r496", "r497", "r498", "r509", "r510", "r534", "r536", "r537", "r539", "r540", "r541", "r547", "r550", "r552", "r553", "r616" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r196", "r260", "r267", "r273", "r366", "r372", "r496", "r497", "r498", "r509", "r510", "r534", "r536", "r537", "r539", "r540", "r541", "r547", "r550", "r552", "r553", "r616" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r196", "r260", "r267", "r273", "r366", "r372", "r496", "r497", "r498", "r509", "r510", "r534", "r536", "r537", "r539", "r540", "r541", "r547", "r550", "r552", "r553", "r616" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r322", "r939", "r1057", "r1097", "r1100" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r403", "r404", "r405", "r406", "r469", "r651", "r721", "r765", "r766", "r825", "r846", "r851", "r852", "r889", "r916", "r917", "r929", "r937", "r945", "r952", "r1056", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r403", "r404", "r405", "r406", "r469", "r651", "r721", "r765", "r766", "r825", "r846", "r851", "r852", "r889", "r916", "r917", "r929", "r937", "r945", "r952", "r1056", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r322", "r939", "r1057", "r1097", "r1100" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r319", "r652", "r710", "r711", "r712", "r713", "r714", "r715", "r920", "r938", "r950", "r978", "r1051", "r1052", "r1057", "r1097" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Products and Services" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r319", "r652", "r710", "r711", "r712", "r713", "r714", "r715", "r920", "r938", "r950", "r978", "r1051", "r1052", "r1057", "r1097" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r403", "r404", "r405", "r406", "r462", "r469", "r492", "r493", "r494", "r626", "r651", "r721", "r765", "r766", "r825", "r846", "r851", "r852", "r889", "r916", "r917", "r929", "r937", "r945", "r952", "r955", "r1046", "r1056", "r1082", "r1083", "r1084", "r1085", "r1086" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r403", "r404", "r405", "r406", "r462", "r469", "r492", "r493", "r494", "r626", "r651", "r721", "r765", "r766", "r825", "r846", "r851", "r852", "r889", "r916", "r917", "r929", "r937", "r945", "r952", "r955", "r1046", "r1056", "r1082", "r1083", "r1084", "r1085", "r1086" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06 [Member]" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "auth_ref": [ "r159", "r680", "r988" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.", "label": "Accrued Investment Income Receivable", "terseLabel": "Accrued investment income receivable" } } }, "localname": "AccruedInvestmentIncomeReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r6", "r20", "r49", "r991", "r992", "r993" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r5", "r20", "r49", "r236", "r992", "r993" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r229", "r236", "r527", "r992", "r993" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Net cash flow hedges" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r222", "r223", "r224", "r229", "r236", "r992", "r993" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]", "terseLabel": "Net unrealized investment (losses) gains" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r990" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax", "periodEndLabel": "AOCI, Debt Securities, Ending Balance", "periodStartLabel": "AOCI, Debt Securities, Beginning Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r7", "r49", "r1059" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedPeriodEndLabel": "AOCI, Defined Benefit Plan, Ending Balance", "negatedPeriodStartLabel": "AOCI, Defined Benefit Plan, Beginning Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r220", "r226", "r228", "r229", "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "periodEndLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance", "periodStartLabel": "AOCI, Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r48", "r49", "r126", "r215", "r676", "r729", "r733" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Accumulated Other Comprehensive Loss, Ending Balance", "periodStartLabel": "Accumulated Other Comprehensive Loss, Beginning Balance", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities": { "auth_ref": [ "r49", "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of accumulated other comprehensive loss related to that portion of other than temporary impairment (OTTI) due to factors other than credit losses on debt securities categorized either as available-for-sale or held-to-maturity that an entity does not intend to sell and which it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis of the debt security. The amount represented by this item is net of tax, as applicable.", "label": "Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities", "periodEndLabel": "AOCI, Other than Temporary Impairment, Not Credit Loss, Ending Balance", "periodStartLabel": "AOCI, Other than Temporary Impairment, Not Credit Loss, Beginning Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r3", "r20", "r49", "r536", "r539", "r618", "r724", "r725", "r991", "r992", "r993", "r1006", "r1007", "r1008" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r120", "r949", "r1103" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r496", "r497", "r498", "r747", "r1006", "r1007", "r1008", "r1069", "r1105" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r261", "r262", "r263", "r264", "r273", "r323", "r324", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r397", "r496", "r497", "r498", "r507", "r508", "r509", "r510", "r519", "r520", "r521", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r570", "r571", "r575", "r576", "r577", "r578", "r591", "r592", "r595", "r596", "r597", "r598", "r614", "r615", "r616", "r617", "r618", "r653", "r654", "r655", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments", "terseLabel": "Convertible debenture repurchases, conversions and tax adjustments" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "auth_ref": [ "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on receivable, classified as other and current.", "label": "Allowance for Credit Loss, Receivable, Other, Current", "terseLabel": "Allowance for doubtful accounts, other receivables" } } }, "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r15", "r72", "r74" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of other intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociLiabilityForFuturePolicyBenefitAfterTax": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in liability for future policy benefit from change in discount rate.", "label": "AOCI, Liability for Future Policy Benefit, after Tax", "periodEndLabel": "AOCI, Liability for Future Policy Benefit, After Tax, Ending Balance", "periodStartLabel": "AOCI, Liability for Future Policy Benefit, After Tax, Beginning Balance" } } }, "localname": "AociLiabilityForFuturePolicyBenefitAfterTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "periodEndLabel": "AOCI, Cash Flow Hedge, Ending Balance", "periodStartLabel": "AOCI, Cash Flow Hedge, Beginning Balance", "terseLabel": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r160", "r207", "r252", "r294", "r309", "r315", "r362", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r523", "r528", "r574", "r670", "r788", "r949", "r966", "r1054", "r1055", "r1079" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Assets and Liabilities, Lessee" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r201", "r217", "r252", "r362", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r523", "r528", "r574", "r949", "r1054", "r1055", "r1079" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain": { "auth_ref": [ "r255", "r635" ], "lang": { "en-us": { "role": { "documentation": "Maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.", "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]", "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]" } } }, "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis": { "auth_ref": [ "r255", "r635" ], "lang": { "en-us": { "role": { "documentation": "Information by maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.", "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]", "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]" } } }, "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r330", "r378", "r669" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Cost or Amortized Cost", "totalLabel": "Available-for-sale securities, Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r1026" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "verboseLabel": "Due after five years through ten years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r339", "r665" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "verboseLabel": "Due after five years through ten years, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r1025" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "verboseLabel": "Due after one year through five years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r338", "r664" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "verboseLabel": "Due after one year through five years, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "auth_ref": [ "r1027" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10", "verboseLabel": "Due after ten years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r340", "r666" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "verboseLabel": "Due after ten years, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r1024" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "verboseLabel": "Due in one year or less, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r337", "r663" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "verboseLabel": "Due in one year or less, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": { "auth_ref": [ "r1022", "r1023" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost", "verboseLabel": "Mortgage-backed securities, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r336", "r662", "r1022" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value", "verboseLabel": "Mortgage-backed securities, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r331", "r378", "r657", "r1018" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Available-for-sale Securities", "totalLabel": "Available-for-sale securities, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r327", "r378" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Fixed maturities, current" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r204", "r327", "r378" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Fixed maturities, long-term" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisOfPresentationandSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BenefitsLossesAndExpenses": { "auth_ref": [ "r172" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.", "label": "Benefits, Losses and Expenses", "totalLabel": "Total expenses" } } }, "localname": "BenefitsLossesAndExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_BenefitsLossesAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Benefits, Losses and Expenses [Abstract]", "terseLabel": "Expenses" } } }, "localname": "BenefitsLossesAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r518", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r88", "r89", "r518", "r943", "r944" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Banking Regulation, Total Capital [Abstract]", "terseLabel": "Capital [Abstract]" } } }, "localname": "CapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r58", "r203", "r921" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r58", "r136", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r136" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClaimsDevelopmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Claims Development [Line Items]", "terseLabel": "Claims Development [Line Items]" } } }, "localname": "ClaimsDevelopmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r192", "r211", "r212", "r213", "r252", "r277", "r278", "r280", "r282", "r288", "r289", "r362", "r409", "r411", "r412", "r413", "r416", "r417", "r447", "r448", "r450", "r453", "r460", "r574", "r739", "r740", "r741", "r742", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r775", "r797", "r817", "r906", "r907", "r908", "r909", "r910", "r973", "r1002", "r1010" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r80", "r81", "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "auth_ref": [ "r1023", "r1029", "r1030", "r1058" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by commercial real estate mortgage loans.", "label": "Commercial Mortgage-Backed Securities [Member]", "terseLabel": "Commercial Mortgage-Backed Securities [Member]" } } }, "localname": "CommercialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r114", "r161", "r1090" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "Commercial Paper", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r143", "r957", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r109", "r673", "r774" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies \u2013 Note 10" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r141", "r400", "r401", "r915", "r1047" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments And Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Cash dividends per share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Dividends per share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r953", "r954", "r955", "r957", "r958", "r959", "r960", "r1006", "r1007", "r1069", "r1102", "r1105" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r119", "r775" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r119", "r775", "r794", "r1105", "r1106" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r119", "r675", "r949" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.01, shares authorized \u2013 900,000,000; shares issued and outstanding \u2013 235,861,650 and 237,958,067" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r50", "r233", "r235", "r242", "r659", "r691" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total shareholders\u2019 comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r125", "r241", "r658", "r687" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r144", "r419", "r420", "r430", "r431", "r432", "r436", "r437", "r438", "r439", "r440", "r932", "r933", "r934", "r935", "r936" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Senior Convertible Debenture [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible debentures" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r940", "r942", "r1101" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r130", "r652" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r142", "r250", "r418", "r424", "r425", "r426", "r427", "r428", "r429", "r434", "r441", "r442", "r444" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r34", "r116", "r117", "r162", "r163", "r256", "r419", "r420", "r421", "r422", "r423", "r425", "r430", "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r594", "r932", "r933", "r934", "r935", "r936", "r1003" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCovenantCompliance": { "auth_ref": [ "r34", "r111" ], "lang": { "en-us": { "role": { "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.", "label": "Debt Instrument, Covenant Compliance", "terseLabel": "Covenant compliance" } } }, "localname": "DebtInstrumentCovenantCompliance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCovenantDescription": { "auth_ref": [ "r34", "r111" ], "lang": { "en-us": { "role": { "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.", "label": "Debt Instrument, Covenant Description", "terseLabel": "Covenant description" } } }, "localname": "DebtInstrumentCovenantDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r105", "r107", "r419", "r594", "r933", "r934" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r42", "r420" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r256", "r419", "r420", "r421", "r422", "r423", "r425", "r430", "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r443", "r594", "r932", "r933", "r934", "r935", "r936", "r1003" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r43", "r256", "r419", "r420", "r421", "r422", "r423", "r425", "r430", "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r594", "r932", "r933", "r934", "r935", "r936", "r1003" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Debt instruments, repurchased face amount" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r43", "r78", "r79", "r104", "r105", "r107", "r110", "r146", "r147", "r256", "r419", "r420", "r421", "r422", "r423", "r425", "r430", "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r443", "r594", "r932", "r933", "r934", "r935", "r936", "r1003" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instruments [Abstract]", "terseLabel": "Debt Instruments [Abstract]" } } }, "localname": "DebtInstrumentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r332", "r378", "r383", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "negatedTerseLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent": { "auth_ref": [ "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current", "terseLabel": "Fixed maturities, allowance for credit loss, current" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent": { "auth_ref": [ "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Noncurrent", "terseLabel": "Fixed maturities, allowance for credit Loss, noncurrent" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "auth_ref": [ "r378", "r1021" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current", "terseLabel": "Fixed maturities, amortized cost, current" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "auth_ref": [ "r378", "r1021" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent", "terseLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r182", "r380", "r930" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "verboseLabel": "Estimated fair value, 12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r182", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedLabel": "Gross unrealized loss, 12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r1042" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Number of securities, 12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r182", "r380", "r930" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "verboseLabel": "Estimated fair value, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r182", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Gross unrealized loss, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r1042" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Number of securities, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain", "terseLabel": "Debt Securities, Available-for-sale, Realized Gain" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r1031" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "terseLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss)" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Loss", "terseLabel": "Debt Securities, Available-for-sale, Realized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r15", "r151", "r186", "r513", "r514", "r1005" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r500", "r501", "r672" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue": { "auth_ref": [ "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to return cash received as collateral for security loaned to another party.", "label": "Deposits Received for Securities Loaned, at Carrying Value", "terseLabel": "Collateral received for securities loaned, at carrying value" } } }, "localname": "DepositsReceivedForSecuritiesLoanedAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r15" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Depreciation, Amortization and Accretion, Net", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": { "auth_ref": [ "r218", "r875", "r876", "r923" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.", "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement", "terseLabel": "Derivative assets" } } }, "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r763", "r766", "r780", "r781", "r782", "r784", "r785", "r786", "r787", "r789", "r790", "r791", "r792", "r805", "r806", "r807", "r808", "r811", "r812", "r813", "r814", "r872", "r873", "r874", "r877", "r953", "r955" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r1067" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Derivative, Gain (Loss) Recognized" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r95", "r96", "r97", "r98", "r763", "r766", "r780", "r781", "r782", "r784", "r785", "r786", "r787", "r789", "r790", "r791", "r792", "r805", "r806", "r807", "r808", "r811", "r812", "r813", "r814", "r872", "r873", "r874", "r877", "r923", "r953", "r955" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r155", "r530", "r542" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r22", "r95", "r97" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": { "auth_ref": [ "r218", "r875", "r876", "r923" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.", "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement", "negatedTerseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeMember": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).", "label": "Derivative [Member]", "terseLabel": "Derivatives [Member]" } } }, "localname": "DerivativeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Payment date", "verboseLabel": "Dividends Payable, Date to be Paid" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r11", "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "terseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r11", "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "negatedLabel": "Dividends and dividend equivalents" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Summary of Cash Dividend Activity" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Dividends Payable, Amount Per Share" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format.", "label": "Dividends Payable, Date Declared", "terseLabel": "Declaration date" } } }, "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Record date", "verboseLabel": "Dividends Payable, Date of Record" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Shareholders\u2019 net income per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r243", "r265", "r266", "r267", "r268", "r269", "r275", "r277", "r280", "r281", "r282", "r286", "r553", "r554", "r660", "r692", "r926" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r243", "r265", "r266", "r267", "r268", "r269", "r277", "r280", "r281", "r282", "r286", "r553", "r554", "r660", "r692", "r926" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r274", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r581" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r21", "r196", "r236", "r237", "r238", "r257", "r258", "r259", "r262", "r270", "r272", "r287", "r366", "r372", "r461", "r496", "r497", "r498", "r509", "r510", "r534", "r536", "r537", "r538", "r539", "r541", "r552", "r582", "r584", "r585", "r586", "r587", "r589", "r618", "r724", "r725", "r726", "r747", "r817" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r208", "r572", "r922" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r696", "r1035" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "Net gains (losses) on equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r694", "r1035" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Net realized gains (losses) recognized on equity securities sold during the period" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r695", "r1035" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains (losses) recognized on equity securities still held at the end of the period" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r69", "r961", "r962", "r963", "r1107" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExchangeTradedFundsMember": { "auth_ref": [ "r1058", "r1071" ], "lang": { "en-us": { "role": { "documentation": "Investment that follows an index, commodity or basket of assets that trades similar to a stock on an exchange.", "label": "Exchange Traded Funds [Member]", "terseLabel": "Exchange Traded Funds [Member]" } } }, "localname": "ExchangeTradedFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]", "terseLabel": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment of Debt, Type [Domain]", "terseLabel": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r557", "r558", "r566" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r557", "r558", "r566" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)", "terseLabel": "Change in unrealized gains (losses) included in net income related to assets still held" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r23", "r103" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r23", "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r432", "r463", "r464", "r465", "r466", "r467", "r468", "r558", "r623", "r624", "r625", "r933", "r934", "r940", "r941", "r942" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r557", "r558", "r559", "r560", "r567" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r432", "r463", "r468", "r558", "r623", "r940", "r941", "r942" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level I [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r432", "r463", "r468", "r558", "r624", "r933", "r934", "r940", "r941", "r942" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level II [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r432", "r463", "r464", "r465", "r466", "r467", "r468", "r558", "r625", "r933", "r934", "r940", "r941", "r942" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level III [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r561" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Total gains (losses) recognized in net income" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "auth_ref": [ "r562" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Total gains (losses) recognized in accumulated other comprehensive loss" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "negatedTerseLabel": "Sales" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "negatedTerseLabel": "Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfers into Level III" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r563" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "negatedTerseLabel": "Transfers out of Level III" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r23" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r432", "r463", "r464", "r465", "r466", "r467", "r468", "r623", "r624", "r625", "r933", "r934", "r940", "r941", "r942" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r557", "r558", "r559", "r560", "r565", "r567" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Fair Value, Nonrecurring [Member]" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r556", "r567" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueInNextRollingTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of advances from Federal Home Loan Bank (FHLBank) maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Federal Home Loan Bank, Advances, Maturities Summary, Due in Next Rolling 12 Months", "verboseLabel": "Federal Home Loan Bank, advances, short-term" } } }, "localname": "FederalHomeLoanBankAdvancesMaturitiesSummaryDueInNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalHomeLoanBankAdvancesMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans.", "label": "Federal Home Loan Bank Advances [Member]", "terseLabel": "Federal Home Loan Bank Advances [Member]" } } }, "localname": "FederalHomeLoanBankAdvancesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r373", "r374", "r375", "r376", "r377", "r379", "r381", "r382", "r443", "r458", "r542", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r688", "r930", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r1031", "r1032", "r1033", "r1034" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "negatedTerseLabel": "Total liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedMaturitiesMember": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "This element provides types of investments that may be contained within the fixed maturity category which are securities having a stated final repayment date. Examples of items within this category may include bonds, including convertibles and bonds with warrants, and redeemable preferred stocks.", "label": "Fixed Maturities [Member]", "terseLabel": "Fixed Maturities [Member]" } } }, "localname": "FixedMaturitiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignGovernmentDebtMember": { "auth_ref": [ "r1020", "r1028" ], "lang": { "en-us": { "role": { "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity.", "label": "Foreign Government Debt [Member]", "terseLabel": "Foreign Government Securities [Member]" } } }, "localname": "ForeignGovernmentDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingenciesByNatureAxis": { "auth_ref": [ "r1053" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of gain contingency.", "label": "Gain Contingencies, Nature [Axis]", "terseLabel": "Gain Contingency, Nature [Axis]" } } }, "localname": "GainContingenciesByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainContingencyNatureDomain": { "auth_ref": [ "r1053" ], "lang": { "en-us": { "role": { "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.", "label": "Gain Contingency, Nature [Domain]", "terseLabel": "Gain Contingency, Nature [Domain]" } } }, "localname": "GainContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestmentsTextBlock": { "auth_ref": [ "r994", "r995" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.", "label": "Gain (Loss) on Securities [Table Text Block]", "terseLabel": "Net Investment Gains (Losses)" } } }, "localname": "GainLossOnInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfOtherInvestments": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) included in earnings for investments classified as other.", "label": "Gain (Loss) on Sale of Other Investments", "terseLabel": "Net losses on other investments" } } }, "localname": "GainLossOnSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r205", "r385", "r656", "r931", "r949", "r1043", "r1045" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r388", "r931" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r1", "r1044" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r127", "r168", "r294", "r308", "r314", "r317", "r661", "r683", "r928" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income tax expense", "totalLabel": "Income before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r15", "r128", "r167", "r301", "r361", "r682" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in net earnings of other invested assets" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r253", "r499", "r504", "r505", "r506", "r511", "r515", "r516", "r517", "r744" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r183", "r187", "r271", "r272", "r302", "r502", "r512", "r698" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r108", "r988" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income taxes receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r1000" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of assets, which may include but are not limited to cash and investments, received as collateral pertaining to securities loaned to a counterparty to the transaction. Includes the change during the period in any unrealized gain or loss on such investments.", "label": "Increase (Decrease) in Collateral Held under Securities Lending", "negatedTerseLabel": "Changes in securities lending collateral" } } }, "localname": "IncreaseDecreaseInCollateralHeldUnderSecuritiesLending", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r918" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Unearned income" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": { "auth_ref": [ "r1000" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.", "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable", "terseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInsuranceLiabilities": { "auth_ref": [ "r14" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in insurance liability balances during the period.", "label": "Increase (Decrease) in Insurance Liabilities", "terseLabel": "Policy liabilities" } } }, "localname": "IncreaseDecreaseInInsuranceLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r14" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r14" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities": { "auth_ref": [ "r16", "r59" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in cash during the period due to the net increase or decrease in outstanding checks, the liability that represents checks that have been issued but that have not cleared. The entity may classify these cash flows as financing or operating activities.", "label": "Increase (Decrease) in Outstanding Checks, Financing Activities", "terseLabel": "Changes in bank overdrafts" } } }, "localname": "IncreaseDecreaseInOutstandingChecksFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r14" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables, net" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSecuritiesLendingPayable": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of the liability pertaining to obligations to return collateral that the entity received when it loaned securities to the counterparty to the transaction.", "label": "Increase (Decrease) in Securities Lending Payable", "terseLabel": "Changes in securities lending payable" } } }, "localname": "IncreaseDecreaseInSecuritiesLendingPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTradingSecurities": { "auth_ref": [ "r14", "r57" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income.", "label": "Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI", "negatedLabel": "Other invested assets" } } }, "localname": "IncreaseDecreaseInTradingSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-Lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived Intangible Assets Acquired" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Insurance [Abstract]", "terseLabel": "Insurance [Abstract]" } } }, "localname": "InsuranceAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r71", "r73" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r106", "r170", "r239", "r298", "r593", "r801", "r964", "r1104" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r693", "r735", "r736", "r737", "r738", "r842", "r844" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment, Policy" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r759", "r760", "r761", "r762", "r764", "r822", "r831", "r847", "r855", "r868", "r878", "r879", "r898", "r902", "r903", "r904", "r905", "r955" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r759", "r760", "r761", "r762", "r764", "r822", "r831", "r847", "r855", "r868", "r878", "r879", "r898", "r902", "r903", "r904", "r905", "r955" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]", "terseLabel": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r158", "r171", "r177", "r193", "r325", "r328", "r568", "r569" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r605", "r948" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease, Cost and Other Information [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r1076" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Disclosure [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease and Other Information [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Leases" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r1077" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "verboseLabel": "Total future minimum payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Operating lease payments, Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Operating lease payments, 2023; excluding the six months ended June 30, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Operating lease payments, 2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Operating lease payments, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Operating lease payments, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Operating lease payments, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Imputed Interest, Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r1075" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r252", "r362", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r524", "r528", "r529", "r574", "r773", "r927", "r966", "r1054", "r1079", "r1080" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r124", "r165", "r679", "r949", "r1004", "r1036", "r1072" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r202", "r252", "r362", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r524", "r528", "r529", "r574", "r949", "r1054", "r1079", "r1080" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r112", "r175" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.", "label": "Liability for Claims and Claims Adjustment Expense", "terseLabel": "Gross medical claims payable, end of period", "verboseLabel": "Medical claims payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Claims and Claims Adjustment Expense [Abstract]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Abstract]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Medical Claims Payable [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Medical Claims Payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefits": { "auth_ref": [ "r719", "r720", "r727", "r951", "r1089" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.", "label": "Liability for Future Policy Benefit, before Reinsurance", "terseLabel": "Reserves for future policy benefits, noncurrent" } } }, "localname": "LiabilityForFuturePolicyBenefits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]", "terseLabel": "Medical Claims payable" } } }, "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions", "terseLabel": "Business combinations and purchase adjustments" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "terseLabel": "Net payments attributable to current period medical claims" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "terseLabel": "Net payments attributable to prior periods medical claims" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "auth_ref": [ "r174" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "terseLabel": "Total net incurred medical claims" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": { "auth_ref": [ "r112", "r175", "r1089" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net", "terseLabel": "Net medical claims payable, end of period" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Subsidiary Credit Facilities [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r34", "r163", "r431", "r445", "r933", "r934", "r1091" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term Debt", "verboseLabel": "Senior revolving credit facility" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r209" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r210" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Investments [Abstract]", "terseLabel": "Long-term investments:" } } }, "localname": "LongTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Long-term purchase commitment, amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r43", "r75" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r402", "r403", "r404", "r408", "r1049", "r1050" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualPayments": { "auth_ref": [ "r1048" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow reducing loss contingency liability.", "label": "Loss Contingency Accrual, Payments", "terseLabel": "Loss Contingency Accrual, Payments" } } }, "localname": "LossContingencyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r1048", "r1049", "r1050" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Approximate amount of damages sought for breaches" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r403", "r404", "r407", "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Aggregate settlement amount" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r402", "r403", "r404", "r408", "r1049", "r1050" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Equity Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Equity Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MaturityOvernightMember": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Maturity period of the day after the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements.", "label": "Maturity Overnight [Member]", "terseLabel": "Overnight and Continuous [Member]" } } }, "localname": "MaturityOvernightMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r113", "r152" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Business Acquisitions" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r47", "r164", "r252", "r362", "r409", "r411", "r412", "r413", "r416", "r417", "r574", "r678", "r777" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.", "label": "Equity, Attributable to Noncontrolling Interest", "periodEndLabel": "Noncontrolling interests, Ending Balance", "periodStartLabel": "Noncontrolling interests, Beginning Balance", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.", "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Noncontrolling Interest, Period Increase (Decrease)" } } }, "localname": "MinorityInterestPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r185", "r191" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r248" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r248" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r136", "r137", "r138" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r129", "r138", "r169", "r200", "r231", "r234", "r238", "r252", "r261", "r265", "r266", "r267", "r268", "r271", "r272", "r279", "r294", "r308", "r314", "r317", "r362", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r554", "r574", "r686", "r796", "r815", "r816", "r928", "r964", "r1054" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Shareholders' net income", "totalLabel": "Shareholders\u2019 net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r93", "r154", "r231", "r234", "r271", "r272", "r685", "r993" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Net (income) loss attributable to noncontrolling interests", "terseLabel": "Net Income (Loss) Attributable to Noncontrolling Interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentIncome": { "auth_ref": [ "r184", "r689", "r690", "r802", "r964" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.", "label": "Net Investment Income", "negatedTerseLabel": "Net investment income", "terseLabel": "Net investment income" } } }, "localname": "NetInvestmentIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]", "terseLabel": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r90", "r461", "r1006", "r1007", "r1008", "r1105" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r34", "r163", "r1091" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Notes" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r1012" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which the Company is licensed to conduct insurance operations" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax": { "auth_ref": [ "r225", "r226" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of unrealized gain (loss) from (increase) decrease in liability for future policy benefit from change in discount rate.", "label": "OCI, Liability for Future Policy Benefit, Gain (Loss), after Reclassification Adjustment and Tax", "terseLabel": "Change in future policy benefits, net of tax", "verboseLabel": "Change in future policy benefits" } } }, "localname": "OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentTax": { "auth_ref": [ "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification adjustment, of tax expense (benefit) for unrealized gain (loss) from (increase) decrease in liability for future policy benefit from change in discount rate.", "label": "OCI, Liability for Future Policy Benefit, Gain (Loss), after Reclassification Adjustment, Tax", "terseLabel": "Change in future policy benefits, tax expense" } } }, "localname": "OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r294", "r308", "r314", "r317", "r928" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Reportable segments operating gain", "verboseLabel": "Operating gain (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r606", "r948" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r601" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating Lease Liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r601" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Balance sheet location of current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r601" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Balance sheet location of noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r603", "r609" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r600" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Balance sheet location of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r612", "r948" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r611", "r948" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r77", "r99", "r100", "r157" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]", "terseLabel": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherAggregatedInvestmentsMember": { "auth_ref": [ "r760", "r761", "r854" ], "lang": { "en-us": { "role": { "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.", "label": "Other Security Investments [Member]", "terseLabel": "Other Asset-Backed Securities [Member]" } } }, "localname": "OtherAggregatedInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r216", "r949" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r206" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r222", "r223", "r226" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "verboseLabel": "Change in net unrealized losses/gains on investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax", "terseLabel": "Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r221", "r226" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Cash flow hedges, holding gain (loss), net of tax", "verboseLabel": "Change in net unrealized gains/losses on cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Cash flow hedges, holding gain (loss), tax (expense) benefit" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r4" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 6.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment, net of tax", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r4", "r8", "r580", "r588" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Expense) Benefit" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r33", "r232", "r235", "r241", "r582", "r583", "r589", "r658", "r687", "r991", "r992" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r12", "r19", "r153", "r232", "r235" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "negatedTerseLabel": "Other comprehensive loss (income) attributable to noncontrolling interests", "terseLabel": "Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r12", "r19", "r153", "r232", "r235" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "verboseLabel": "Shareholders' other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r7", "r126" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Change in net periodic pension and postretirement costs", "negatedTerseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r10", "r126", "r230", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax", "negatedTerseLabel": "Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r12", "r19", "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r12", "r19", "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Tax (Expense) Benefit, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r222", "r226", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r1041", "r1058", "r1071" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other Asset-backed Securities [Member]" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r697", "r798", "r893", "r894", "r895" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "elv_OperatingRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Service fees" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r40", "r949" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestments": { "auth_ref": [ "r668", "r987" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term investments classified as other.", "label": "Other Long-Term Investments", "terseLabel": "Other invested assets", "verboseLabel": "Other invested assets" } } }, "localname": "OtherLongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPolicyholderFunds": { "auth_ref": [ "r671" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other.", "label": "Other Policyholder Funds", "terseLabel": "Other policyholder liabilities" } } }, "localname": "OtherPolicyholderFunds", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r214", "r783" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities": { "auth_ref": [ "r178", "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other than temporary impairment (OTTI) loss on investment in available-for-sale debt security, recognized in other comprehensive loss.", "label": "Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-Sale Securities", "terseLabel": "Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-sale Securities" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "auth_ref": [ "r13", "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "terseLabel": "Total net payments" } } }, "localname": "PaymentsForLossesAndLossAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r974", "r996" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r55" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase and retirement of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r55" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Cash dividends", "terseLabel": "Total payment" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r246" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Taxes paid through withholding of common stock under employee stock plans" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r53" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Purchases of subsidiaries, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r134" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r135" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": { "auth_ref": [ "r1096" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.", "label": "Policyholder Benefits and Claims Incurred, Net", "terseLabel": "Benefit expense" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r118", "r775" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r118", "r447" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r118", "r775", "r794", "r1105", "r1106" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r118", "r674", "r949" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, without par value, shares authorized \u2013 100,000,000; shares issued and outstanding \u2013 none" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsEarnedNet": { "auth_ref": [ "r189", "r190", "r714", "r734" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "elv_OperatingRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Premiums Earned, Net", "terseLabel": "Premiums" } } }, "localname": "PremiumsEarnedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts": { "auth_ref": [ "r976", "r1014", "r1039", "r1040", "r1095" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.", "label": "Premium Receivable, Allowance for Credit Loss", "terseLabel": "Premium receivable, allowance for doubtful accounts" } } }, "localname": "PremiumsReceivableAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsReceivableAtCarryingValue": { "auth_ref": [ "r1092", "r1093", "r1094" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.", "label": "Premiums Receivable, Net", "terseLabel": "Premium receivables" } } }, "localname": "PremiumsReceivableAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivateEquityFundsMember": { "auth_ref": [ "r1058" ], "lang": { "en-us": { "role": { "documentation": "Investments held in private equity funds.", "label": "Private Equity Funds [Member]", "terseLabel": "Private Equity Funds [Member]", "verboseLabel": "Private Equity Securities [Member]" } } }, "localname": "PrivateEquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "verboseLabel": "Proceeds originally received at time of divestiture" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r54", "r739" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from long-term borrowings" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r244", "r245", "r1019" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Maturities, calls and redemptions from investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r975", "r997" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "auth_ref": [ "r998", "r999", "r1001" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.", "label": "Proceeds from (Repayments of) Commercial Paper", "terseLabel": "Net proceeds from commercial paper borrowings" } } }, "localname": "ProceedsFromRepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r51", "r244", "r326", "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from Sale of Available-for-sale Securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r54" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-Term Debt", "terseLabel": "Proceeds from short-term borrowings" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r9", "r26" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock under employee stock plans" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r200", "r231", "r234", "r247", "r252", "r261", "r271", "r272", "r294", "r308", "r314", "r317", "r362", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r522", "r525", "r526", "r554", "r574", "r661", "r684", "r746", "r796", "r815", "r816", "r928", "r946", "r947", "r965", "r993", "r1054" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r667", "r681", "r949" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r1013", "r1015", "r1016", "r1017" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r66", "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "verboseLabel": "Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r65", "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "verboseLabel": "Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": { "auth_ref": [ "r112", "r175", "r1088", "r1098", "r1099" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.", "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments", "negatedPeriodStartLabel": "Ceded medical claims payable, beginning of period", "periodEndLabel": "Ceded medical claims payable, end of period", "terseLabel": "Ceded medical claims payable end of period" } } }, "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r56", "r742" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayments of long-term borrowings", "terseLabel": "Repayments of Long-term Debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r56" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-Term Debt", "negatedTerseLabel": "Repayments of Short-term Debt" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "auth_ref": [ "r1020", "r1023", "r1028", "r1029", "r1030", "r1058" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by residential real estate mortgage loans.", "label": "Residential Mortgage-Backed Securities [Member]", "terseLabel": "Residential Mortgage-Backed Securities [Member]" } } }, "localname": "ResidentialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndInvestmentsCurrent": { "auth_ref": [ "r913", "r914", "r989" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.", "label": "Restricted Cash and Investments, Current", "terseLabel": "Customer funds and cash and cash equivalents on deposit for regulatory requirements" } } }, "localname": "RestrictedCashAndInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r121", "r148", "r677", "r728", "r733", "r743", "r776", "r949" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r196", "r257", "r258", "r259", "r262", "r270", "r272", "r366", "r372", "r496", "r497", "r498", "r509", "r510", "r534", "r537", "r538", "r541", "r552", "r724", "r726", "r747", "r1105" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]", "verboseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r799", "r919", "r924" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r240", "r252", "r295", "r296", "r307", "r312", "r313", "r319", "r321", "r322", "r362", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r574", "r661", "r1054" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r610", "r948" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]", "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]" } } }, "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r49", "r1073", "r1074" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Reconciliation Of Components Of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "verboseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Current and Long-Term Investments, Available-For-Sale" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r88", "r89", "r518" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Business Acquisitions [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r1011" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Denominator for Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r557", "r558" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems": { "auth_ref": [ "r994", "r995", "r1031" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Gain (Loss) on Securities [Line Items]", "terseLabel": "Investment [Line Items]" } } }, "localname": "ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGainLossOnInvestmentsTable": { "auth_ref": [ "r994", "r995", "r1031" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about realized and unrealized gain (loss) on investment in security.", "label": "Schedule of Gain (Loss) on Securities [Table]", "terseLabel": "Investment [Table]" } } }, "localname": "ScheduleOfGainLossOnInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r132", "r133", "r688" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]", "terseLabel": "Investment Income [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [ "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r843", "r845", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r896", "r897", "r898", "r899", "r900", "r901" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "terseLabel": "Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable" } } }, "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r62", "r63", "r64", "r70" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r62", "r63", "r64", "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Financial Data By Reportable Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r24", "r25", "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "verboseLabel": "Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r80", "r81", "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Summary of Share Repurchases" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesHeldAsCollateralAtFairValue": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount (fair value) as of the balance sheet date of securities held that had been pledged by counterparties under financing and lending arrangements, pursuant to which the entity has the right by agreement or custom to sell or re-pledge such securities.", "label": "Securities Held as Collateral, at Fair Value", "terseLabel": "Securities lending collateral" } } }, "localname": "SecuritiesHeldAsCollateralAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuritiesLoanedFairValueOfCollateral": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the securities pledged as collateral against securities loaned.", "label": "Securities Loaned, Fair Value of Collateral", "verboseLabel": "Fair value of collateral received at time of securities lending transactions" } } }, "localname": "SecuritiesLoanedFairValueOfCollateral", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r291", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r322", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r398", "r399", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r931", "r978", "r1097" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]", "terseLabel": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]" } } }, "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r306", "r311", "r315", "r316", "r317", "r318", "r319", "r320", "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r131" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Operating expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r14" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited, Restricted Stock Shares And Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted, Restricted Stock Shares and Units", "verboseLabel": "Restricted stock units issued under stock incentive plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted stock awards granted during the period", "verboseLabel": "Granted, Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails", "http://www.elevancehealth.com/role/CapitalStockScheduleOfWeightedAverageFairValuesDeterminedForThePeriodsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at Ending Balance, Restricted Stock Shares and Units", "periodStartLabel": "Nonvested at Beginning Balance, Restricted Stock Shares and Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Shares and Units [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at Ending Balance, Weighted-Average Grant Date Fair Value per Share", "periodStartLabel": "Nonvested at Beginning Balance, Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested, Restricted Stock Shares And Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested, Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Quarterly dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility factor" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r1060" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited or expired, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r1060" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited or expired, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r1061" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "verboseLabel": "Granted, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options granted during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockScheduleOfWeightedAverageFairValuesDeterminedForThePeriodsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Schedule of Weighted-Average Fair Values Determined for the Periods" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding at end of period, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period, Number of Shares", "periodStartLabel": "Outstanding at beginning of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period, Weighted-Average Option Price per Share", "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Option Price Per Share [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "verboseLabel": "Exercisable at end of period, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Weighted-average expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at end of period, Weighted-Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at end of period, Weighted-Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares), Ending", "periodStartLabel": "Balance (in shares), Beginning" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2021Member": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2021 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2021 [Member]", "terseLabel": "Short-Duration Insurance Contract, Accident Year 2021 [Member]" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2021Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2022Member": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2022 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2022 [Member]", "terseLabel": "Short-Duration Insurance Contract, Accident Year 2022 [Member]" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2022Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2023Member": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2023 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2023 [Member]", "terseLabel": "Short-Duration Insurance Contract, Accident Year 2023 [Member]" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2023Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r115", "r162", "r949", "r1090" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "terseLabel": "Short-term borrowings", "verboseLabel": "Short-term borrowings" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r607", "r948" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term Lease, Cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-Duration Insurance Contracts, Accident Year [Axis]", "terseLabel": "Short-duration Insurance Contracts, Claim Year [Axis]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-Duration Insurance Contracts, Accident Year [Domain]", "terseLabel": "Short-duration Insurance Contracts, Claim Year [Domain]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Claims Development [Table]", "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]" } } }, "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet": { "auth_ref": [ "r31", "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net", "terseLabel": "Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net" } } }, "localname": "ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reconciling item for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts, classified as other.", "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item", "terseLabel": "Insurance lines other than short duration" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]", "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]", "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]", "terseLabel": "Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r199", "r291", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r322", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r398", "r399", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r931", "r978", "r1097" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r192", "r211", "r212", "r213", "r252", "r277", "r278", "r280", "r282", "r288", "r289", "r362", "r409", "r411", "r412", "r413", "r416", "r417", "r447", "r448", "r450", "r453", "r460", "r574", "r739", "r740", "r741", "r742", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r775", "r797", "r817", "r906", "r907", "r908", "r909", "r910", "r973", "r1002", "r1010" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r46", "r196", "r236", "r237", "r238", "r257", "r258", "r259", "r262", "r270", "r272", "r287", "r366", "r372", "r461", "r496", "r497", "r498", "r509", "r510", "r534", "r536", "r537", "r538", "r539", "r541", "r552", "r582", "r584", "r585", "r586", "r587", "r589", "r618", "r724", "r725", "r726", "r747", "r817" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r257", "r258", "r259", "r287", "r652", "r735", "r758", "r767", "r768", "r769", "r770", "r771", "r772", "r775", "r778", "r779", "r780", "r781", "r782", "r784", "r785", "r786", "r787", "r789", "r790", "r791", "r792", "r793", "r795", "r799", "r800", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r817", "r956" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r257", "r258", "r259", "r287", "r652", "r735", "r758", "r767", "r768", "r769", "r770", "r771", "r772", "r775", "r778", "r779", "r780", "r781", "r782", "r784", "r785", "r786", "r787", "r789", "r790", "r791", "r792", "r793", "r795", "r799", "r800", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r817", "r956" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r21", "r118", "r119", "r148" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under employee stock plans, net of related tax benefits, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r118", "r119", "r148", "r478" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised, Number of Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r21", "r46", "r148" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock under employee stock plans, net of related tax benefits" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Authorization remaining at the end of the period" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r21", "r118", "r119", "r148" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Repurchase and retirement of common stock, shares", "verboseLabel": "Shares repurchased" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r21", "r118", "r119", "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Repurchase and retirement of common stock", "terseLabel": "Aggregate cost" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r119", "r122", "r123", "r140", "r777", "r794", "r818", "r819", "r949", "r966", "r1004", "r1036", "r1072", "r1105" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Total shareholders' equity, Ending Balance", "periodStartLabel": "Total shareholders' equity, Beginning Balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r90", "r91", "r92", "r196", "r197", "r237", "r257", "r258", "r259", "r262", "r270", "r366", "r372", "r461", "r496", "r497", "r498", "r509", "r510", "r534", "r536", "r537", "r538", "r539", "r541", "r552", "r582", "r584", "r589", "r618", "r725", "r726", "r745", "r777", "r794", "r818", "r819", "r911", "r965", "r1004", "r1036", "r1072", "r1105" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Total equity, Ending Balance", "periodStartLabel": "Total equity, Beginning Balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r145", "r251", "r446", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r459", "r461", "r543", "r820", "r821", "r912" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "Capital Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r608", "r948" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r590", "r619" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r590", "r619" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r590", "r619" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r717" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.", "label": "Current Year Claims and Claims Adjustment Expense", "terseLabel": "Current period net incurred medical claims" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r717" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.", "label": "Prior Year Claims and Claims Adjustment Expense", "negatedLabel": "Prior periods redundancies" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementaryInsuranceInformationOtherOperatingExpense": { "auth_ref": [ "r708" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense classified as other, disclosed in supplementary insurance information.", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense", "terseLabel": "Quality improvement and other claims expense" } } }, "localname": "SupplementaryInsuranceInformationOtherOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r443", "r458", "r542", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r688", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r1031", "r1032", "r1033", "r1034" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r261", "r262", "r263", "r264", "r273", "r323", "r324", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r397", "r496", "r497", "r498", "r507", "r508", "r509", "r510", "r519", "r520", "r521", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r570", "r571", "r575", "r576", "r577", "r578", "r591", "r592", "r595", "r596", "r597", "r598", "r614", "r615", "r616", "r617", "r618", "r653", "r654", "r655", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r925", "r940", "r1087" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "United States Government Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r1058", "r1087" ], "lang": { "en-us": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Government Sponsored Securities [Member]" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "auth_ref": [ "r940", "r1101" ], "lang": { "en-us": { "role": { "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.", "label": "US States and Political Subdivisions Debt Securities [Member]", "terseLabel": "States, Municipalities And Political Subdivisions [Member]" } } }, "localname": "USStatesAndPoliticalSubdivisionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnearnedPremiums": { "auth_ref": [ "r188" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date.", "label": "Unearned Premiums", "verboseLabel": "Unearned income" } } }, "localname": "UnearnedPremiums", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r1011" ], "calculation": { "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Effect of dilutive securities \u2013 employee stock options, nonvested restricted stock awards and convertible debentures" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r276", "r282" ], "calculation": { "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Denominator for diluted earnings per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r275", "r282" ], "calculation": { "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Denominator for basic earnings per share - weighted-average shares" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1000": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1001": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1002": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1003": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1004": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1005": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1006": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1007": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1008": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1009": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1025": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1029": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1038": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1043": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1047": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1057": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1061": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1062": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1063": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1064": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1065": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1066": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1067": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1068": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1069": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1070": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1071": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1072": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1073": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1074": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1075": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1076": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1077": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1078": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1079": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1080": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1081": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1082": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1083": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1084": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1085": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1086": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1087": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1088": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1089": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1090": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1091": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1092": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1093": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1094": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5)(c))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1095": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1096": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1097": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1098": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479616/944-310-45-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1099": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1100": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(g)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//205-20/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org//220/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org//815/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//940-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//942-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.5,6,7)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//946-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481889/320-10-35-35", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-9A", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(13)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(c))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(m)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4E", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "50", "Subparagraph": "(a)", "Topic": "405", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org//830/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(14))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(17))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(d))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column G))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column H))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column I))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column J))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column K))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//944-40/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(3)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "29E", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r967": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r968": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r969": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r971": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r972": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r973": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r976": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r978": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r979": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r980": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r981": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r982": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r983": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r984": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r985": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r990": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" } }, "version": "2.2" } ZIP 88 0001156039-23-000088-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001156039-23-000088-xbrl.zip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end

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